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AB STRAC T 
The identification of apparently healthy carriers of the lethal, 
X- linked gene for Duchenne muscular dystrophy (DMD) is of importance 
for genetic counselling purposes. At present the accepted most 
reliable test for determining DMD carrier status is the estimation 
of serum creatine kinase activity. However, approximately one third 
of genetic carriers remain undetected by this method. This study was 
designed to evaluate other possible methods of DMD heterozygote 
recognition with a view to improving the carrier detection rate. 
There is considerable evidence to suggest a generalised 
membrane defect is responsible for the degenerative muscle fibre 
alterations which occur in DMD. Increased intracellular calcium has 
been implicated as an early biochemical change which would account 
for many of the membrane abnormalities reported. Several changes 
exhibited by DMD erythrocytes could be attributed to an increased 
intraerythrocytic calcium content. If this increased calcium level 
is related to the primary defect then, according to the Lyon hypothesis, 
a proportion of erythrocytes from a genetic carrier of DMD should 
manifest this abnormality. The relative intraerythrocytic calcium 
content of individual erythrocytes within DMD patient, DMD carrier 
and control erythrocyte populations were examined. Quantitative 
measurement of the elemental content of single erythrocytes was 
carried out using electron probe X -ray microanalysis (EPXMA). However 
the extremely low level of intraerythrocytic calcium and the wide 
variation in relative calcium concentrations of each erythrocyte 
population render EPXMA insufficently sensitive to be capable of 
distinguishing two erythrocyte populations within a DMD carrier. 
i 
An alternate approach to the demonstration of cellular 
mosaicism is the additional measurement of secondary biochemical 
parameters which, if non -correlated, could improve the carrier 
detection rate over that obtained using serum creatine kinase 
estimation alone. Serum levels of haemopexin and myoglobin were found 
to be raised significantly in a series of 10 DMD patients compared to 
10 age and sex matched, normal, healthy controls. Measurements of 
serum pyruvate kinase, haemopexin and myoglobin levels were then 
carried out in a series of 15 DF'T carriers and 15 age matched, normal, 
healthy women, in conjunction with serum creatine kinase estimation. 
The mean serum pyruvate kinase activity of the DMD carrier group was 
significantly higher than that of the control group but this test 
selected only 4/14 (28.5%) carriers and failed to identify 3 carriers 
whose serum creatine kinase levels were within normal limits. The 
mean serum haemopexin level of the carrier group was not significantly 
different from that of the control group. The mean serum myoglobin 
level of the carrier group was significantly higher than that of the 
control group. Nine of 15 (60%) carriers had myoglobin levels outside 
the 95% confidence limits. However serum myoglobin was within normal 
limits in all 3 carriers with normal serum creatine kinase levels. 
Discriminant analysis suggested that combining serum myoglobin and 
creatine kinase measurements might improve the detection rate. Serum 
levels of myoglobin and creatine kinase were measured in a series of 
20 DMD carriers (all with serum creatine kinase activities within 
normal limits) and 20 age matched, normal, healthy women. Three of 20 
(15 %) carriers had myoglobin levels outside the calculated 95% 
confidence limits but all 3 had serum creatine kinase activities close 
to the 95th percentile of the control series. The positive correlation 
between serum myoglobin and creatine kinase levels implies the 
ii 
combined use of these tests may be of value only in cases where the 
subjects' creatine kinase level is borderline normal. Otherwise the 
results of this study suggest the additional measurement of either 
serum pyruvate kinase of haemopexin in combination with serum 
creatine kinase estimation will have little value in DMD carrier 
detection. 
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CHAPTER 1: INTRODUCTION 
1 -l. DEFINITION OF THE MUSCULAR DYSTROPHTES 
The muscular dystrophies represent a group of genetically inherited, 
myopathic disorders. All are characterised by their primary involvement 
of the voluntary muscles, which undergo progressive degeneration and 
necrosis. The disorders differ widely in their mode of inheritance as 
well as the age at onset of clinical symptoms and the rate of progression 
of the disease process. 
There are several forms of muscular dystrophy reported to have an 
X- linked, recessive inheritance. Of these the most severe form of 
muscular dystrophy, named after Duchenne (1868) and the more benign 
Becker type (Becker and Keiner 1955) have both been well characterised. 
The families described by Emery and Dreifuss (1966), Rotthauwe et al. 
(1972), Thomas et al. (1972) and others, may represent further forms of 
X- linked, recessive muscular dystrophy. 
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1-2. DUCH= MUSCULAR DYSTROPHY (DIíD) 
Duchenne muscular dystrophy (DID) is inherited in an X- linked 
recessive manner. DIM' occurs only in males but females with an abnormal 
X chromosome constitution may also manifest the disease. 
The locus (or loci) for DMD is considered to be present on the 
proximal part of the short arm of the X chromosome. However the nature 
of the specific gene defect involved is unknown. 
The incidence of the disease has been reported as 1 in 3,000 live 
male births. One third of these cases are considered to be new mutations 
(Emery, 1980). 
1 -2.1. Clinical Features 
Boys with DUD appear physically normal at birth. Although the 
disease can be diagnosed at the preclinical stage (by measurement of 
serum creatine kinase activity) usually clinical investigation is under- 
taken when the boy is 3 -5 years of age, following observations of 
unsteady walk, frequency of failing and difficulty climbing stairs. In 
the early stages of the disease proximal muscle weakness and wasting is 
apparent. Calf hypertrophy is an early feature. The waddling gait and 
Cowers manoeuvre (when standing up from the floor the boy "walks" up his 
legs with his arms) are characteristic. 
An elevated serum creatine kinase activity and /or the typical 
abnormal histology seen on muscle biopsy confirm diagnosis. 
Muscle weakness and atrophy progress relentlessly, Particularly in 
the proximal muscle groups although there is also involvement of the 
distal musculature. Dependant upon contractures and relentlessly 
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increasing weakness the affected boy becomes wheelchair- bound at 
approximately 10 years of age. Cardiac involvement is usually 
apparent at this stage. There is progressive skeletal distortion and 
eventually muscle weakness and thoracic deformity lead to chronic 
respiratory insufficiency. Death by the age of 16 -20 years is 
usually the result of a respiratory infection or cardiac failure. 
1 -2.2. Treatment 
As yet there is no effective treatment for DMD. Over the years 
many drugs have been used in clinical trials but despite occasional 
unconfirmed claims to the contrary no therapeutic agent has succeeded 
in arresting the dystrophic process. Since the nature of the gene 
defect is unknown, selection of specific_dug- have "mainly'been - 
based on hypotheses related to pathogenesis or on results observed in 
animal models. 
Drug trials in DMD patients are inherently difficult to undertake 
due,at least in part,to the erratic course of the disease and the 
difficulty of matching controls. Consequently many past trials have 
been considered to be of little value. Dubowitz and Heckmatt (1980) 
have critically assessed therapeutic trials in DMD. A standardized 
protocol for evaluation of potential DMD drug treatments has been 
established (Brooke et al., 1981). 
Therapeutic trials have involved the use of various amino acids, 
vitamins, anabolic and cortico- steroids, nucleotides, proteinase 
inhibitors and other agents. Most recent are those exploring the 
use of calcium antagonists. 
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1 -2.3. Antenatal Diagnosis 
Mahoney et al. (1977) first suggested using serum creatine kinase 
estimation of fetal blood, sampled in utero, in order to determine the 
homozygosity or normality of an "at risk" for DMD male fetus. (a fetus 
whose mother is a definite DMD carrier or has a high probability of being a 
D1FID carrier). Fetal serum creatine kinase activities in normal male 
fetuses have been measured (Emery, 1980). Elevated fetal serum creatine 
kinase values have been found in terminated "at risk" pregnancies where 
abnormal muscle hi.stology was also reported (Mahoney et al., 1977; 
Emery et al., 1979). 
Although Mahoney et al. (1977) and Dubowitz et al. (1978) have 
reported the birth of normal boys from "at risk" pregnancies where fetal 
serum creatine kinase activities were normal, sadly the birth of affected 
boys following measurement of normal levels of fetal serum creatine 
kinase (Ionasescu et al., 1978; Golbus et al., 1979) indicate the unreliabl 
nature of this test for antenatal diagnosis. 
The most promising technique with the potential of both detection 
of DIN carriers and antenatal diagnosis involves recombinant 
deoxyribonucleic acid (DNA) technology. This method permits the isolation 
of deoxyribonucleic acid sequences corresponding to the whole genome of 
a subject or the expressed sequences of a given cell type. Probes which 
are gene -specific are then used to study the consequence of genetic 
mutation. Deoxyribonucleic acid sequence polymorphisms can be used in 
the construction of a map of the human genome, allowing the development 
of a possible antenatal diagnostic test for DMD, even in the absence of 
an understanding of the biochemical lesion. The application of this 
technique to muscular dystrophy has been discussed by Jones (1980) and 
Housman (1983). Harper et al.(1982)reported the isolation of 3 human X 
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specific probes from a human X- chromosome specific library and the same 
group (Harper et al., 1983) have recently described the use of linked 
DNA polymorphisms for genotype prediction in families with DMD. 
1-2.4. Screenin 
The blood level of creatine kinase in DMD neonates is elevated in 
the absence of clinical symptoms. This finding has been exploited as a 
screening test for the detection of DMD neonates in the newborn male 
population. Zellweger and Antonik (1975) proposed that neonatal creatine 
kinase estimation should be carried out as a screening procedure for all 
male neonates. These authors discuss the complex ethical considerations 
involved in screening for DMD when no cure can be offered. Certainly 
supportive treatment can be started at an earlier age and parents would 
have the opportunity of planning for life with a future handicapped 
child. Perhaps more importantly, such a method might prevent second DIED 
cases in a family when the mother has been diagnosed as a carrier 
following the post -natal diagnosis of her DMD son. 
A recent report on neonatal screening by creatine kinase assay 
detected 12 cases of DMD (later confirmed by muscle biopsy) in a male 
neonate population of 71,091, an incidence of 1 in 5,924 (Dellamonica 
et al., 1983). 
Screening the female neonate population by creatine kinase assay as 
a method of DMD carrier detection has not, until recently been considered 
a viable proposition (due to lack of sensitivity of the technique). 
However, Nicholson and co- workers (1982) have reported a creatine kinase 
assay system which they propose has the required sensitivity for neonatal 
carrier detection. 
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1-3. PATHOGENF,SIS OF DiM 
The primary genetic lesion responsible for DND.has yet to be 
determined. Many attempts have been made to explain the pathogenesis 
of the disease. Three major hypotheses have emerged, two of Which (the 
vascular and neurogenic hypotheses) have been mainly discounted in 
favour of the membrane hypothesis. 
1 -3.1. Vascular Hypothesis 
The vascular hypothesis was formulated following the report by 
Démos (1961) of a decreased blood circulation time exhibited by DID 
patients. This led to the suggestion that the dystrophic process might 
be due to occlusion of the muscle microcirculation, causing chronic 
anoxia in areas of muscle and leading to necrosis. The injection of 
beads into the microcirculation of healthy experimental animals 
resulted in the artificial production of muscle lesions similar to 
those found in dystrophic muscle (Hathaway et al., 1970). However, there 
have been conflicting reports concerning blood flow in human dystrophic 
muscle (Bradley et al., 1975). Overall there is little evidence to 
suggest an ischaemic lesion is responsible for the progressive degener- 
ative changes Which occur in DMD. 
1 -3.2. Neurogenic Hypothesis 
McComas et al. (1971) considered the myopathic changes evident in 
dystrophic muscle might be due to some abnormality of the motor neurones - 
the "sick" motor neurone hypothesis. Analyses of motor neurones in DMD 
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patients demonstrated decreased numbers of motor units per muscle cell 
(McComas et al., 1974), disputed by Ballantyne and Hansen (1974) who 
reported normal numbers in Duchenne muscle. Furthermore Jerusalem et al., 
(1974) and Harriman, (1976) could find no abnormality in the motor end 
plates of dystrophic muscle by electron microscopy. 
The conflicting data reported have been discussed by Sica and 
McComas (1978). 
1 -3.3. Membrane Hypothesis 
The membrane hypothesis (reviewed by Rowland, 1980) developed 
following observations on the apparent "leakiness" of DMD muscle, 
with raised serum levels and decreased muscle levels of several 
muscle- residing enzymes. Aldolase was the first enzyme reported to be 
abnormally raised in Duchenne sera (Schapira et al., 1953). However 
it has been the elevated level of serum creatine kinase in DMD boys 
which has been used for diagnostic purposes due to its consistently 
raised level even in clinically asymptomatic newborn END cases (Heyck 
et al., 1966). 
The hypothesis considers that the degenerative muscle changes that 
occur in DMD are resultant of a genetic lesion which leads to an 
abnormal sarcolemma. The defective membrane may be the result of 
either a functionally or structurally altered protein. Rowland (1980) 
has discussed in detail the evidence implying a disturbance in sarco- 
lemmal integrity, both from the concept of a "leaky" membrane (functional 
abnormality) and the concept of physical interruptions in the sarcolemma 
(structural abnormality). Such interruptions or delta lesions have 
been found by electron microscopy (Mokri and Engel, 1975; Carpenter and 
Karpati, 1979). As Rowland (1980) points out both abnormalities may be 
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involved in the dystrophic process. Mokri and Engel (1975) have demons- 
trated an abnormal permeability of the muscle cell membrane to horse- 
radish peroxidase in the vicinity of the delta lesions. An abnormal 
permeability of Duchenne muscle fibres to Procian Yellow has also been 
found (Bradley and Fuithorpe, 1978). Schotland et al, (1977; 1980) 
demonstrated that the intramembranous particles demonstrated in muscle 
membranes by freeze -fracture analysis were decreased in number in DMD 
(confirmed by Shotton, 1982), suggesting an alteration in the molecular 
structure of Duchenne muscle membranes. 
1 -3.3i, Investigations on Non -Muscle Cells 
There is considerable evidence that the membrane abnormality which 
appears to be expressed in DMD affects not only muscle tissue but is a 
generalised membrane defect. Certainly recognition of the primary 
defect in DMD may be confounded by the variable muscle degenerative 
changes and the infiltration by both adipose and connective tissues in 
Duchenne muscle. This and technical reasons, such as the scarcity of 
human muscle biopsy material, led to the examination of non -muscle cells 
in order to assess the validity of this hypothesis. 
Many abnormalities have been reported in non -muscle cells from DMD 
patients, however it has been suggested that at least some of these 
abnormalities might be due to a circulating plasma factor (Siddiqui and 
Pennington, 1977; Lloyd and Emery, 1981) or be secondary changes result- 
ant from a basic biochemical defect (or defects) located elsewhere in 
the cell (Lucy, 1980). Non - muscle tissues investigated have included 
fibroblasts and several peripheral blood cell types, although mogt 
investigations have focused on the erythrocyte. 
Reports concerning the examination of cultured skin fibroblasts from 
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Duchenne patients have led to conflicting data. Wyatt and Cox (1977) 
reported abnormal inclusion bodies in fibroblasts from 4 DMD subjects 
not present in cells from 15 controls. This was disputed by Cullen and 
Parsons (1977) who examined fibroblasts from 4 DIM and 4.normal cell 
lines in a "blind' study and failed to find abnormal inclusions. 
Connolly et al. (1979) compared the organisation of microtubules from 
Duchenne and normal fibroblasts, considering a defect in the microtubule 
system might explain DIM membrane alterations, but they were unable to 
find differences between Duchenne and control cells. Jones and Witowski 
(1979) examined the collision efficiencies of Duchenne and control 
fibroblasts using a viscometer and reported the DMD fibroblasts to be 
less adhesive than normal cells. They suggested this phenomenon was 
possibly due to an altered surface membrane of the DMD cells. 
Using one -dimensional: polyacrylañide_gel electrophoresis (PAGE) 
Pena et al. (1978) reported no consistent abnormality in the protein 
patterns of Duchenne fibroblasts compared to control cells. Workers 
from the same group described the lack of a fibroblast protein 
(molecular weight approximately 56,000 daltons) in Duchenne cells using 
a more sensitive two -dimensional PAGE technique in combination with 
double -label autoradiography. This protein was reported to be 
consistently absent from Duchenne fibroblasts originating from 6 
patients, which were compared to 6 control cell lines ( Rosenmann et al., 
1982). However the difference between Duchenne and control fibroblasts 
in this study has very recently been determined as being due to a 
difference in skin biopsy site (Thompson et al. 1983). 
Gelman and co- workers (1980) reported a decreased activity of 
lysosomal dipeptidyl aminopeptidase I in DMD fibroblasts compared to 
fibroblasts from age and sex matched controls. They further reported 
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the catalytic function of this enzyme appeared to be unimpaired and 
that the decreased activity might be due to fewer molecules being 
present in the DMD cells, implying the DMD cells were metabolically 
altered. 
More recently this group have reported DMD lysosomal membranes 
have altered biochemical and morphological. characteristics (Gelman et 
al., 1981; Davis et al., 1982a). However, the significant alteration 
in dipeptidyl aminopeptidase I activities observed in DMD lysosomes 
were not found in lysosomes from 2 definite and 3 possible carriers 
compared to those from sex matched controls (Davis et al., 1982b). 
Kohlschutter et al: (1976) could find no abnormality in the 
phospholipid or fatty acid composition of DMD fibroblasts. Examining 
the stimulated turnover of phosphatidylinositol and phosphatidate in 
fibroblast cell lines from 3 DMD patients and 3 controls, Rounds et al. 
(1.980) found an increase in concanavalin A- induced phosphatidate 
labelling and a decrease in phosphatidylinositol labelling in the DMD 
cells (i.e. the rate of resynthesis of phosphatidylinositol from 
phosphatidate may be decreased in Duchenne fibroblasts). 
Statham and Dubowitz (1979) studied calcium exchange in 
fibroblasts using radioactively labelled calcium (45Ca) and found this 
process was similar in cultures from both Duchenne and control cell 
lines. 
Despite leucocytes being a relatively easily accessible tissue in 
which to demonstrate the hypothesised membrane defect in DMD, few 
studies have concentrated on them and most of these reports remain 
unconfirmed. However, considerable attention has been focused on the 
lymphocyte capping phenomenon first reported to be exhibited by both 
DMD patient and carrier lymphocytes by Verrill et al. (1977). 
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The biochemical basis of the capping process is not well 
understood but it may require normal fluidity and an adequate ATP 
supply (Verrill et al., 1977) and may involve actin, microfilaments 
and microtubles (Nicholson and Sugars, 1982). Verrill and co- workers 
(1977) reported decreased lymphocyte cap formation in both Duchenne 
patients and their mothers compared to normal male controls. Several 
workers reported similar findings (Bader,4979;,n et:al., 
1980; Horenstein and Emery, 1980) whilst others could not find this 
abnormality, including Nicholson and Sugars (1982) who reviewed all 
the reports and suggested discrepancies could have arisen due to 
methodological differences and /or due to the use of controls which 
were unmatched with regard to age or.sex, since they found cap 
formation to increase with increasing age. 
Scholte and Busch (1980) investigated several leucocyte enzymes 
in both DMD patients and carriers in order to test the integrity of 
the,.p asma--membrane and cytosolic,'components --Whilst 5'_7.nuzcleotidase 
activity (located on the plasma membrane) was reported to be 
increased in Duchenne leucocytes, cytosolic enzymes were not 
significantly altered in DMD patients)but phosphorylase activity was 
found to be significantly decreased in DMD carriers. Four of 7 
definite carriers (57%) exhibited decreased phosphorylase activity 
whilst only 2 of 7 (28 %) had elevated serum creatine kinase levels. 
Hausmanowa- Petrusewicz et al. (1980) measured DMD carrier 
.leucocyte triglycerides, total lipids, malate dehydrogenase and 
palmitate oxidation in a pilot study. All measurements except 
palmitate oxidation were reported to improve carrier selection over 
that obtained using serum creatine kinase carrier assessment alone. 
There have been two unconfirmed reports relating to possible 
Duchenne platelet abnormalities. Murphy et al. (1973) found both a 
significantly decreased initial rate of serotonin 
140 
uptake in DMD 
platelets and a slightly decreased serotonin level. Démos (1973) 
reported decreased diphenoloxidase activity in platelets from patients 
with DMD and DFT carriers. The significance of these reported 
abnormalities remains unclear. 
A vast number of morphological, biophysical and biochemical 
characteristics of Duchenne erythrocytes havé been investigated. In 
some cases both interpretation of reported abnormalities and 
confirmation of these studies have been made more difficult due to 
the lack of standardisation of preparationaJ procedures. 
Erythrocyte shape alterations are known to occur in certain 
disease processes. Following a report by Morse and Howland (1973) 
describing surface alterations in dystrophic mice erythrocytes using 
scanning electron microscopy (SEM), Matheson and Howland (1974) 
investigated the surface morphology of erythrocytes from patients 
with congenital muscular dystrophy and (3) DMD carriers. These 
authors reported the in vitro formation of a large proportion 
(between 20 -98%) of distorted erythrocytes -- termed echinocytes 
(Bessis, 1973) in DMD erythrocytes visualised by both light 
microscopy and SEM. Between 34-39% echinocytes were found in the DMD 
carriers compared to approximately 3% in controls. 
Lumb and Emery (1975) investigated a larger series of DMD 
patients and carriers and confirmed the light microscopy findings of 
Matheson and Howland (1974). However Lumb and Emery (1975), Miale 
et al. (1975) and Tagliavini et al. (1979) considered echinocyte 
measurement would have little value in DMD carrier detection. 
Subsequently Matheson et al. (1976) reported an inability to confirm 
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the findings of Matheson and Howland (1974) and expressed doubts as 
to the reproducibility of the procedure. Solton (1977) could 
find no significant erythrocyte shape abnormalities in DMD cells. 
In a "double blind" study in which erythrocytes were not pre- 
treated prior to fixation Miller et al. (1976) described an increased 
but variable percentage of abnormally shaped erythrocytes -- termed 
stomatocytes (Bessis, 1973) in DMD patients and carriers by SEM. 
Wakayama et al. (1978) found a decreased density of intra- 
membranous particles in DPW erythrocytes, evidence in favour of a 
generalised membrane defect in DMD. However Lloyd et al. (1981.) in a 
"blind" study (using glycerol as fixative) could not confirm this 
report, finding no significant difference in the total number of 
intramembranous particles in DMD patients or controls and suggesting 
the gluteraldehyde fixative used by Wakayama et al. (1978) may 
decrease the intramembranous particle count. 
Measurements of the viscoelastic properties of erythrocyte 
membranes were carried out by Percy and Miller (1975) who reported 
both DMD patient and carrier erythrocytes demonstrated a decreased 
deformability. This was confirmed by Brain et al. (1978) and Nash and 
rivard_ (1982) but disputed by Somer et al. (1979), who could find no 
significant differences in membrane deformability (by either 
microsieving or from flow channel measurements) between Duchenne and 
control erythrocytes. 
Butterfield (1977) examined the physical-state of the 
Duchenne erythrocyte membrane by electron spin resonance spectroscopy 
(ESR) and found an increased ESR spectral amplitude ratio in these 
membranes. The abnormal ESR produced by DMD erythrocyte membranes 
has been confirmed by other workers using different spin labels 
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Sato et al., 1978; ',c`ilkerson et al., 1978; Laurent et al., 1980). The 
observed abnormalities of the ESR could result from alterations in 
either protein or lipid conformation or organisation or, as suggested 
by Lucy (1980), be consistent with increased rigidity of the Duchenne 
erythrocyte membrane. 
Bosmann.et al. (1976) reported the electrophoretic mobility of 
Duchenne erythrocytes to be increased compared to the electrophoretic 
mobility of control cells, indicating DMD erythrocyte membrane surfaces 
were more negatively charged than corresponding control membranes. 
This altered electrokinetic property could be attributed to either a 
redistribution of negatively charged sites or to an absolute increase 
in sialic acid components of the erythrocyte surface. 
Fisher et al. (1976) reported an increased osmotic fragility 
exhibited by Duchenne erythrocytes compared to control cells. Adornato 
et al. (1977) did not support this finding, but Lloyd and Nunn (1978), 
Somer et al. (1979) and Ruitenbeek et al. (1979) have confirmed the 
report of Fisher and his colleagues. The increased osmotic fragility 
of Duchenne erythrocytes is indicative of an altered membrane 
organisation in these cells. Danieli and Marchesini (1980) found 
adenosine triphosphate (ATP) depletion enhanced the abnormal osmotic 
response of DMD erythrocytes. These authors found the mean rate of 
haemolysis of ATP depleted erythrocytes to be greater in 4 definite DND 
carriers compared to that of 37 controls and suggested 53% of their 
possible carrier series investigated would have been classed as 
heterozygotes (taking the maximum control value as cut -off). This 
method, if confirmed may be a valuable carrier detection test. 
The lipid composition of the erythrocyte membrane was first 
reported to be altered in muscular dystrophy by Kunze et al. (1973). 
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However many reports since then have yielded conflicting data on both 
the phospholipid and neutral lipid composition of the Duchenne 
erythrocyte membrane. These reports have been reviewed in detail by 
Plishker and Appel (1980) who consider part of the discrepancy might 
have resulted from auto -oxidation and from other deficiencies in 
experimental design. Overall Plishker and Appel suggest there are no 
major alterations in the predominant membrane lipids in DMD erythrocytes. 
Howland and Iyer (1977) reported a significant decrease in 
palmitoleic acid in both DMD and DMD carrier erythrocyte membranes. 
However other workers could find no difference in erythrocyte 
palmitoleic acid content in either DMD subjects (Plishker and Appel, 
1980) or in DMD carriers (McLaughlin and Engel, 1979) compared to. 
controls. 
Several erythrocyte membrane enzymes have also been examined in 
DMD. Brown et al. (1967) observed that ouabain, which inhibits the 
rate of ATP hydrolysis by adenosine triphosphatase ( ATPase) in normal 
erythrocytes, stimulated Duchenne erythrocyte ghost ATPase. Peter et 
al. (1969); Araki and Mawatari (1971); Niebroj -Dobosz (1976) and 
Pearson (1978) also found stimulation of the DMD ATPase by ouabain. 
Another positive affect, decreased inhibition of the ATPase of DMD 
erythrocyte ghostsby ouabain, has been reported by others (Mawatari 
et al., 1976; Siddiqui and Pennington,(1977) whilst a negative effect 
(inhibition to a normal extent)was reported by Hodson and Pleasure 
(1977); Souweine et al. (1978) and Ruitenbeek, (1979). The highly 
variable results obtained may be explained at least in part as being 
due to sub -optimal assay conditions used in some experiments and 
differences in erythrocyte ghost preparation. Plishker and Appel 
(1980) suggest the variable results might demonstrate a membrane 
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abnormality influenced by erythrocyte ghost preparation rather than an 
abnormality of the ATPase. The activity of the calcium- stimulated- 
magnesium -dependent ATPase in Duchenne erythrocytes has been discussed 
in 2-1.2. 
Mawatari et al. (1976) first reported that the stimulation of 
erythrocyte membrane adenylate cyclase by epinephrine that occurred in 
normal erythrocytes did not occur in Duchenne cells. Wacholtz et al. 
(1979) also found DMD erythrocyte membrane adenyl cyclase to be 
insensitive to epinephrine. However Fischer et al. (1978) found no 
epinephrine stimulation in normal cells. Rowland et al. (1980) 
suggested adenylate cyclase activity_ may have been partially inhibited by 
the use of theophyline (to block phosphodiesterase action) in the assay 
used by Fischer et al. 
A high endogenous phosphorylation of spectrin band II was reported 
in erythrocyte membranes from Duchenne patients (Roses et al., 1975) 
and DMD carriers (Roses et al.,1976a) compared to control erythrocytes. 
1- 3.3.ií. Involvement of Calcium 
It has been suggested that a membrane abnormality which allows 
leakage of muscle- residing enzymes at an early stage of the disease 
process may also permit the ingress of calcium (via the extracellular 
fluid) leading eventually to cell necrosis (Wrogemann and Pena, 1976; 
Oberc and Engel, 1977). Excessive accumulation of calcium within 
muscle fibres could lead to myofibrillar overcontraction; activation 
of calcium sensitive proteases (which will in turn damage the myofibrils) 
and inhibition of protein synthesis. 
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An uncontrolled influx of calcium would lead to mitochondria) 
calcium sequestration and a subsequent diversion from ATP formation 
thereby decreasing the energy supply to the calcium pumping mechanism 
of the muscle cell membranes and resulting in intracellular calcium 
overload (Wrogemann and Pena, 1976). Certainly ultrastructural studies 
have shown an increased calcium precipitation in mitochondria, nuclei 
and sarcoplasmic reticulum of dystrophic fibres (Oberc and Engel, 1977). 
Also, in other cell systems where membrane injury brings about cell 
necrosis and death the influx of calcium has been required for the 
effect (Schanne et al., 1979). The decreased uptake of calcium by 
DMD sarcoplasmic reticulum (Samaha, 1977; Wood et al., 1978) could 
result in an elevated intracellular calcium concentration (Cullen and 
Mastaglia, 1980). By inducing necrosis experimentally in normal 
muscle in vitro (using nerve stimulation in the presence of 
acetrlcholinesterase inhibitor) Leonard and Saltpeter (1979) suggested 
the necrotic changes produced were mediated through acetylcholine - 
induced calcium influx, implying similar changes in Duchenne muscle 
might result from a calcium -overloaded sarcoplasmic reticulum. 
Experimental evidence implicating a role for calcium in the 
dystrophic process has been discussed for muscle in 2 -1.1. and for 
erythrocytes in 2 -1.2. 
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1 -4. GENETIC COUNSELLING 
Without, as yet, an effective treatment for DMD, genetic 
counselling of females "at risk" of carrying the disease must aim 
to prevent the birth of affected boys. 
Such "at risk" females will be counselled on the probability 
of their having an affected boy, based on pedigree and biochemical 
data (see Emery 1980). They will be offered advice on contraception. 
If the decision to go ahead with a pregnancy is made then 
amniocentesis for fetal sexing can be offered, with resultant 
selective abortion of a male child, pregnancy with a female child 
being allowed to go to term. 
Clearly this is a most unsatisfactory situation since only 
50% boys aborted will have DMD. Also up to 50ó daughters born 
will be carriers of DMD who may, in turn, transmit the disease to 
their children. 
1-5. CLASSIFICATIOAT OF DMD C.4RRIERS 
Transmission of the X- linked, recessive DMD gene is through 
female carriers. DMD carriers are normally cl assified by genetic 
evidence in the following way: 
(1) Definite carriers 
(2) Probable carriers 
(3) Possible carriers 
Definite carriers are mothers of one (or more) DMD son(s) who 
also have either an affected brother(s) or other affected male 
relative(s) through the female line 
Probable carriers are mothers of two (or more) DMD sons who have 
no other family history of the disease. Probable carriers are considered 
almost certainly to carry the DAD gene (Bayesian analysis). Theoretically, 
however, the DAD sons of a probable carrier could be the result of a 
new mutation during embryogenesis. 
Possible carriers are either mothers of one DMD son (but with no 
other family history of the disease) or sisters of DMD boys. 
Much greater difficulty lies in assessing the true carrier status 
of the possible carrier since 1/3 of DMD cases are considered to be 
new mutations occuring during the boys embryogenesis. 
A genetic carrier of DAD has a 505 probability of producing an 
affected son and the same probability of giving birth to a carrier 
daughter. Recognition of DMD carriers is therefore of great 
importance in order to enable genetic counselling to be given. 
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1 -6. DMD CARRIER DETECTION 
Many of the abnormalities seen in DMD have been found to a less 
severe extent in DMD carriers. The measurement of these abnormal 
parameters forms the basis of DMD carrier detection work. 
A small percentage of women who carry the gene for DMD show 
clinical muscle wasting and weakness to a varying degree but others 
are apparently clinically normal. The most sensitive method of DMD 
carrier recognition (serum creatine kinase estimation) can detect up 
to 70% of heterozygotes. However, there is considerable overlap 
between levels in the carrier and control populations. The great 
variability in expression of heterozygosity can be explained in terms 
of random X chromosome inactivation (Lyon, 1962). 
The Lyon hypothesis considers the inactivation of either the 
maternally or paternally derived X chromosome occurs entirely randomly 
early on in fetal life. That once inactivated the situation is 
irreversible and all subsequent cells derived from the original will 
exhibit the same inactivated chromosome. Following the inactivation 
process a female's cells will consist of a mosaic reflecting the 
X- chromosome pattern present during embryogenesis. Only the germ cells 
escape inactivation. 
1 -6.1. Clinical Symptoms 
Moser and Emery (1974) estimated approximately 8% DMD carriers 
exhibit clinical symptoms, ranging from pseudohypertrophy of the calf 
muscles to overt muscle wasting and weakness. 
Using manual muscle testing Roses et al. (1976b: 1977a) found 
muscle weakness in a high percentage of female relatives of DMD patients. 
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-6.2. Investigations :on Muscle 
The pathological changes that occur in Duchenne muscle have been 
well characterised (see Cullen and Mastaglia, 1980) and may be used 
diagnostically. There have been reports of muscle biopsies from some 
DMD carriers exhibiting similar pathological features (but to a variable 
and milder degree) using light (Dubowitz, 1963; Emery, 1963, 1965a) 
and electron microscopy (Milhorat et al., 1966; Roy and Dubowitz, 1970; 
Afifl et al., 1973). Often, however, workers have expressed difficulty 
in interpreting the significance of the minimal changes seen in some 
biopsies. iiaunder -Sewry and Dubowitz (1981) have attempted to quantify 
the pathological features shown by Duchenne carrier muscle to aid such 
interpretation. Interestingly, carriers demonstrating pathological 
muscle alterations but possessing normal serum creatine kinase levels 
have been reported (Roy and Dubowitz, 1970). Fur,er work on carrier 
muscle related to calcium measurement has been discussed in Section2 -1.1 
Quantitative electromyography (EMG) has been used. in carrier 
detection with varying degrees of success (Gardner- Nedwin, 1968; 
I:ioosa et al., 1972; Valli et al., 1976) . Some authors believe the 
technique to be capable only of distinguishing DMD carriers from 
controls as a group and to be of little value in individual cases 
(Rausma n0wa-Petruse icz et al., 1977) . Overall more studies are 
necessary to assess fully the usefulness of this essentially complex 
method of carrier detection. 
Using muscle biopsy material, muscle protein turnover was examined 
first in 10 DiID carriers (lonasescu et al., 1971) then in larger series 
1 al., 19 ".975 ; ' -976) . In each of these of DMD carriers (on.s,.Jcu e .._ . , , 7a ,
studies an increased in vitro amino acid incorporation by polyribosomes 
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was found in a very high percentage of DMD carrier samples compared to 
controls in 46/47( 97.8 %) definite and 47/87 (54 %) possible carriers 
in the 1976 study). Several carriers with a normal creatine kinase level 
were reported to have an increased polyribosomal amino acid incorporation. 
The method has been suggested as an adjunct to routine carrier detection 
work (Ionasescu et al., 1975). However Tomkins et al. (1982) reported 
both in vitro muscle protein and ribonucleic acid incorporation in DMD 
carrier muscle to be normal. 
Monkton et al. (1981) compared the in vitro uptake of tritiated 
leucine in single muscle fibres of muscle biopsies from DMD carriers 
(3 obligate and 11 possible) and 10 controls. All 3 obligate carriers 
and 7/11 (36 %) possible carriers were reported to have an abnormally 
increased uptake of tritiated leucine into some muscle fibres, consistent 
with heterozygote mosaicism. However increased leucine uptake could be 
due to muscle fibre regeneration resulting from injury other than that 
due to the dystrophic process, as stated by Monkton et al. (1981). This 
preliminary study awaits confirmation. 
1-6.3. Investigations on Body Fluids 
Altered serum levels of many muscle- specific proteins have been 
reported in patients with DMD (discussed in detail by Pennington, 1980) 
consistent with the concept of a "leaky" membrane (see 1- 3.3.). Raised 
serum levels of such proteins in DMD carriers are thought to be resultant 
of the population of dystrophic muscle fibres within the Lyonised carrier 
muscle. This would at least partially explain the extremely wide range 
of serum protein levels obtained within the carrier population, even in 
the case of serum creatine kinase activity, the most reliable and 
routinely applied carrier detection test (Emery, 1980). Interpreting 
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raised serum creatine kinase activity as indicative of carrier status 
results in approximately 70% genetic carriers being identified. The 
remaining 30% with normal serum creatine kinase levels could 
conceivably have (following Lyonisation) too few dystrophic muscle 
fibres to result in an abnormal serum level of this enzyme. As the 
widely accepted most sensitive method of carrier detection, considerable 
irork has been done in attempts to improve the sensitivity of serum 
creatine kinase estimation (discussed fully in Chapter 3). 
Leyburn et al. (1961) investigated serum levels of aldolase, 
glutamic oxalacetic transaminase and glutamic pyruvic transaminase in 
a series of DMD carriers and controls but found no significant 
difference in the levels of these enzymes in the two groups. 
Emery (1964) examined the isoenzyme patterns of lactate 
dehydrogenase (LDH) in both DMD carrier muscle and sera. Whilst the 
level of the isoenzyme LDH -5 was decreased in carrier muscle, serum 
LDH isoenzymes were not significantly different in carriers and controls. 
Roses et al. (1977) reported serum LDH-5 measurement to be a better 
indicator of carrier status than serum creatine kinase estimation. 
This was disputed by Burt and Emery (1979) who found LDH -5 selected 0/6 
(0%) and 1/22 (5%) definite and possible DMD carriers respectively, 
compared to 4/6 (67%) and 6/22 (27 %) selected by serum creatine kinase. 
Serum pyruvate kinase measurement has also been investigated as a 
method of carrier detection following the reports of Alberts and Samaha 
(1974). Work relating to this enzyme has been discussed in Chapter 4. 
Various combinations of serum enzymes have also been investigated 
(Chapter 7). 
Studies involving the serum proteins haemopexin and myoglobin have 
been discussed in Chapters 5 and 6, respectively. 
The urinary excretion of creatine relative to creatinine has been 
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shown to be raised in many muscle wasting conditions, including DMD. 
The altered urinary composition is considered to be due to the decreased 
muscle uptake of creatine resulting in creatinuria and decreased 
creatinine excretion. Leyburn et al. (1961) examined the creatinejfreatinine 
ratio in the urine of a series of DMD carriers and controls but found the 
mean ratios were not significantly different comparing the two groups, 
confirmed by Maskrey et al. (1979). Maskrey and co- workers (1979) also 
reported no significant difference in the mean molar ratio of the amino 
acid 3- methylhistidine relative to creatinine (considered to represent 
the in vivo rate of myofibrillar protein catabolism) in their series of 
11 carriers and 10 controls. 
Frearson et al. (1981), using two dimensional electrophoresis, 
reported the presence of additional protein spots (named C and D) on the 
urine electropherograms of DMD patients. Spot C was variably present 
in urine samples from 12/21 (57iß), and spot D from 3/21 (l4ó) definite 
DMD carriers. Spot C (molecular weight 26,000 daltons) was also present 
in urine from patients with other neuromuscular diseases and in a small 
percentage of controls. Frearson et al. (1981) consider spot C to be a 
non -specific indicator of muscle damage and suggest its possible use in 
carrier detection work particularly in pregnant women where serum 
creatine kinase estimation becomes unreliable. 
-24- 
1 -6.4. Other Methods 
Non -muscle cell membrane abnormalities reported in DMD carriers 
have been discussed in Section 1- 3.3.íi. 
Abnormal electrocardiograms (ECG) with patterns similar to the 
Duchenne ECG have been reported in 3/18 (16%) DMD carriers (Mann et al., 
1968) but are considered rare (Lane et al., 1980). Other ECG 
abnormalities have been found in comparison of carrier and control 
groups, including an increased amplitude sum (R -S) in lead V1 (Emery, 
1969a; Lane et al., 1979). In a sizable series (31 DIN carriers and 
112 normal women), Lane et al. (1980) reported electrocardiographic 
abnormalities and a lack of correlation between ECG and serum creatine 
kinase activity in the carrier group, implying the possible value of 
including ECG measurements in carrier probability calculations. 
Whilst ECG has the appeal of being a non -invasive procedure with 
routine application in other fields, several tests suggested as methods 
of carrier detection involve complex and technically exacting 
procedures not easily applied. The measurement of limb blood flow and 
estimation of whole body potassium and rubidium half -life fall into this 
category. DOmOs et al. (1962) reported DMD carriers to have a decreased 
peripheral circulation time. However, Emery and Schelling (1965) could 
find no significant difference in limb blood flow in Duchenne carriers 
and controls. 
A significantly decreased total body potassium level in DMD 
patients and carriers compared to controls was reported by Bland et al. 
(1964; 1967) and Nagai et al. (1969) who found a decreased whole body 
potassium level in 4/15 (37%) fathers of patients as well. Nagai and 
co- workers (1969) also reported an altered metabolism (a decreased 
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half -life of rubidium chloride (86ßb) in a small series of DMD carriers. 
Bradley et al. (1971) was unable to confirm either finding and 
considered neither of value in carrier detection. 
Stephens et al. (1.980) examined one effect of exercise on the 
metabolic response of DMD carriers. The maximal work capacity of the 
carriers and their age matched controls was determined using a cycle 
ergometer. No significant abnormality of either the dynamic or 
metabolic exercise response was found in the Duchenne carriers compared 
with the controls) although the maximal work capacity of the carrier 
group was slightly decreased. 
More recently Stephens et al. (,.982) reported a small increase in 
collagen type III in the muscle of some carriers; the increase could 
have resulted from connective tissue infiltration or, as Stephens 
suggests, may be indicative of a primary role of collagen in DED . 
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CHAPTER 2: CALCIUM 
2 -1. INTRODUCTION 
The current routinely applied method of carrier detection, the 
estimation of serum creatine kinase activity, relies on the abnormal 
leakage of the enzyme from carrier muscle. However, such measurements 
are secondary phenomena and may be far removed from the primary lesion. 
The possibility of attaining a detection rate approaching 100% genetic 
carriers may only reside in either the demonstration of cellular 
mosaicism or the méasurement of some abnormality directly resultant of 
the primary defect. 
There is increasing evidence to imply that intracellular calcium 
may play an important role in the dystrophic process. There have been 
reports of increased intracellular calcium levels and altered calcium 
transport properties in DHD cells. 
2 -1.1. Calcium in Duchenne Muscle 
Cullen and. 4ulthorpe (1975) postulated that an abnormal influx of 
calcium through the sarcolemma of Duchenne muscle might be responsible 
for some of the morphological changes characteristic of the disease. 
Bodensteiner and Engel (1978) investigated a large series of 
muscle biopsies and found non -necrotic, large -dark fibres 12 times more 
frequently in DFID than in other neuromuscular disorders. In the 
Duchenne biopsies 43% of the eosinophilic (large -dark) fibres exhibited 
increased intracellular calcium when treated with calcium stains. 
Emery and Burt (1980) succeeded in demonstrating a significant increase 
in the proportion of eosinophilic, increased -calcium- content fibres in 
muscle from male fetuses at risk of DMD. Since the calcium- positive 
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fibres appeared in advance of the gross changes evident in DMD muscle 
at a later stage it was concluded that such fibres must represent a 
very early structural alteration. Consequently the increased 
intracellular calcium level may represent an early biochemical change 
in the disease. 
Bertorini et al. (1982) combined a histochemical study of calcium - 
positive fibres in Duchenne muscle with chemical analysis. Using 
atomic absorption spectrophotometry these authors found the calcium 
content of DMD muscle was 50% higher than that of controls. No 
relationship was evident between the number of calcium positive fibres 
demonstrated histochemically and the actual calcium content in 6 DAN 
patients. The calcium leve]. in Duchenne muscle did not decrease with 
patient age, further evidence that increased intracellular calcium 
occurs early in the disease process. 
Using the extremely sensitive technique of electron probe X -ray 
microanalysis (EPXMA) Maunder et al. (1977) found a consistent elevation 
of the calcium to phosphorus ratio in interstitial cell nuclei in 
Duchenne muscle and in myonuclei in both DMD and DMD carrier muscle 
(Maunder - eirry and Dubowitz, 1979). This group confirmed the increased 
amount of calcium in Duchenne muscle using X-ray fluorescence 
spectrometry (I1aunder -Sewry et al., 1980). 
Normal mammalian muscle loaded with calcium in vitro has been found 
to exhibit a similar pattern of calcium accumulation as that seen in 
degenerating muscle, using increased calcium in the buffer and 
measurement by EPXMA (Oberc and Engel, 1D77) and by use of the calcium - 
specific ionophore A23187 (Publicover et al., 1978). These observations 
led Oberc and Engel (1977) to propose that in pathologically altered 
muscle fibres a damaged plasmalemma results in an influx of calcium, 
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accumulation of the ion by organelles and resultant calcification,leading 
to structural damage and decreased functional ability. 
Following the report by Busch et al. (1972) of a calcium activated 
sarcoplasmic protein factor in normal mammalian muscle which 
preferentially attacks Z bands, a significantly increased activity of 
calcium activated neutral protease (CANP) was found in Duchenne muscle 
(Kar and Pearson, 1976). CAMP and possibly a calcium activated serine 
protease were shown to decrease troponin I and C (a very early event in 
muscle cell degradation) in normal mammalian muscle (Ebashi and Sugita, 
1979). These observations led to the suggestion that intracellular 
calcium in Duchenne muscle reaches a level sufficient to activate CANP, 
resulting in myofibrillar overcontraction and disassembly and 
eventually cell necrosis (Cullen and Mastaglia, 1980). It has also been 
suggested that the intramembraneous particles demonstrated in muscle 
membranes by freeze -fracture analysis and present in reduced numbers 
in DMD muscle (Schot'.and et al., 1977) might be decreased in DIM due to 
the action of calcium activated proteases in this tissue (Lucy, 1980). 
Calcium dependant proteolysis has, very recently, been reviewed by 
Ishiura (1983). 
However, the increased protein breakdown seen in Duchenne muscle 
has been considered to be mediated through Prostaglandins (Horrobin 
et al., 1978; Rodemann et al . , 1982) . Using rat, skeletal, muscle 
treated with ionophore A23187 (to increase the intracellular calcium 
concentration) Rodemann and co- workers (1982) found the calcium induced 
proteolysis was not decreased in the presence of CAN? inhibitors. But 
protein breakdown in ionophore- treated muscle was decreased both in the 
presence of lysosomal protease inhibitors and prostaglandin synthesis 
inhibitors. 
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Abnormalities of calcium homeostasis in Duchenne muscle could also 
result in the abnormal release of muscle enzymes (a consistent feature 
of DIID). An increased efflux of both creatine kinase and lactate 
dehydrogenase have been observed in normal human skeletal muscle 
in vitro upon raising the calcium level of the incubating medium 
(Anand and Emery, 1980). The accelerated enzyme efflux could be 
partially reversed upon addition of Verapamil (a calcium blocker 
thought to inhibit the transmembrane influx of calcium) to the bathing 
medium (Anand and Emery, 1982). 
Few studies have centred on calcium transport in Duchenne muscle. 
Samaha (1977) reported a decreased uptake of calcium by the sarcoplasmic 
reticulum in DMD muscle. Yagiela and Benoit (1979) found that 
treatment of normal skeletal muscle with quinidine (a drug thought to 
inhibit calcium binding to the sarcoplasmic reticulum and inhibit 
mitochondria) calcium uptake and storage) resulted in muscle degeneration 
which was reversed in the presence of Verapamil. 
2 -1.2. Duchenne Erythrocyte Calcium 
The potential significance of the involvement of calcium in the 
dystrophic process in muscle and the increasing evidence pointing to a 
generalised membrane defect have led to the examination of calcium 
homeostasis in DMD erythrocytes. 
Many of the erythrocyte abnormalities in DMD (discussed in Chapter 
I) are consistent with an increased intraerythrocytic calcium content 
or an altered sensitivity of Duchenne erythrocytes to calcium. Several 
of these abnormalities have been reproduced in normal erythrocytes by 
artificially increasing the intraerythrocytic calcium level, including 
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decreased deformability (Weed et al., 1969); increased potassium efflux 
(Dise et al., 7.977); increased echinocyte formation (White, 1.974) and 
decreased osmotic fragility (Dise et al., 1977) . 
Calcium fluxes in Duchenne erythrocytes have been :examined. 
Mollman et al. (1980) found calcium was transported at' a faster rate by 
DMD erythrocytes inside -out vesicles, compared to controls but also 
found the transport protein of the ion to have a decreased affinity in 
the Duchenne cells. .Shoji (1981), however, reported both the influx 
and efflux rates of calcium to be similar in both Duchenne and age - 
matched control intact erythrocytes. 
A significant finding which suggests DIM erythrocytes may be 
attempting to correct an increased intracellular /eve/ of calcium 
involves the report of an increased activity of calcium -stimulated- 
magnesium- dependant adenosine triphosphatase (Ca2 +- stimulated Mg2~- 
dependant- ATPase). Hodson and Pleasure (1977) reported ah - 
increased activity of this enzyme in Duchenne erythrocyte membranes 
compared to controls, as did Luthra et al. (1979). Luthra and co- 
workers extended the investigation to include a study of a cytoplasmic 
activator protein factor present in erythrocytes (calmodulin) which 
stimulates Ca 
2± 
-stimulated Mgt -dependant -ATPase, but could find no 
evidence that the activator was altered in Duchenne cells. Ruitenbeek 
(1979) confirmed the increased activity of Ca2T- stimulated Mg2T- 
dependant ATPase in DIM erythrocytes but found no significant alteration 
in the affinity of this enzyme for calcium in Duchenne cells. 
Hausmanowa- Petrusewicz et al. (1977) reported a significantly increased 
mean activity of Ca2+- stimulated Mg2T- dependant -ATPase in erythrocytes 
from a series o.f 24 DMD carriers compared to 10 female controls. 
A recent report which does not agree with the above findings is 
that of Johnsson et al. (1983) who studied a small series of 13 DMD 
patients and 7 normal control boys. Despite using an experimental 
procedure designed to preserve calmodulin, these authors found Ca2,-- 
stimulated Mg2+- dependant- ATPase activity was not significantly different 
comparing the two groups. 
2 -1.3. E ythroyte Calcium Measurement 
- -. Normal erythrocytes contain a very l.oir level of calcium which, at 
equilibrium, comprises of calcium bound to the membrane, calcium bound 
to cytoplasmic buffers and ionised calcium in the aqueous phase. 
Calcium, thought to be at an intracellular concentration of less than 
10 
-6M 
( Schatzmann, 1975), is maintained at a low level due to the 
impermeability of the erythrocyte membrane to this ion (Ferriera and 
Lew, 1.976) and to the active extrusion of intracellular calcium by a 
powerful calcium pump, the Ca2T- stimulated Mg ' -dependant- ATPase 
(Schatzmann and Vincenzi, 1969). An increase in free intraerythrocytic 
calcium accelerates the pump mechanism in such a way that a two fold 
increase in calcium concentration leads to a six fold increase in 
pumping, whilst a ten fold increase in calcium concentration accelerates 
the pump seventy fold. The cytoplasmic activator protein calmodulin 
also interacts with this pump to regulate physiological calcium levels 
(Cox et al., 1982). 
Estimates of intraerythrocytic calcium have been seriously 
hindered by the extremely low level of calcium present within 
erythrocytes which are surrounded by plasma containing a considerably 
greater level of calcium. Techniques devised in attempts to overcome 
these problems have mainly involved artificially increasing the 
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the intraerythrocyticcalcium pool, for example by disrupting the 
erythrocyte membranes and incorporating calcium buffers or by the use 
of ionophores (Bookchin and Lew, 1980; Simons, 1982). None of these 
methods offer the possibility of measuring calcium in individual 
erythrocytes. If, as evidence suggests, DMD erythrocytes contain an 
increased calcium level, and if the raised intraerythrocytic calcium 
content is related to the primary defect then the measurement of calcium 
in individual erythrocytes from a genetic carrier of DMD may demonstrate, 
according to the Lyon hypothesis, (Lyon, 1962) two erythrocyte 
populations; a normal population and a population manifesting an 
increased level of calcium. To investigate this possibility, relative 
intraerythrocytic calcium levels were compared by use of fluorescent 
stains. Electron probe X-ray microanalysis (EPXMA) was employed to 
give a quantitative assessment of individual intraerythrocytic calcium 
levels. 
2 -1.4. Electron Probe X -Ray Microanalysis (EPXMA) 
The technique of EPXMA is essentially a non -destructive method 
which can be applied to the localization and identification of chemical 
elements intracellularly. Qualitative and quantitative elemental 
analysis can be carried out using either a scanning or transmission 
mode electron microscope and is based on the measurement of the 
resultant x- radiation produced following excitation of the sample by an 
electron beam. X -ray spectra produced fall into two categories; 
characteristic and continuous. The characteristic x -ray spectrum of 
each element involves the emission of an x -ray spectrum of discrete 
spectra, lines with wavelengths characteristic of that element and with 
-33- 
intensities related to elemental concentration. Such x -rays are 
emitted when incidence electrons (from the electron beam) expel 
electrons from the inner orbitals of the atoms in the specimen and 
electrons from orbitals further out fall into the vacancies. For a 
given element the characteristic x -rays, since they have the same energy, 
form a group, resulting in a peak in the spectrum of emitted x -rays. 
Each element has more than one characteristic peak. However, only the 
K a peak (resulting from an L shell to K shell electron transition 
within the atom) and the I: 
ç 
peak of higher energy but lower amplitude 
(resulting from an M shell to IC shell transition) are of importance 
when considering the elements potassium and calcium.- 
In the x -ray spectrum potassium Kç,and. calcium K a peaks overlap. 
The considerably higher potassium content in the erythrocyte compared 
to calcium results in interference from potassium Kf,counts in the 
channels set for calcium K,;measúrements. Therefore, preparative 
techniques retaining both ions were unsuitable for this study. 
The continuous x -ray spectrum consists of a continuous band 
of wavelengths starting with a minimum wavelength, rising to a peak 
(maximum intensity) then falling in intensity at longer wavelengths. 
The continuum is generated when the incident electrons undergo 
incremental deceleration in the specimen. The continuous x -rays form 
the background in the x -ray spectrum and can be used in the estimation 
of the specimen mass. The peak /background ratio (P /B ratio) of an 
element (the ratio of characteristic to continuous x -rays) is employed 
to indicate the mass concentration of that element in the specimen. 
The energy -dispersive detector is the one of choice in this work. 
In energy- dispersive EPXP`A, x -rays generated by the specimen impinge 
upon a detector made of lithium -treated silicon. Upon striking the 
detector each x -ray photon releases its energy resulting in the 
production of an electric pulse. The current pulse formed (proportional 
to the x -ray energy) is amplified and converted to a voltage pulse, the 
height of which is proportional to the energy of the incident x -ray. 
The height of the voltage pulse is then measured by a pulse height 
analyser and stored in a computer which possesses many channels. Five 
hundred channels are usually used, each collecting pulses within a 
range of 20 eV. The information accumulated in the computer after a 
significant period of time forms a spectrum whose ordinate is the x -ray 
energy. The abscissa represents the number of pulses proportional to 
the number of x -rays (of this particular energy) which entered the 
detector. The spectrum can be stored in the computer and recorded 
digitally on teletype. 
Resolution (ability to separate two adjacent peaks) is measured as 
the full peak width at half maximum intensity and even at maximum 
resolution the width of the peak (the result of pulses from a single 
element being spread over several channels) decreases the relative 
height of the peak and lowers the P/B ratio. The P/B ratio determines 
sensitivity. When the concentration of the element being analysed is 
very low the actual mass of the element is very small. Consequently 
count rates are low and to achieve statistically meaningful results 
sufficient counts at the peak must be accumulated to differentiate them 
from background counts. With low counting rates counting times greater 
than 100 seconds must be used, which may involve errors due to 
instrumental drift,contamination deposition and beam current fluctuations. 
Using the "thick sction" technique (where a "thick section" is one 
in which the incident electron beam is wholly absorbed) quantitation is 
carried out by producing a calibration curve from peak /background ratio 
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measurements On a series-of standards. If the:conditions of analysis _ 
are kept the same for standards and specimens then the calibration 
curve can be used to obtain the mass concentration_inthe specimens. For 
this technique the background is measured using separate regions of the 
spectrum which do__ not contain peaks. These background channels are 
situated close to the peaks being assayed so that when x -ray absorption 
occurs in the specimen it is similar in both peak and background. In 
the "thin section" technique the incident electron beam is not wholly 
absorbed and so there will inevitably be some scattered electrons in 
the column and therefore additions to the background from the film, 
support grid and specimen holder. Using a low atomic number material 
(such as nylon) minimises this contribution. For analysis of the 
results additional to the background measured as described above, an 
area of film free from sample in analysed and this background 
subtracted from the results to exclude the contribution. 
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2 -2. MATERIALS AND METHODS: FLUORESCENT STAINS 
Blood samples were taken from the following groups of subjects: 
(1) Two DMD patients 
(2) Two DMD carriers 
(3) Six male controls 
(4) Eight female controls 
DMD Patients 
DMD patients had been previously diagnosed on genetic, clinical and 
biochemical evidence and in most cases confirmed by abnormal histology 
of muscle biopsy. Blood samples were taken when the DIN patients 
attended the muscle clinic in the Department of Human Genetics at the 
Western General Hospital, Edinburgh. 
DIM Carrier 
DIN carriers were classified in the following way: 
Those women who are definite carriers on genetic evidence, i.e. 
- have at least one DMD son and at least one other affected male 
relative through the female line (2 subjects). 
Throughout the thesis DMD patients and carriers have been identified 
in terms of their family number, followed by their generation number 
and finally the subject's personal number within that generation. All 
pedigrees have been listed in Appendix I. 
Controls 
Control. subjects were normal, healthy males or females with no 
history of neuromuscu'ar disease. 
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All subjects used in this thesis were volunteers who gave informed 
consent and, where applicable, parental consent was obtained as well. 
Blood samples (other than DMD patient samples) were taken either in the 
Department of Human Genetics or at the subject' home. 
All chemicals used throughout this thesis were purchased from 
BDH Chemicals Ltd., Dorset, U.K. unless otherwise stated. 
5 -10 ml venous blood samples were obtained by venepuncture, 
collected into heparinised tubes and immediately processed in one of the 
following ways: 
(A) Air -dried blood smears were prepared on glass microscope slides. 
(B) Erythrocytes were deposited on 'slides as a fine spray via a 
nitrogen gas delivery of 25 pounds per square inch for 3 
seconds (sec's) through a 0.6 mm gauge needle, across the end of 
a capillary tube filled with blood. The needle was sealed to 
an adapted 25 cm3 syringe through pressure tubing and a pressure 
gauge to the nitrogen cylinder and positioned 3 cm from the 
capillary tube. The distance and height of the capillary tube 
from the 'slides was set at 11.3 cm and 7.5 cm respectively. 
This procedure was carried out in a fume cupboard. 
2 -2.1. Erythrocytes Stained with 3, 5,7,2',4' -Pentahydroxyflavanol (Morin) 
Optimal staining conditions were obtained using the following 
protocol, adapted from Pearse (1972): 
(1) Blood samples processed as stated in (A) or (B) were brought 
to 65ó ethanol for 5 minutes (min's). 
(2) Stained in 0.2% Morin in 85 ethanol (Analar grade) containing 
0.5% acetic acid (5 min's). 
(3) '.;ached in 70% ethanol (2 sec's). 
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(4) Washed in distilled water (2 sec's). 
(5) Mounted in distilled water using glass coverslips. 
Control Slide 
One from each batch of slides stained was pre- treated (10 min's.) 
by immersion in 1% aqueous hydrochloric acid. 
Stained blood samples were examined by fluorescence microscopy 
using a Leitz Ortholux microscope ( Leitz Instruments Ltd., Luton, UK) 
with fluorescent attachment; 154 oil immersion objective and filters 
1530, BG12.(15 mm) and BG12 (3 mm). 
2 -2.2. Lymphocytes Stained with 3,5 ,7,2',4',- Pentahydro,yflavanol (Morin) 
Lymphocytes were prepared from heparinised blood samples according 
the by B8yum (1968) and and examined under 
the conditions stated in Section 2 -2.1. Cells from 4 normal male -and 
4 normal female: subjects were examined. 
2 -2.3. erythrocytes Stained with Chlorotetracyc,ine (CTC) 
Optimal staining conditions were obtained using i mM CTC (United 
States Biochemical Corporation, Ohio, USA) dissolved in Tris buffered 
Ringer's (pH 7.4 at 37 °C) containing per litre: 
mM 
134.00 Sodium chloride 
10.00 Tris 
1.23 Calcium chloride 
0.56 Magnesium chloride 
1.00 Sodium dihydrogen phosphate 
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4.70 Potassium chloride 
adjusted to the pH with sodium hydroxide. A 1 in 30 dilution of whole 
blood to 1 mN CTC in Tris buffered Ringer's was incubated for 60 min's 
at 37 °C with gentle agitation. Air dried blood smears were prepared 
following this procedure and examined by fluorescence microscopy as 
described in Section 2 -2.1. 
Control Slide 
One from each batch of slides were treated as described in Section 
2 -2.1. (control slide) 
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2 -3. MATERIALS AND METHODS: ELECTRON PROBE X -RAY MICROANALYSIS (EPXMA) 
Blood samples from the following groups of subjects were analysed: 
(1) Five patients with DIM 
(2) Three DMD carriers 
(3) Two male controls 
(4) Five female controls 
DID Patients 
As defined in Section 2 -2. 
DIM Carriers 
Dim carriers were classified in the following way: 
(1) Those women who are definite carriers on genetic evidence - 
have at least one DIM son and at least one other affected male 
relative through the female line (2 subjects). 
(2) Those women who are possible carriers on genetic evidence but 
considered "definite" carriers on combined genetic and 
biochemical evidence - having one DMD son and a first degree 
female relative with a serum creatine kinase level greater 
than 1.5 x 95th percentile of the control series (1 subject). 
Controls 
As defined in Section 2 -2. 
5 -10 ml venous blood samples taken by venepuncture were collected 
into heparinised tubes and immediately processed. 
2 -3.1. Preparation of Samples: "Thick Section" Technique 
All apparatus used throughout this study, including the graphite 
stubs, were hydrochloric acid -washed and rinsed three times using triple 
distilled, deionised water (TDW) to eliminate calcium contamination. 
All reagents were prepared using TDW. 
Heparinised blood samples were centrifuged using an MSE bench 
centrifuge (MSE Ltd, Crawley, UK) immediately following collection 
10 min's, 1250 g). Both plasma and buffy coat were removed and the 
erythrocytes then washed twice in isotonic saline (0.90). 0.5 ml 
washed erythrocytes were transferred to 5 ml modified Millonig fixative - 
buffer (for :.fixative- buffer preparation refer to Appendix III). After 
5 minutes the fixed erythrocytes were centrifuged (5 min's, 150 g, MSE 
centrifuge) and the fixative washings discarded. 
Following one post -fixative wash (isotonic saline), the erythrocytes 
were resuspended to a 20% v/v suspension in isotonic saline. Drops of 
the suspension were then transferred onto graphite stubs, the 
erythrocytes being spread across the stub using glass coverslips. 
After air -drying the stubs were stored in a vacuum desiccator prior to 
analysis, within a 48 hour (hr) period. 
Quantitation of the measurements was achieved by analysis of a 
series of albumin standards containing known amounts of calcium. 
2 -3.2. Preparation of Standards: "Thick Section" Technique 
Calcium standards of molarity 0, 1, 2 and 4 pmol calcium per gram 
albumin were produced by the addition of appropriate dilutions of a 
commercially prepared 1 mgml -1 calcium nitrate solution in TDW to 
dialysed bovine plasma albumin Cohn fraction V (dialysis of albumin 
described in Appendix III). 
Final calcium concentrations of the albumin standards were 
measured by atomic absorption spectrophotometry (AAS). AAS was 
carried out by Mr. G. Moon of the Dept. of Biochemistry, Animal 
Diseases Research Association, Edinburgh. 
One drop of each prepared standard was placed onto a graphite 
stub, being spread evenly over the surface using a glass coverslip and 
then frozen in liquid isopentane cooled in liquid nitrogen. The 
standards were then freeze -dried prior to storage in a vacuum 
dessicator and subsequent analysis within a 48 hr period. 
To determine the extent of interference of the potassium Kf,peak 
on the measurement of the calcium Kocpeak a potassium standard was 
prepared. Preparation and analysis of the potassium standard was the 
same as that of the calcium standards except potassium chloride 
solution was added to the albumin to produce a standard of 76.7,umol 
potassium per gram albumin (confirmed by AAS). 
2 -3.3. EPXMA: "Thick Section" Technique 
EPXMA of prepared samples and standards was carried out using a 
Jeol JSM -35 scanning electron microscope (Jeol Ltd, Tokyo, Japan). 
The microscope was fitted with.a K_evex (Kevex Corp., California, USA) 
energy dispersive, lithium -drifted silicon detector which was coupled 
to a pulse height analyser and computer (Link Systems Ltd, 
Buckinghamshire UK). Specimens were examined at 45° to the electron 
beam and all instrument parameters including distance of the detector 
from sample, beam current and condenser current were standardised for 
each EPXMA session. 
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'.Windows (groups of channels counted) were set for potassium, 
calcium and two backgrounds (refer to Table 2.1. and Figure 2.1.). 
Analysis was performed at 30 kV accelerating voltage for a live 
counting time of 200 sec's per erythrocyte. High count rates were 
used (1000 -2000. counts per sec.) and count rates corrected for dead 
time (time required to detect an x -ray photon and process its pulse). 
Only intact erythrocytes were analysed. Following selection of 
an erythrocyte, magnification was increased to x 10,000 and the 
electron beam focused over the entirety of the cell. Charging rarely 
occurred but samples affected by charging were not analysed. "Thick 
section" EPXMA was carried out in collaboration with Professor D.A.T. 
Dick, University of Dundee. 
Computation of raw data used standard EPXMA theory. The computer 
program used was developed by Professor Dick. 
Total background x -ray counts for both potassium Kocand calcium Koc 
peaks were assessed by use of the measurements of background BA and BB. 
Following subtraction of the appropriate amount of background the 
remaining x -ray counts in the potassium window were considered to be 
the potassium Ko< peak. 
Counts in the calcium window after appropriate background 
subtraction and subtraction of 1/30th of the counts in the potassium 
K,Lpeak (to overcome interference of any remaining potassium K,f counts 
in the calcium window) were considered to be the true calcium Roc peak. 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































i// Channels not counted 
Channels used 
2920 -3100 3240 -3360 3660 -3720 
X -RAY ENERGIES 




Prefix R = raw data 
K = potassium 
Ca = Calcium 
BA = 1st background 
BB = 2nd background ' 
BK = total background for potassium 
PK = peak for potassium 
KC = correction for potassium 
BCa = total background for calcium 





( RBA - RBB ) x 
10 
BK = (0.357 x RBA) + (0.343 x RBB) 
PK = RK - BK 
KC = 0.033 x PK 
Calcium 
Ca [REE + .*RBA - RBB) x 
BCa = x RBA) + (0.282 x RBB) 
PCa = RCa - BCa - KC 
P/BCa = PCa/BCa 
The amount of calcium per gram dry weight for each erythrocyte 
was calculated using the calcium P/B ratio and the formula derived 
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from regression analysis of the calcium standards. 
Using known figures for erythrocyte mass and cell water content 
(equivalent to 0.33 g haemoglobin per 0.67 ml H20) calcium expressed as 
per gram cell water was equivalent to calcium per gram cell solid 
x 0.5. 
2 -3.4. Blood Treated with Ionophore A23187 and a Calcium Complexing 
Agent 
One 10 ml sample of fresh, heparinised normal, female control 
blood having undergone the washing procedure described in Section 2 -3.1. 
was divided into three aliquots. Treatment to each aliquot of 
erythrocytes prior to fixation was as follows: 
(1) 0.5 ml washed erythrocytes underwent no further treatment 
prior to fixation. 
(2) 0.1 ml of a 1 mgml -stock solution of ionophore A 23187 
(Calbiochem, Herts, UK) in 85% ethanol was diluted 1 in 10 
(isotonic saline) and this solution added to 5-ml of a 
10% v/v (erythrocyte in saline suspension). Following 
incubation (30 min's at 37 °C) and centrifugation (5 min's, 
1250 g, MSE centrifuge) the washings were discarded and the 
erythrocytes given one wash (isotonic saline) prior to 
fixation. 
(3) ._1 ml packed erythrocytes were incubated in 5 ml 0.1 mM 
ethylene diamine tetra acetic acid (FfTA) in isotonic 
saline, 30 min's at 37 °C. Treated erythrocytes were 
centrifuged (5 min's 1250 g, MSE centrifuge), the washings 
discarded and the erythrocytes given one wash (isotonic 
saline) prior to fixation. 
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In:all cases the resultant treated erythrocytes were fixed as 
described in Section 2 -3.1. and analysed under the conditions stated 
in Section 2 -3.3. Fifteen erythrocytes from each aliquot were 
analysed. 
2 -3.5. Preparation of Samples: "Thin Section" Technique 
Erythrocyte collection, washing and fixation procedure were as 
described in Section 2 -3.1. Drops of the 20% v/v fixed erythrocyte in 
saline suspension were transferred onto carbon coated nylon mesh grids 
(Graticles Ltd, Kent, UK) covered with a layer of formvar (0.5% in 
chloroform, air -dried). 
The grids were pre -treated with 1% aqueous alcian blue solution 
(alcian blue GX, Gurr Ltd, Dorset, UK) to facilitate adhesion of the 
erythrocytes, briefly washed with TDW and allowed to dry. Drops of the 
erythrocyte suspension were left in contact with the grids for . 
1 minute. After this time excess fluid was drained and the preparation 
air -dried. Location of erythrocytes on the grids was checked by light 
microscopy. Samples were stored in a vacuum desicator and analysed 
within a 48 hour period. A minimum of 20 erythrocytes from each grid 
were analysed per session. 
2 -3.6. Preparation of Standards: " Thin Section" Technique 
As described in Section 2 -3.2. Drops of the albumin standards 
containing known amounts of calcium (confirmed by ASS) were smeared 
across formvar -coated grids and freeze dried. 
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2 -3.7. EPXMA: "Thin Section" Technique 
EPXMA of prepared samples and standards was carried out using a 
Cambridge Stereoscan S180 electron microscope (Cambridge Instruments 
Ltd., Cambridge, UK) used in transmission mode. The microscope was 
fitted with a Kevex energy dispersive, lithium- drifted silicon 
detector coupled to a pulse height analyser and computer (Link Systems 
Ltd,). 
Windows for potassium, calcium and two backgrounds were set as in 
Section 2 -3.3. Additionally, windows were set for iron and two 
further backgrounds (details given in Table 2.1.). 
Specimens were examined at 45° to the electron beam and all 
instrument parameters were standardised for each EXPMA session. 
Analysis was performed at 25 kV accelerating voltage for a live 
counting time of 300 sec's per erythrocyte. Only intact erythrocytes 
positioned away from the grid bars were analysed. Following selection 
of an erythrocyte, magnification was increased to x 10,000 and the 
electron beam focused over the entirety of the cell. Samples affected 
by charging were not analysed. 
Computation of the raw data first involved subtraction of 
background contribution resultant of film, support, grid and specimen 
holder (refer to Section 2 -1.4.) but otherwise was as described in 
Section 2 -3.3. 
Peak /background ratios for iron were calculated as follows: 
For channels set refer to Table 2.1. 
Channels Total X -ray counts 
(Energies) 




Prefix R = raw data 
B3 = third background set 
PFe = peak for iron 
BFe = background for iron 
BFe = (0.65 x RB3) + (0.65 x RB4) 
PFe = RPFe - BFe 
P/B ratio Fe = PFe /BFe 
174 = fourth background set 
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2-4. RESULTS: FLUORESCENT STAINS 
2-4.1. Erythrocytes á.nd Lymphocytes Stained with 3,5,7,2',4', - 
Pentahydroxyflavanol (Morin) 
All cells prepared by method A or B (described in Section 2 -2.) 
and from all subjects used (DMD patients: 2 III2, 5 II13 and 6 112; 
DMD carriers 11 II13 and 15 114; 4 normal male and 4 normal female 
controls) exhibited a uniform, dull, yellow -green fluorescence when 
examined by fluorescence microscopy. It was not possible to see any 
differences in fluorescence intensity in any given population of cells. 
Method B appeared to generate less background fluorescence 
(surrounding the erythrocytes) than Method A. 
Preparations which had been pre -treated with hydrochloric acid 
demonstrated a considerably reduced (greater than 95% loss) 
fluorescence. 
Approximately 1% granulocytic leucocytes on whole blood smears 
(prepared by method A) exhibited a bright white -yellow fluorescence. 
Cells prepared by method A have been shown in Plate 2.1. 
2 -4.2 Erythrocytes Stained with Chlorotetracycline (CTC) 
All cells prepared by method A or B (refer to Section 2 -2.) and 
from all subjects used (2 normal males and 4 normal females) exhibited 
only very slight background fluorescence surrounding each cell which 
was entirely absent from preparations which had been pre -treated with 
hydrochloric acid. 
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Approximately 2% of the total leucocyte population of whole blood 
smears contained highly fluorescent, multi -lobed nuclei.(refer to 
Plate 2.1.) . 
Plate 2.1. Whole Blood Smears (original magnification x 540) Stained 
with Fluorescent Stains: 
Upper: Stained with Morin 
All erythrocytes demonstrated a background yellow -green 
fluorescence. 
Positioned centrally in the photograph is a brightly 
fluorescent granulocytic leucocyte. Approximately 1% of 
the total leucocyte population fluoresced in this manner. 
Lower: Stained with Chlorotetracycline 
All erythrocytes demonstrated only very slight background 
fluorescence. 
Positioned centrally in the photograph is a leucocyte 
containing a highly fluorescent multi -lobed nucleus. 
Approximately 2% of the total leucocyte population 
fluoresced in this manner. 

2 -5. RESULTS: EPXMA 
2 -5.1. Effects of. the Fixative- Buffer on Erythrocytes 
From the action of the fixative- buffer on the erythrocytic membrane, 
greater than 95% of the intraerythrocytic potassium content was released 
(confirmed by AAS). Remaining potassium was measured and the appropriate 
(small) correction, subtracted from the calcium peak. 
For the effects of washing and fixation processes on the erythrocyte 
X -ray spectrum (refer to Plate 2.2 .) , 
2-5.2 Comparison of "Thick Section" and "Thin Section" Techniques 
Some difficulty was encountered in distinguishing erythrocytes 
from the suspending matrix using the "thick section" technique,whilst 
erythrocytes were much easier to visualise using the "thin section" 
_: -ray spectra of specimens (erythrocytes and albumin protein 
standards) obtained using both techniques were similar except with 
regard to contributions made by:specimen supports (and these support - 
derived peaks did not influence calcium measurement). 
"Thin section" EPYLA demonstrated a very slight improvement in 
technique sensitivity (in terms of a slightly increased P/B ratio) 
compared to that observed using the "thick section" technique. However 
this increased sensitivit y was not sufficient to improve on the 
information obtained from use of the "thick section" technique. 
Apart from the differences between "thick section" and 
"thin section" techniques cited above, for the purposes of this study 
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complete X -ray spectrum of an unfixed erythrocyte. 
Following the marker peak are visible peaks for 
phosphorus, sulphur, chlorine, potassium K;,d.hen 
K g, and iron. 
magnified area of X -ray spectrum from an unfixed 
erythrocyte showing phosphorus (P), sulphur (S), 
chlorine (Cl) and potassium K and. Kr, peaks. 
complete X-ray spectrum of a fixed erythrocyte with 
greater than 95% of the potassium removed. In this 
case, following the marker peak are visible peaks for 
silicon, phosphorus, sulphur, chlorine, potassium K x 
(which is markedly reduced), calcium (previously 
swamped by potassium), and iron. The white stippled 
spectrum represents the contribution to the total 
spectrum due to film, support grid and specimen 
holder (using the "thin section" technique). 
Lower Right magnified area of X -ray spectrum from a fi xed 
erythrocyte showing phosphorus (P), sulphur (S), 
and chlorine (Cl) peaks followed by a greatly reduced 
potassium K. peak and small calcium (Ca) peak (masked 
by potassium K a peak in upper left spectrum). 
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both methods produced reasonably comparable results and hence these 
results have been discussed together. 
Even with the slightly increased P/B ratio of the "thin section" 
technique the calcium peak was hardly ever visually distinguishable 
from the background, indicating that these measurements were on the, 
borderline of sensitivity of the .EPXMA technique. Whilst it was evident 
from the measurements made that reliable absolute calcium values could 
not be obtained it was considered that relative quantitation would be 
acceptable, providing sensitivity were sufficient to enable the recognition 
of a normal and an abnormal population of erythrocytes within a DMD 
carrier sample. 
2 -5,3, Erythrocyte Populations Examined 
There was wide variation in relative calcium.condentratioñs - in 
erythrocytes from one individual. In one normal female control (aged 
24 years) in which 33 erythrocytes were examined, the coefficient of 
variation (CV) was 12% (refer to Figure 2.2). Note that measurements made, 
unless otherwise stated, fell within a normal distribution when tested 
by Kolmogorov- Smirnov test (Siegel, 1956). 
Repeated measurements on one erythrocyte were not always possible 
due to sample damage by the electron beam (refer to Table 2.2., noting 
the decreasing calcium concentration measured with each subsequent 
analysis). When such measurements were carried out without apparent 
sample damage ensuing (Table 2.3.), the coefficient of variation of 
calcium measurements (expressed either as P/B ratio or as the calcium 
.concentration .pmolml -1 cell water) was extremely high :(CV = 30% for 
calcium P/B ratio). 
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Figure 2.2. Erythrocyte Calcium Measurements of One Formal Female 
Control Sample 
m mean 
EC standard deviation 
CV coefficient of variation 
cn




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Note that in both Tables 2.2. and 2.3. intraerythrocytic iron 
measurements were much more stable than those of calcium. Variation in . 
intraerythrocytic iron levels was much smaller than variation encountered 
with calcium measurements (in Table 2.3. CV=4% for iron P/B ratio). 
Relating calcium to iron measurements in each erythrocyte studied did 
not decrease the variation encountered (refer to Table 2.3.). 
Intraerythrocytic measurements of calcium amd iron in one normal 
female subject, aged 32 years, made on 2 separate occasions (7 days apart) 
were assessed using one way analysis of variance. For calcium the F. 
value. = '5.85 (p < 6.01) whilst : - for iron F = 0.95, p = NS 
A scatter diagram demonstrated the lack of relationship between 
intraerythrocytic calcium and iron measurements within a population of 
erythrocytes fron one normal male subject aged 30 years (refer to 
Figure 2.3.). The correlation coefficient (r) of these 2 measurements, 
r = 0.16, was not significant, 
2-5.4. Albumin Protein Calcium Standards 
For the complete X -ray spectrum of a freeze -dried, albumin protein 
calcium standard (measured using the "thick section" technique) refer to 
Plate 2.3. 
1721.IA of albumin protein standards containing known amounts 
oof calcium (confirmed by AAS) demonstrated a reasonably linear 
relationship between calcium and P/B ratio using both the "thick section" 
(refer to Figure 2.4.) and "thin section" (refer to Figure 2.5.) 
techniques. 
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Figure 2.3. :scatter Diagram of Calcium and Iron Measurements in 
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Plate 2. 3. Photograph from the Oscilloscope Screen: 
Complete x -ray spectrum of a freeze -dried albumin protein 
standard ( "thick section" technique). The first small peak 
is of silicon (an impurity in the graphite stub), followed 




Figure 2.4. Calcium Calibration Curve ( "Thick Section" Technique) 
This graph shows the relationship between measured 
peak /background ratio and concentration of calcium 
from albumin standards which contain known 
concentrations of calcium and varying concentrations 
of chloride. 
Equation for the Line 
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Figure 2.5. Calcium Calibration Curve ( "Thin Section" Technique) 
This graph shows the relationship between measured 
peak /background ratio and concentration of calcium 
from albumin standards which contain known concentrations 
of calcium and varying concentrations of chloride. 
Equation for the Line 
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2 -5.5 Blood treated with Ionophore A23187 and a Calcium Complexing 
Agent 
To confirm that measurements made were of intraerythrocytic 
calcium within the samples, erythrocytes with artificially increased 
and artificially decreased calcium levels were analysed and the mean 
calcium concentrations compared to the mean calcium concentration of 
untreated erythrocytes from the same sample. Ionophore A23187 was used 
to increase intraerythrocytic calcium and the mean calcium concentration 
was significantly higher than that of untreated cells. EDTA was the 
calcium chelating agent used to decrease intraerythrocyte calcium. 
However, although the mean calcium concentration of EDTA- treated 
cells was lower than that of untreated cells it was not significantly 
lower (refer to Table 2.4) . 
2 -5.6. Summary of Results Obtained in Subjects Studied . 
Calcium measurements in populations of erythrocytes from 5 DND 
patients, 3 DMD carriers, 2 normal male and 5 normal female control 
subjects have been summarised in Figure 2.6. and Table 2.5. 
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Concentration Level of 
jmol.m1 -1 cell Significance 
water 
1. Untreated 
2. Treated with 
Ionophore A23187 






p level of significance using unpaired t test comparing aliquots 
nos. i and 2 
NS not significant using unpaired t test, comparing aliquots 
nos. 1 and 3 
for unpaired t test, refer to Snedicor and Cochran, 1967 
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Figure 2.6. Measurements in Erythrocyte Populations of Subjects 
Examined: 
2 normal male controls 
5 MID patients 
and (overleaf): 
5 normal female controls 





































































































































































































































































































































































































































































































































































































2 -6. DISCUSSION: FLUORESCENT STAINS 
The 'flavanol stain (Morin) and the antibiotic chlorotetracycline 
(CTC) have been used sucessfully as fluorescent chelate probes for 
calcium in biological systems including dystrophic muscle (Emery and 
Burt, 1980) and pancreatic acinar cells (Chandler and Williams, 1978). 
The conditions employed in this study were selected to favour 
fluorescence resulting from calcium binding to the fluorescent probes 
over fluorescence produced by the binding of other divalent cations, 
The lack of fluorescence found in the hydrochloric acid, pre- treated 
control slides (in the case of both stains) suggested the fluorescence 
observed in untreated cells studied resulted from fluorescent probe 
binding of calcium. 
Spraying erythrocytes or lymphocytes onto glass slides (refer to 
Section 2 -2., method B) appeared to slightly reduce background 
fluorescence when compared to method A (probably by physically 
separating cells from surrounding suspending fluid on impact with the 
glass slides). However, despite the slight improvement observed using 
method B, neither fluorescent stain (Morin or CTC) was sufficiently 
sensitive to detect differences in erythrocyte (or lymphocyte) 
calcium levels in any subject group. Technical and physiological 
factors affecting intraerythrocytic calcium distributions in cell 
populations have been discussed more appropriately in Section 2-7. 
The failure of these fluorescent chelate probes in this study 
emphasise the need for a technique of greater sensitivity in order to 
explore the possibility of finding proof of the Lyon hypothesis (via 
calcium measurement) in blood cells from a DMD carrier. 
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The very small percentage of leucocytes (in the case of: Morin, 
1%; CTC, 2%) which exhibited considerable fluorescence compared to 
other cells may represent activated neutrophils since it has been 
suggested that an increase in intracellular calcium level is involved 
in the activation process (Romeo et al.,1975). 
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2...7. DISCUSSION: EPXMA- 
At present TPXflA is the only technique which offers the possibility - 
of measuring calcium in individual erythrocytes. Many factors affect 
intraerythrocytic calcium measurements obtained by EPXMA, including, of 
primary importance,the sensitivity of the technique itself. 
In EPXMA. discrimination of the peak from the background on which it 
is superimposed is critical (refer to Section 2- 1.4.). In this study 
calcium P/B ratios were very low and, as stated in Section 2- 6.2.,the- 
absolute calcium measurements obtained could not be considered reliable. 
However relative Quantitation would be of value if technique sensitivity 
were such that a population of erythrocytes containing an increased 
calcium concentration could be distinguished from cells with a normal 
intraerythrocytic calcium content in a DND heterozygote. 
There was very considerable variation in relative calcium 
concentrations measured in erythrócz tes from one sample (refer to Section 
2- 6.3.). Differences in intraerythrocytic calcium content may involve 
the preparative procedure and EPXMA measurement as well as actual 
physiological differences in ionic concentrations within the erythrocytes 
themselves. 
Removal of the buffy coat and washing the erythrocytes to remove 
trapped plasma were both necessary steps to eliminate calcium 
contamination of the erythrocyte membranes. Washing erythrocytes in 
isotonic saline has been shown not to extract intraerythrocytic calcium 
(Harrison and Long, 1969). However the effects of fixation and post - 
fixation procedures on erythrocyte calcium content are subject to 
controversy. To minimise the possible loss of calcium from its 
physiological site, oxalate was added to the fixative- buffer 
as a 
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precipitating agent, since this ion has a low solubility as the calcium 
salt. 
The extremely low permiability of the erythrocyte membrane to 
calcium effectively excluded. the possibility of the preparative 
procedure introducing calcium into freshly treated erythrocytes. However 
a non -specific physical process of accumulation of extracellular calcium 
ions around the erythrocyte cell surfaces has been demonstrated after 
air -drying of the cells in a suspending medium containing calcium. 
(Kimsey and Burns, 1973). Wiley and Mailer (1977) considered calcium 
ions might bind to phosphate leaking from the erythrocytes,causing surface 
contamination. Chemical elements may be re- distributed during air - 
drying from a fluid suspension. Lechenne et al. (1977) found mean X -ray 
intensities varied significantly in different areas of the same support 
when measuring sodium and potassium content in air -dried erythrocytes. 
Gutlasch et al. (1974) comparing air -drying and cryoprocedures also 
concluded that local electrolyte distribution patterns were not preserved 
by air -drying, but Chandler and Battersby (1976) observed similar elemental 
distributions in air -dried, freeze dried and frozen cells. It is 
extremely difficult to assess the effects of this preparative procedure 
on erythrocyte calcium content and therefore how the results obtained 
relate to the in vivo state. 
Certainly, interference of potassium on the X -ray microanalysis of 
calcium was successfully reduced by using formaldehyde in the fixative - 
buffer (refer .to Section 2 -6.1.) and the small amount of remaining 
potassium measured, and corrected for, in the appropriate channels. High 
counts in the calcium channels could conceivably be obtained if more than 
one cell were excited by the electron beam. However, microscopic 
examination made this unlikely (unless erythrocytes were positioned 
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directly above one another). Lower counts might be due to excitation 
of less than the totality of the cell (due to a drift in the position 
of the electron beam). Negative results would occur if the actual 
background counts were also lower than calculated and the calcium 
K ccounts also low, which would result in nett counts of less than 
zero. 
Actual physiological differences in intraerythrocytic calcium 
levels within an erythrocyte population may be correlated to the age 
of the cells. Certainly the distribution of electrolyte concentrations 
within a population of erythrocytes cannot be considered to be uniform 
since the cells range in age between 0 -120 days and biochemical, 
changes that occur during cell ageing are reflected by differences 
in ionic.regulation and content. Lacelle et al. (1973) suggested 
that normal senescent erythrocytes are characterised by an increased 
intracellular calcium concentration and this could account for higher 
values found in certain cells within erythrocyte populations studied. 
Appropriate standards are required in EPXMA since both standards 
and specimens must react similarly under the electron beam. In this 
study freeze -dried albumin standards were selected for their resemblance 
to the cell matrix. However there remains a slight possibility that 
the differences in the response of albumin standards and erythrocytes 
to EPXMA contributed adversely to calcium measurement. Negative P/B 
ratios found in the presence of actual quantities of calcium in the 
standards (refer to the calcium calibration curves: Figures 2.4. and 
2.5) demonstrated the difficulty in placing the base line for these 
measurements as zero P/B for zero calcium. 
In all erythrocyte populations examined the width of distributions 
of calcium measurements prevented the possibility of selecting 
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erythrocytes with an increased intraerythrocytic calcium level from 
within a population of normal erythrocytes in a DMD heterozygote. 
Expressing intraerythrocytic calcium measurements relative to those of 
iron (a tightly bound element representative of cell mass) did not 
appreciably decrease the considerable variation in calcium measurements 
encountered. Comparison of intraerythrocytic calcium and iron levels 
in blood samples taken from one normal subject on different occasions 
indicated that whilst intraerythrocytic iron measurements (both within 
and between occasions) were of comparable levels, measurements of 
intraerythrocytic calcium were much more consistent with one another 
within one sample than with equivalent analyses made on different 
occasions. 
Eaton et al. (1973) used the ratio of calcium to aluminium counts 
to demonstrate a relative increase in erythrocyte calcium in 
irreversibly sickled erythrocytes compared to sickle cells of normal 
morphology. These workers found irreversibly sickled erythrocytes 
contained approximately 8 x as much calcium as undistorted sickle 
cells. Although erythrocyte shape alterations related to intracellular 
calcium level have been reported in DMD (refer to Section 2 -1.2) 
erythrocyte deformity equivalent to sickled cells has not been 
observed. This suggests it would be unlikely that increased calcium 
(if present) in Duchenne erythrocytes would attain the level of this 
ion Eaton et al. (1973) observed in irreversibly sickled cells. 
Unfortunately in the study of Eaton et al. (1973) no reference was 
made to the potassium 
I{Ñ 
peak interference on calcium measurement or 
method of correction of this interference (if any) used. 
Measurements on blood treated to artificially increase or 
decrease the intraerythrocytic calcium level confirmed that it was 
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this ion being measured in samples studied (refer to Section 2 -5.5). 
However, Whilst the results obtained using ionophore A23187 to increase 
intraerythrocytic calcium levels were significantly higher than 
control levels the decrease in intraerythrocytic calcium level 
achieved using the chelator EDTA did not reach statistical significance. 
The ionophore A23187 is known to selectively transport calcium 
(and other divalent cations) across cellular membranes including the 
erythrocyte membrane (White, 1974). The effectiveness of EDTA at 
removing erythrocytic calcium (and other divalent cations) however, 
is less clear. Whilst Harrison and Long (1969) reported the removal 
of greater than 90% erythrocytic calcium by treatment with 1 TA, 
Palek (1977) could not confirm this finding and suggested an absence 
of calcium at external membrane sites accessible to EDTA extraction. 
The problem in determining at what level the calcium measured relates 
to the amount of intraerythrocytic calcium rather than to calcium 
closely associated to the erythrocyte membrane makes interpretation 
of these data on EDTA treated erythrocytes very difficult. 
Furthermore, since measurement of intraerythrocytic calcium in non - 
chelator- treated cells represents the use of EPXMA at the borderline 
of sensitivity, measurements in erythrocytes where calcium has been 
artificially decreased will be even more subject to errors induced 
by operating under such conditions. 
There was a very slight suggestion of a possible trend in some 
DI'D patients studied txards an increased mean intraerythrocytic 
calcium level relative to such measurements made in controls and DMD 
carriers studied. Overall, however, the very wide variation in 
intraerythrocytic calcium measurements encountered in all subject_ 
groups prevented the possibility of demonstrating (if present) 
either: 
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a significant relative increase in intraerythrocytic calcium 
measurements in DIN patients compared to levels in control subjects 
or (dependant upon the previous point) identification of two 
populations of cells within a DND carrier (a population containing an 
increased intraerythrocytic calcium content and a population 
containing a normal amount of this ion) which would be a sucessful 
demonstration of the Lyon hypothesis. 
Until a method which sucessfully demonstrates cellular mosaicism- 
in genetic DND carriers becomes available it may not be possible to 
attain a figure approaching 100% correct genetic UND heterozygote 
recognition. However the UND carrier detection rate (approximately 
70%) achieved by the current most routinely applied test (serum creatine 
kinase estimation) may be improved upon by the additional measurement 
of other non -correlated serum proteins (explored in subsequent 
Chapters). 
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CHAPTER 3: CREATINE KINASE 
3-1. INTRODUCTION 
Altered serum activities of many muscle- specific enzymes have 
been reported in patients with muscle dicease. Extensive studies 
have shown an elevated serum level of the enzyme creatine kinase (ATP: 
creatine N - phosphotransferase E.C. 2.7.3.2.) to be a sensitive 
indicator of muscle defect or damage. 
Creatine kinase (CK), molecular weight 80,000 daltons, catalyses 
the reversible conversion of creatine to phosphocreatine: 
CK 
ATP + creatine, \ADP + phosphocreatine 
where: 
ATP = adenosine triphosphate 
ADP = adenosine diphosphate 
and has a role in the maintenance of constant cellular levels of ATP. 
The enzyme is found in highest concentration in skeletal and cardiac 
muscle and is also present in brain but not other tissues. 
Significantly increased serum creatine kinase activities have 
been reported in the following conditions: 
(1) acute myocardial infarction 
(2) muscular dystrophies 
(3) metabolic myopathies 
(4) polymyositis 
(5) skeletal muscle damage 
(6) extreme exertion in normal individuals 
(7) tetanus 
(8) cerebral vascular incident 
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(9) hypothyroidism 
(10) the onset of psychosis 
In these conditions, the elevation of serum creatine kinase level is 
resultant of enzyme leakage from diseased or damaged tissue. Early 
pregnancy (King et al., 1972) and steroid therapy (but possibly not 
the contraceptive pill (Simpson et al., 1974) have been reported to 
decrease serum creatine kinase activity. 
Ebashi et al. (1959) first suggested the use of serum creatine 
kinase as a biochemical diagnostic test for muscular dystrophy. 
Following this report many workers (Dreyfus et al., 1960; Aebi et al., 
1961) have documented the greatly elevated serum creatine kinase levels 
in DIM patients although the serum activity has been shown to decrease 
considerably with disease progression (Pearce et al., 1964a). 
Creatine kinase isoenzymes have been reviewed very recently by 
Lang and Wurzburg (1982) who describe the "cytoplasmic"creatine kinase 
isoenzymes MM, MB and BB and additionally a mitochondrial creatine 
kinase isoenzyme Mt. The creatine kinase isoenzymes MM, MB and BB 
(regarded as skeletal muscle type, cardiac muscle type and brain type 
respectively) have been investigated in muscular dystrophy and 
controversy exists regarding the isoenzyme patterns found. Only MM 
isoenzyme has been found in serum from normal individuals by most 
authors, whilst some have reported MB is also present in cases of DMD 
(Somer et al., 1976). Silverman et al. (1976) suggested creatine 
kinase isoenzyme analysis may be of value in the differentiation of 
DMD from Becker Dystrophy in sporadic cases. 
Okinaka et al. (1959) first investigated the use of serum 
creatine 
kinase estimation as a method of DMD carrier detection. Since then 
many authors (Dreyfus and Schapira 1961: Emery 1965b; Dreyfus 
et al., 
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1966; Thompson et al 1967) have reported elevated serum creatine 
kinase activities in a high proportion of DMD carriers and verified 
the usefulness of this test. Arro_.'imately two thirds of the carriers 
of the DMD gene are considered to exhibit significantly increased 
serum creatine kinase- activities (Emery, 1969b; Pennington,1981). 
The estimation of this enzyme is accepted as the single most reliable 
test that can be applied in the detection of carrier status (Emery, 
1980). 
Several methods have been employed in attempts to improve the 
detection effiency of serum creatine kinase. Moser and Vogt (1974) 
reported that serum creatine kinase levels decrease with increasing 
age in carriers but not in normal women, but Zatz and Otto (1980a) 
could not find significant differences in mean serum creatine kinase 
levels in a series of adult carriers examined over a period of years. 
However, Zatz et al. (1976) and Nicholson et al. (1979) found the 
mean creatine kinase activities of young suspected carriers to be 
higher than the corresponding activities of their carrier mothers. 
Also Moser et al. (1980) reported that the probability of identifying 
a carrier by serum creatine kinase analysis was greater than 9Q% at 
school age but decreased to 68% in adults. This work suggests the 
detection efficiency of serum creatine kinase may be improved by 
measuring creatine kinase activities of suspected carriers at an 
early age, taking into account that creatine kinase activities are 
higher in normal female children than in adult females (Bundey et al., 
(1979). 
The effect of exercise on carrier serum creatine kinase activities 
has also been examined. In a study by Iiudgson et al. (1967) some 
carriers demonstrated significantly increased post- exercise serum 
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creatine kinase levels not exhibited by controls. Recent work by 
Gaines et al. (1982) showed a significant exercise effect on several 
carrier creatine kinase levels and to a lesser extent in control 
subjects, although no control levels exceeded the normal range. 
Other workers however, using varied exercise loads, have been unable 
to find a significant exercise effect in carrier serum creatine kinase 
activities (Hughes et al., 1971; Thomson et al., 1975). 
Hausmanowa -Petrusewicz and co- workers (1980) reported that 
intravenous hydrocortisone raised serum creatine kinase activity in a 
high percentage of DMD carriers studied. Of particular interest, 
several carriers with normal creatine kinase levels were reported to 
respond to hydrocortisone injection with an increase in their serum 
creatine kinase levels. However, this preliminary study awaits 
confirmation. 
Lane and Eadoff (1981) examined serum creatine kinase and blood 
alcohol levels in a small group of DAD carriers before and after 
alcohol infusion. They did not find the elevation in serum creatine 
kinase response to ethanol challenge reported in cases of alcoholic 
myopathy. 
Roses and co- workers (1D77b) suggested that measurement of serum 
lactate dehydrogenase isoenzyme 5 (LDH -5) might be superior to serum 
creatine kinase analysis in carrier detection and reported some DMD 
carriers with normal creatine kinase levels but elevated levels of 
serum LDH -5 isoensyme. However, other workers (Burt and Emery 1979; 
Somer et al., 1980) have failed to confirm either the greater 
sensitivity of this isoenzynie in carrier detection or the lack of 
correlation between serum LDH -5 isoenzyme and creatine kinase levels 
found by Roses' group. 
The increased serum creatine kinase activities found in a very 
high percentage of DIM patients and in a considerable proportion of 
carriers have been widely documented. As the accepted most reliable 
test for determining carrier status, the serum creatine kinase test 
has been employed in this study in two ways: 
(a) to compare the carrier detection efficiency of serum 
creatine kinase with that of other serum tests; 
(b) to examine whether other tests used in combination with 
serum creatine kinase improved the carrier detection 
capability over that of serum creatine kinase alone. 
Comparisons of the carrier detection efficiency of serum creatine 
kinase have been made with serum pyruvate kinase, serum haemopexin and 
serum myoglobin measurements and these have been discussed in the 
relevant chapters (Chapters 4,5, and 6, respectively). The use of 
these tests in combination is discussed in Chapter 7. 
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3-2. MATERIALS AND METHODS 
Serum creatine kinase activities were determined during everyday 
activity in the following groups of subjects: 
(1) Ten patients with DED together with 10 age -matched, 
normal boys. 
(2) Carrier and control group A, comprising 15 DMD carriers 
and 15 age- matched normal, healthy women. 
(3) Carrier and control group B, comprising 20 DMD carriers 
selected as having serum creatine kinase activities 
within the 95th percentile of the control series and 
20 age -matched normal, healthy women, 
DID Patient and Control Group 
DIM patients were diagnosed as described in Section 2-2. 
Single blood samples were taken when the DIM patients attended 
the Muscle Clinic in the Department of Human Genetics, Western 
General Hospital, Edinburgh. 
Age- matched controls were normal, healthy boys with no history of 
neuromuscular disease. 
DMD Carrier and Control Group A 
(1) Those women who are definite carriers on genetic evidence, 
i.e. have at least on DiiD son and at least one other 
affected male relative through the female line (9 subjects). 
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(2) Those women who are probable carriers on genetic evidence, 
i.e. have 2 or more affected sons but no other family history 
of DMD (2 subjects). 
(3) Those women who are possible carriers on genetic evidence 
but considered "definite" carriers on combined genetic and 
biochemical evidence, 
- having one DIW son, a serum creatine kinase level greater 
than 1.5 x 95th percentile in the control series and a first 
degree female relative with a serum creatine kinase level 
greater than 1.5 x 95th percentile in the control series 
(3 subjects) 
- having one DIiJD son and a first degree female relative with 
a serum creatine kinase level greater than 1.5 x 95th percentile 
of the control series (1 subject). 
D D Carrier and Control Group B 
These carriers are more appropriately defined in Section 6 -2. 
Age matched controls for Group A and B were normal, healthy females 
with no history of neuromuscular disease. 
5 -10 ml venous blood samples were obtained by venepuncture and 
collected into plastic tubes containing no anticoagulant. Blood samples 
were allowed to clot for a minimum of 45 minutes at room temperature 
prior to centrifugation (15 min's, 1250g, MSE centrifuge) to ensure 
it was cell free. Two blood samples were obtained 4 -7 days apart 
from 
all subjects in carrier and control group A. In these cases the 
mean 
activity of creatine kinase of both samples was used. In all other 
groups creatine kinase estimations were from single serum samples. 
Three plasma samples were included in carrier group B 
since no 
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significant differences have been found between serum and plasma 
creatine kinase levels (Rosalki, 1967 and Lum and Gambino, 1974) 
All sera were stored in aliquots at -70 °C overnight for analysis 
within 24 hours of collection. Whole blood may be stored at room 
temperature for about 24 hours (Pennington, 1980), sera fór 48 hours 
and frozen sera at -20 °C for at least one month without serum creatine 
kinase activity being significantly decreased (Spikesnan and. Brock 1969) 
All sera were frozen and thawed once only since repeated -freezing 
and thawing has been reported to result in a rapid decrease in serum 
creatine kinase activity (Pearce et al. 1964b). 
No samples analysed showed signs of haemolysis, with the exception 
of the second sample obtained from a carrier in group A where slight 
haemolysis had occurred. Although creatine kinase has been reported 
absent from erythrocytes (Ebashi et al. 1959) haemolysis is thought to 
liberate erythrocyte adenylate kinase which could interfere in the assay. 
However, adenosine monophosphate, an inhibitor of adenylate kinase is 
included in the kit reaction mixture and so this sample was analysed. 
Serum creatine kinase activities were measured by a commercially 
available kit Calbiochem- Behring "Stat Pack" (Hoechst UK Ltd.) which is 
based on the method of Rosalki (1967). In this procedure serum creatine 
kinase activity is assayed by measurement of the rate of reaction in the 
direction of ATP formation. The ATP produced is measured indirectly 
(by means of coupled enzyme reactions) as an increase in ultra -violet 
absorbance resultant of the reduction of nicotinamide- adenine dinucleotide 
phosphate. The reaction may be described by the following equations 
which are shown overleaf. 
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CK 
ADP + phosphocreatine ' ATP + creatine 
HK 
ATP + glucose glucose -6- phosphate + ADP 
G -6 -PDH 
glucose6- phosphate + NADP -7 NADPH + 6- phosphogluconate 
where: 
HK = hexokinase 
G -6 -PDH = glucose -6- phosphate dehydrogenase 
NADP = nicotinamide- adenine dinucleotide phosphate 
NADPH = nicotinamide- adenine dinucleotide phosphate, reduced. 
The rate of change in absorbance at 340 nm (measured spectrophotometrically) 
is proportional to the activity of creatine kinase in the sample. 
Samples were analysed according to kit instructions using a Pye 
Unicam SP8 -100 recording spectrophotometer with temperature control 
(Pye Unicam Ltd., Cambridge, UK). Commercially prepared control sera 
(normal and high creatine kinase activity) were run with each sample 
batch. Assays were performed at 340 nm and 30 °C using glass cuvettes with 
a 1 cm light path and water as blank. Serum samples were warmed to 30 °C 
prior to assay. Only samples with creatine kinase activities greater 
than 250 IUl 
1 
were diluted and re- assayed, since a dilution effect 
resulting in increased enzymic activity on dilution of serum with an 
initially high creatine kinase activity has been noted (Spikesman and Brock, 
1969). Distilled, deionised water was used as diluent in these cases. 
Samples and control sera of known creatine kinase activity were run 
in duplicate and the mean result used. Creatine kinase activities were 
obtained by calculating the change in absorbance (AA) for a five minute 
period, where: 
AA= Af - Ai 
A 
= initial absorbance 
i 
Af = final absorbance 
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the reaction being measured during the linear phase. 
Creatine kinase results were expressed in international units (IU), 
where an international unit may be defined as that amount of enzyme 
(creatine kinase) which will convert one micromole of substrate 
(phosphocreatine) in one minute under standard conditions: 
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3-3 RESULTS 
For distributions of serum creatine kinase activities in DMD Patients, 
DMD carrier Group A and their matched controls refer to Figure 3.1. 
Technical variation in measurement of this enzyme expressed as the 
coefficient of variation (CV) was CV = 0.5%. In one normal 25 -year old 
female subject, who underirent no strenuous exercise over the period of 
study, biological variation (7 serum samples taken over an 8 -hour period) 
was CV = 18.95 (refer to Figure 3.3). 
In this and subseauent chapters tabulated means and standard deviations 
have been reported untransformed in order to summarise results obtained. 
Non -parametric statistical tests have been used to compare and assess the 
relatively small DMD patient and matched control groups. Non- parametric 
analyses have also been carried out when non -normal distributions have been 
found in the DMD carrier or their matched control groups. The reference 
for each ststistical test used has been cited by the relevant test at 
first time of usage. 
DMD Patient and Control Group 
For mean and individual serum creatine kinase activities in the 'MB 
patient and control group, refer to Tables 3.1. and 3.2. respectively. 
A significant difference (p<:- 0.01) was found between serum creatine 
kinase levels in DMD patients compared to their matched controls by 
Wilcoxon test (Seigel, 1956) . There was no overlap between the results 
of the two groups. 
Serum creatine kinase activity decreased significantly with increasing 
subject age in the DMD patients, shown by Spearmans rank correlation 
coefficient, rs= -0.81, p 0.01 (Seigel, 1956). There was no overlap 
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Figure 3.1. Distribution 
of Serum Creatine Kinase Levels in 
DiID 
Patients, DID Carriers and 
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Table 3.2. Individual Serum Creatine Kinase Levels in DMD Patients 
and their Age and Sex Matched Controls 
AGE AND SEX MATC?DD CONTROLS DMD PATIENTS . 
Subject 
Subject CK Pedigree Age CK 
No. & Age IU 1 No. Yrs . IU -1 
1 7 48 6112 5 22842 
2 8 69 1 II,, 6 21600 
3 8 33 2 III, 6.75 6026 
4 9 47 7 lv2 9 324o 
5 10 47 3. Iv1 9 4147 
6 11 8o 4 III2 10 1253 
7 11 82 5 III, 
J 
10.5 3672 
a 11 55 8 IIi3 10.5 3024 
9 13 105 9 II14 13 1701 
10 14 67 10 I2 14 1980 
CK serum creatine kinase 
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Figure 3.2. Relationship Between Serum Creatine Kinase Level 

















o D.M.D. CARRIERS n =15 
CONTROLS n =15 
= 130 o ° 
120- o 
CID 
z 110- 0 














1 0 10 20 30 40 50 60 70 
AGE YEARS 
Figure 3. 3. Alterations in Serum Creatine Kinase Activity in One 
Normal Female Subject over an 8 -hour Period 
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between the enzyme levels of these two groups. A significant positive 
correlation was found between serum creatine kinase activity and age in 
the healthy control boys (rs' =0.60, p 4_0.05). Note that in this case 
(and subsequently when relevant) where a number of tied observations have 
occurred within a group of measurements the Spearmans rank correlation 
coefficient, rs, has been replaced by the modified Spearmans rank 
correlation coefficient, rs'. 
Relationships between serum creatine kinase activity and other 
serum proteins studied in these subjects have been discussed in the 
relevant subsequent chapters. 
DMD Carrier and Control Croup A 
For mean and individual serum creatine kinase levels in this DMD 
carrier and control group refer to Tables 3.3 and 3.4. respectively. 
Mean serum creatine kinase activities in both DMD carriers and their 
controls were found to be normally distributed by Kolmogorov- Smirnov 
test (Seigel, 1956) and therefore these groups were compared parametrically. 
However, methodology, reagents and equipment for creatine kinase 
estimation were the same as those used routinely for DMD carrier 
detection purposes by Department of Human Genetics, Edinburgh, where 
in this considerably larger study involving 94 DMD carriers and 200 
controls, (Emery, 1981), serum creatine kinase activities in control 
women were not normally distributed. Therefore DMD carrier and control 
Group A were also compared non -parametrically. 
A significant difference was found between mean serum creatine 
kinase activities in the Croup A DMD carriers and controls by Students 
paired t test (Snedicor and Cochran; 1967) (p e--- 0.025) confirmed by 



































































































































































































































































































































































































Table 3.4. Individual Serum Creatine Kinase Levels in DMD Carriers 
and Their Age and Sex Matched Controls 






Subject Pedigree Age 
No. &.Age 1st 2nd Mean No. Yrs . 1st 2nd Mean 
1 24 27 20 24 10 II2 24 213 41 127 
2 30 33 47 40 11 11 29 123 119 121 




10 108 106 
4 33 23 3o 27 13 11 35 83 76 8o 
5 34 3o 31 31 14 II11 38 la 86 133 
6 40 52 38 45 15 114 4o 37 36 37 
7 41 8o 66 73 16 II; 43 228 16o 194 
8 44 42 46 44 17 114 43 111 8z. loi 
9 49 49 52 51 18 115 50 206 231 
10 50 63 oo 77 10 12 51 27 519_ 423 
11 52 48 42 45 19 113 52 2 __ 182 223 
12 54 19 17 18 20I14: 55 56 69 63 
13 58 49 54 52 21 II1 59 195 194 195 
14 61 49 50 50 22 1118 60 269 189 230 
15 60 65 75 70 23 Il 60 100 110 105 
elevated levels underlined 
CE serum creatine kinase 
Note that in this and subsequent tables an elevated level signifies 
a serum level greater than the 95th percentile of the control series. 
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12/15 (80%) of Group A DMD carriers had mean serum creatine kinase 
activities raised above 86 IUl -1, the upper 95th percentile of serum 
creatine kinase activity in the Department of Human Genetics control 
series cited earlier (Emery, 1981). This 95th percentile based on a 
control series of 200 normal women was considered superior to that 
calculated using 15 normal control women. 
In normal control no. 10 (refer to Table 3.4 creatine kinase 
activity measured in the second serum sample (90 IU1 -1) was raised 
slightly above the 95th percentile of the control series, however, the 
mean serum creatine kinase level of this subject was within the normal 
range. In 2 DIN carriers (10 II2 and 14 III1) creative kinase levels 
greater than the 95th percentile of the control series were found in 
only one of two serum samples taken, however mean results remained 
outwith normal limits. 
A significant relationship was found between mean serum creatine 
kinase activity and age in both DND carrier and control groups 
(rs= 0.76, p < 0.01 and rs= 0.54, p <0.05 respectively); refer to 
Figure 3.2. 
Other proteins measured on the serum samples from these subjects 
have been listed in Table 3.5. Relationships and comparisons of serum 
creatine kinase with serum pyruvate kinase, haemopexin and myoglobin 
and their combined use in carrier detection have been discussed in the 
relevant subsequent chapters. 
DMD Carrier and Control Group B 
DMD carriers in this group, having known genetic carrier status 
but serum creatine kinase levels less than the 95th percentile of the 



















































































































































































































































































































































































































of serum myoglobin measurement. Therefore the single serum sample 
creatine kinase estimations made on these carriers and their age and sex 
matched controls have been detailed in the appropriate chapter (refer to 
Section 6 -3. and Table 6.6). 
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3 -4. DISCUSSION 
As a particularly sensitive marker of DIM, the level of serum 
creatine kinase was considerably elevated in all the DMD patients studied, 
with no overlap in levels of this enzyme between the DIN patients and 
their matched controls. The significant decline in the level of serum 
creatine kinase with increasing age in the Duchenne subjects is considered 
to reflect the decreasing muscle bulk and activity of these patients with 
disease progression. Conversely, serum creatine kinase levels in the 
healthy, age matched control boys increased significantly with increasing 
age, demonstrating the increasing muscle development and growth occurring 
in these subjects. Meltzer (1971) reported serum creatine kinase activities 
in normal males peaked between the ages of 10 -19 and 40-49 years. 
Several workers (Gardner- Medwin et al., 1971; Bundey et al., 1979; 
Tippett et al., 1982) have also reported the non -Gaussian distribution 
of serum creatine kinase activities found in the 200 adult females used as 
a control series by the Department of Human Genetics, Edinburgh (refer to 
Section 3 -3.). Gale and Murphy. (1979) concluded from their analysis of 
published data that the Normal assumption was not justified in the case of 
serum creatine kinase distribution in DI-íT1 carriers either. 
The wide fluctuation in serum creatine kinase level exhibited by 
several of the D_D carriers investigated is often noted where multiple 
sample testing has been carried out (Gardner -Medwin et al., 1971; Bradley 
and Keleman, 1979). 
The reported effects of age on serum creatine kinase level appear 
complex and remain controversial. Some workers have not found a consistent 
relationship between the level of this enzyme and age in DIM carriers 
(Gardner- Med;rin et al., 1971; Zatz and Otto, 1980a) whilst others have 
reported serum creatine kinase activity to decrease with increasing 
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DMD carrier age (Yíoser and Vogt, 1974; Lange and Zatz, 1979) . In normal 
females the level of serum creatine kinase may be highest pre- menarche, 
decrease ground menarche, decrease slightly through adult life and then 
rise slightly after age 40 (2mith et al., 1979; Bundey et al., 1979; 
Lane and Roses, i 9 d1 Some workers, however, found no consistent 
alteration in serum creatine kinase level and age in normal women 
(Thomson, 1968; Meltzer, 1971) whilst others (Perry and Fraser, 1973; 
Sweetin and Thomson, 1973) consider the enzyme level increases with 
increasing age or following the menopause. These studies of age effects 
on serum creatine kinase levels in normal -women have been discussed in 
detail by Tane and Roses (1981) . The variation in serum creatine kinase 
activity found in different age groups may be hormonal in origin, reflecting 
alterations in oestrogen level (Shumate et al., 1979; Lane and Roses, 1981). 
Certainly serum creatine kinase levels appear to be higher in states 
consistent with loitered oestrogen levels relative to the adult woman. 
Also, levels of this enzyme appear to be lower when oestrogen levels are 
increased, as in oregnancf (King `t al., 1972) although the smaller 
more transient increase represented by use of the contraceptive pill, or 
by the menstrual cycle, do not appeal to supress the level of serum 
creatine kinase in normal women (Pearce et al., 196Lb; Bundey et al., 1979; 
TTippett et al., 1982). 
In this study serum creatine kinase levels in both the DMD carrier 
group and their age matched controls exhibited a significant positive 
correlation with age. Ten of the women in each group were age 40 or 
older and so clearly the results obtained in both subject groups will 
reflect mainly the influence of this particular age range. In the DMD 
carriers studied the variation in serum creatine kinase activity with age 
may reflect a decreased oestrogen level with a concommitant increase in 
serum creatine kinase activity in the post menopausal carriers (as has 
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been discussed in normal women) or reflect the action of other age 
re=lated factors such as possible decreased renal clearance of the enzyme 
in older women. In the case of the DUD carrier group the results did not 
ag,rce with those of comparable studies (Gardner- i.ïed:in et al., 1971; 
Lange and `at-, 1979). This may be explained, at least in part, by the 
different age range selected in each study leading to a possible 
influence on results according to the proportion of younger (pre menarchal 
and /or menarchal) to older (post menopausal) women. The results observed_ 
in the normal female controls, taking into account the large proportion 
of women over 40 -rears of age, agree ':'ith those of Perry and 7raser, 1973; 
Sweetin. and Thomson, 1973; Bundey et al., 1979; Lane and Roses. 1931. 
The overlap in distribution between serum levels of creatine kinase 
in the D D carriers and their matched controls indicated the necessity 
for precise measurements of this enzyme in suspected DIT carriers to 
enable reliable genetic counselling to be given. In the Department of 
Human Genetics, I]di nburgh, the probability of a consultand being. a _II) 
hetero rgote is calculated using Bayesian theory, employing combined 
information from pedigree data and serum creatine kinase measurement 
(Emery and Holloway, 1977; :Fiery, 1930) . In these calculations the actual 
serum creatine kinase level of the consultand is taken into account by 
examining the "h" value and the ratio of the proportions of normal_ women 
to D1dD carrier ?'omen with this enoirme level calculated from the distribution 
of levels of this enzyme observed in the Department in a series of controls 
and genetic D =19 carriers (Emery 198l). The serum creatine kinase levels 
of the suspected carriers' first degree female relatives oÎ child bearing 
age and also the presence of healthy sons and brothers are incorporated 
into the Probability calculations. 
Clearly it is irmportant to be aware of any factors which might 
influence serum creatine kinase measurements undertaken for genetic 
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counselling purposes. Apart from the apparently complex effects of age 
and the conditions listed in Section 3 -1. other factors which influence 
serum levels of this enzyme have been investigated. 
The significant decrease in serum creatine kinase activity observed 
in normal women during early pregnancy reported by King et al. (1D72) 
and Bundey et al. (1979) and in DMD carriers by Emery and King (1971) 
emphasise the difficulty involved in determining the carrier status of 
a pregnant suspected DI'ID heterozygote. However most (Perry and Fraser, 
1973; Simpson et al., 1974; Tippett et al., 1982) but not all workers 
(Paterson and Lawrence, 1972) considered use of the contraceptive pill 
did not significantly alter serum creatine kinase activity. Similarly, 
most reports (Pearce et al., 1964b; Perry and Fraser, 1973; Simpson 
et al., 1974) considered the stage of the menstrual cycle did not 
influence'serum levels of this enzyme, although Paterson and Lawrence 
(1972) found serum creatine kinase activity was lower in days 12 -26 of 
the 'cycle than in days 1 -11 in their subjects. 
Standard exercise tests have been suggested as a way of improving 
the detection efficiency of serum creatine kinase measurements in DMD 
heterozygote detection and therefore work on effects of exercise has 
been discussed in Section 3 -1. It would appear that normal daily 
activity does not significantly influence serum creatine kinase levels, 
at least in normal women (Pearce et al., 1964b). 
Meltzer (1971) reported that mean serum creatine kinase levels 
were higher in Negroes than Caucasians. Clearly this could result 
in erroneous DMD heterozygosity risks should the serum creatine kinase 
estimation of a consultand of one ethnic origin be compared to reference 
enzyme levels from women of a different race. 
Diurnal and seasonal variations in serum creatine kinase levels 
have also been noted. Gale and Murphy (1979) concluded from their survey 
of the literature that serum creatine kinase activity increased during 
the course of the day. In this study results from measurements on one 
healthy female, taken under conditions of everyday activity, (refer to 
Figure 3.4.) suggest there is a fluctuation in creatine kinase level 
between the hours of 9 a.m. and 5 p.m. Smith et al..(1979), in a large 
study involving 625 normal females, noted serum creatine kinase levels 
were at their lowest in February and peaked in August. Percy et al. 
(1982a) reported a different seasonal variation of serum creatine kinase 
activities in DMD carriers (whose enzyme measurements were lowest in 
November and at their highest in May) than in control females (where 
creatine kinase levels were lowest in May and highest in November). 
In neither situation were the differences between mean creatine kinase 
activities at the extremes statistically significantly different, however 
Percy et al.(1982a) concluded that the reliability of serum creatine 
kinase estimation in DID heterozygote recognition could be improved by 
consideration of the season. Smith et al. (1979) considered the seasonal 
fluctuation might be related to seasonal hormonal changes. 
An intrafamilial correlation with serum creatine kinase levels has 
been noted in certain families ( Sibert et al., 1979; Tippett et al., 1982). 
Also, unexplained occasional high serum creatine kinase measurements 
in normal women have been noted by Thomson, (1968) and this study (female 
control no. 10, refer to Table 3.4.). Consequently it would appear 
that not all factors capable of influencing serum creatine kinase levels 
in either DPID carriers or normal women are yet fully understood. 
Quite apart from physiological factors, serum creatine kinase 
activities may be altered by treatment of the sample prior to assay and 
by the method of assay itself. Pearce et al. (1964b) reported serum 
levels of creatine kinase decreased rapidly following repeated cycles of 
freezing and thawing. Dilution of DMD carrier serum prior to assay can 
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increase the measured activity of the enzyme, which Thomson (1969) 
considers may be due to the presence of inhibitors of creatine kinase 
in serum. Such inhibitors might, at least partially, account for the 
considerable variation in DND carrier serum creatine kinase levels 
(Pennington, 1977). The various assay systems for creatine kinase 
measurement used by different laboratories have been discussed in detail 
by Gale and Murphy (1979). faith different biochemical bases these 
methods may well have different sensitivities and hence DUD carrier 
recognition capabilities. 
Despite taking all these factors into consideration substantial 
improvement in DUD heterozygote detection may only be obtained by 
supplementary information from the additional measurement of one or more 
non -correlated parameter(s). 
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CHAP'1'liH 4: PYRUVA'1'E KINASE 
4-1. I'ü! ODUO TION 
Pyruvate kinase (ATP: pyruvate phosphotransferase E.û.2.7.1.4.0) is 
a glycolytic enzyme, glycolysis providing an important source of energy 
to muscle and other tissues. Pyruvate kinase catalyses the following 
reaction, which provides a physiological rate limiting step in ATP 
formation: 
PK 
ADP + phosphoenolpyruvate ' ATP + pyruvate 
where: 
ADP = adenosine diphosphate 
ATP = adenosine tri-phosphate 
r;, = pyruvate kinase 
The enzyme is present in many tissues in one of two isoenzyme forms, 
type or type L (with the exception of hepatocytes in which both forms 
are present). Type Iï (molecular weight 250,000 daltons) may be further 
divided by electrophoretic mobility into type El found in skeletal and 
cardiac muscle and brain; type found in liver, lung, leucocytes and 
adipose tissue, type ri present in intestine, testes and ovary and 
type N1 present in smooth muscle and kidney. Type L (molecular weight 
208,300 daltons) is found in liver and erythrocytes and differs from 
type Ii kinetically and in its response to ATP; alanine; fructose 
l,6- diphosphate and in its temperature sensitivity. 
Significantly increased serum pyruvate kinase activities have been 
reported associated with the following conditions: 
(1) acute myocardial infarction 
(2) muscular dystrophies 
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(3) alcoholic myopathy 
(4) polymyositis 
(5) severe hepatitis 
In conditions (1) to (4) increased serum pyruvate kinase activities 
are considered to be due to leakage of type I11 pyruvate kinase from 
diseased or damaged muscle. In a case of severe hepatitis reported to 
have raised serum pyruvate kinase activity, the enzyme exhibited type L 
properties. 
iIarano et al. (1973) first investigated serum pyruvate kinase 
activities in DID and reported elevated activities of this enzyme in all 
20 DMD subjects studied. Even severely affected DIM patients Whose 
serum creatine kinase activities had decreased to normal levels retained 
elevated serum pyruvate kinase activities. Since then, several workers 
have confirmed that a very high proportion of DIU patients do have 
raised serum pyruvate kinase activities (Alberts and Samaha, 1971"; 
i: einstock et al., 1977; Zatz et al., 1D78). 
The Possibility that serum pyruvate kinase might be acre sensitive 
than serum creatine kinase in DIM carrier detection was examined by 
Alberts and Samaha (1474). In a series of 29 DMD patients, 24 carriers 
and 35 contas, all DEL subjects had increased serum pyruvate kinase 
activities as did 5 of 7 (71) definite, 3 of 4 (75:) probable and 7 of 
15 (1'6 ) possible DI:L carriers. Only 2 definite, 1 probable and 1 
possible carrier were reported to have raised serum creatine kinase 
activities. Alberts and Samaha (1974) stated pyruvate kinase was 3 times 
as sensitive as creatine kinase in detecting the carrier state. 
Other workers could not confirm these observations. Hardy et al. 
(1977) investigated 21 control subjects and 17 DEL carriers. Five 
carriers (29;1) had elevated serum pyruvate kinase activities but 11 
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(64%) had raised serum creatine kinase activities. None of the carriers 
whose serum creatine kinase activity fell within normal limits were 
found to have elevated serum pyruvate kinase activities. Similarly, 
Yamuna et al. (1977) and Seay et al. (1978) found serum creatine kinase 
to be superior to serum pyruvate kinase in carrier detection. These 
workers, in contrast to the results of Alberts and Samaha, reported that 
carriers with normal serum creatine kinase activities also exhibited 
normal serum pyruvate kinase activities and considered the combined use 
of these two parameters would not be of value in carrier detection. 
However, others(Percy et al. 1979; Zatz et al. 1980; Zatz and Otto, 
-(1980b) do consider that carrier detection efficiency is improved by 
measurement of both parameters. 
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4 -2. MATERIALS AND METHODS 
4 -2.1. Serum Pyruvate Kinase 
Total serum pyruvate kinase activity was measured during everyday 
activity in the following group of subjects. 
(1) Carrier and control group A, comprising 15 DMD carriers 
and 15 age- matched normal, healthy women. 
The carriers and controls were selected as stated in 3 -2. Blood 
samples were collected and processed according to the protocol 
described in 3 -2. 
Two blood samples were obtained 4 -7 days apart from all subjects. 
The mean activity of serum pyruvate kinase of both samples was used. 
Other analyses were also carried out on different aliquots of these 
serum samples as described in Table 3.5. 
All sera were analysed within 6 hours of collection since 
controversy exists regarding the stability of Type M pyruvate kinase 
isoenzyme There have been reports that this isoenzyme is stable 
in frozen sera stored for at least one year (Harano et al., 1973). 
More recently, however, other workers have reported that all pyruvate 
kinase isoenzymes progressively lose activity upon freezing (Zatz et al, 
1978; Percy et al., 1978). Zatz et al. (1978) found that the pyruvate 
kinase activity of sera stored at -20 °C for two months was reduced 
to half its initial level. 
Certainly serum pyruvate kinase activity decreases rapidly when 
blood is kept at room temperature. In this study the activity of the 
enzyme decreased by 44.7% over a 24 hour period (refer to 4 -2.2). 
With the exception of the second sample obtained fron one DMD 
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carrier (8 II13) no sera showed any sign of haemolysis. This one 
slightly haemolysed serum sample was not analysed due to possible 
assay interference. 
Total serum pyruvate kinase activity was measured using a 
commercially available kit, Boehringer Mannheim test -combination 
( Boehringer Corporation London Ltd., East Sussex, U.K.), based on the 
method of Beisenherz et al. (1953). In this assay system pyruvate 
kinase activity is measured as the rate of reaction in the direction of 
pyruvate formation. A coupled enzymic reaction measures pyruvate 
produced indirectly as the decrease in reduced nicotinamide adenine 
dinucleotide absorbanc.at 340 nm. The reaction may be described by 
the folio ::ing equations: 
PIC 
ADP + phosphoenolpyruvate, ATP + pyruvate 
pyruvate + IZADH + H+ 
where: 
LDH 
T,-lactatë + NAD 
PIADH = nicotinamide- adenine dinucleotide, reduced 
NAD-+ = nicotinamide- adenine dinucleotide 
LDH = lactate dehydrogenase 
The rate of change in absorbance at 340 nm was measured 
(spectrophotometrically) using a Pye Unicam SP8 -100 recording 
spectrophotometer with temperature control. Assays were carried out 
at 25 °C using glass cuvettes with a 1 cm light path and air as a blank. 
Serum samples were warmed to 25 °C prior to assay. Pyruvate kinase 
activities -ere measured using halved quantities of serum and all 
reagents but otherwise as according to kit instructions. 
All samples were run in duplicate and the mean results used. 
Pyruvate kinase activities were obtained by calculating the change 
in absorbance (A) for 10 minute period: 
A = (Af - Ai) 
where: 
Ai = Al - A2 
Af = A3 - A4 
A = initial absorbance of reaction mixture 
(serum and all reagents except ADP) 
A2 = absorbance of reaction mixture (serum and all reagents 
except ADP) exactly 10 minutes after measurement Al 
A3 = initial absorbance of reaction mixture following 
addition of ADP 
A4 = absorbance of reaction mixture exactly 10 minutes 
after measurement of A3 
Pyruvate kinase results were expressed in International Units (IU) 
defined as before (Chapter 3) . 
4-2.2. Effect of Storage of Serum on Pyruvate Kinase Activity 
Total serum pyruvate kinase activity was measured during everyday 
activity in one normal, healthy 24 year old female subject. 
A single blood sample was collected at 11 a.m. and processed 
according to the protocol described. Eight aliquots from the serum 
sample were stored at room temperature (23 °C) and analysed over a 
24 -hour period (from time of collection). A further 2 aliquots were 
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stored at 4 °C and - 70 °C respectively and analysed at 24 -hours from 
time of collection. The method of analysis was as described in 4 -2.1. 
Each aliquot was analysed in duplicate and the mean result used. 
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4-0. RESULTS 
For distributions of serum pyruvate kinase levels in the DMD carrier 
and control group studied refer to Figure 4.1. 
Technical variation in serum pyruvate kinase measurement expressed 
as coefficient of variation (CV) was 0.9%. 
In one normal female control aged 25 years, biological variation of 
pyruvate kinase activity in 10 serum samples (taken between 11 a.m. and 
12 noon; not less than 24 hours apart and analysed four hours from time 
of collection) was CV = 16.2%. 
Storage of serum from one individual for 24 hours at room temperature 
(refer to Section 4 -2.2.) resulted in a 44.75 loss in pyruvate kinase 
activity. Less than 1.2% loss in activity occurred following four hours 
storage at room temperature. Aliquots of this serum sample stored at 
4 °C and - 70 °C lost 26.55 and 14.5% pyruvate kinase activity respectively 
after a 24 -hour period (refer to Figure 4.2.) . 
For mean and individual serum pyruvate kinase levels refer to 
Tables 4.1. and 4.2. respectively. 
In this and subsequent chapters the precise ages of the control 
subjects have been omitted from tables listing individual results but 
may be found in the comparable tables in Section 3 -3. Mean serum pyruvate 
kinase activities in both DMD carriers and their controls were not 
normally distributed but log base 10 (log10) pyruvate kinase levels 
fitted within the normal distribution ( Kolmogorov- Smirnov test). 
A significant difference was found between log10 mean serum pyruvate 
kinase levels in the DMD carriers tested compared to their matched controls 
(Students paired t test, pt.. 0.001). However, there was a large degree 
of overlap between results in the two groups. 
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Figure 4.1. Distribution of Serum Pyruvate Kinase Levels in DMD 
Carriers and Age and Sex Matched Controls 
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Figure 4.2. Decrease in Pyruvate Kinase Activity Observed in Serum 
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Table 4.2. Individual Serum Pyruvate Kinase Levels in DMD Carriers and 
their Age and Sex Matched Controls 
AGE AND SEX MATCHED CONTROLS 
Subject PK IU1 -1 Mean CK 








PK IU1 -1 
1st 2nd Mean 
Mean CK 
IU1 
1 18 22 20 24 10 II2 24 21 17 19 127 
2 17 23 20 40 11 II3 29 18 19 19 121 
3 29 17 23 44 12 1114 33 30 24 27 106 
4 13 18 16 27 13 112 35 20 24 22 80 
5 29 32 31 31 14 III1 38 40 18 29 133 
6 13 12 13 45 15 114 40 18 22 20 37 
7 16 14 15 73 16 II1 43 26 22 24 194 
8 22 13 18 44 17 114 43 32 H 32t 101 
9 18 18 18 51 18 I15 50 26 28 27 231 
10 22 15 19 77 10 I2 51 28 28 28 423 
11 20 15 18 45 19 113 52 19 51_ 25 223 
12 11 11 11 18 20 I14 55 17 17 17 63 
13 13 25 19 52 21 II 1 59 30 32 31 125 
14 10 10 10 50 22 1118 60 2f 25 30 
230 
15 16 15 16 70 23 Il 60 26 23 25 125 
elevated levels underlined 
haemolysed sample, PK not measured 
single sample result 
PK serum pyruvate kinase 
CK serum creatine kinase 
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95% confidence limits were calculated from the regression of log10 
mean serum pyruvate kinase levels on age in the control subjects (Snedicor 
and Cochran; 1967). Although no significant relationship was found 
between log10 mean serum pyruvate kinase activities and age in the 
DMD carrier group (r = 0.48), a significant negative regression of 
logged mean results of this enzyme on age were found in the control 
subjects (r--0.53, p < 0.01). -4/14 (28.5%) DMD carriers had log10 mean 
serum pyruvate kinase levels outwith the calculated 95 confidence limits. 
(refer to Figure 4.3.). Age Correcting the DiW carrier results did not 
alter the number of carriers detected by this enzyme. The age corrected, 
single serum result on Dim carrier 17 114 was not outside the calculated 
upper 95% confidence limit. 
Lean serum pyruvate kinase and creatine kinase activities were 
significantly correlated in the DW carrier group (rs = 0.69, p < 0.01) 
but no significant relationship was found between these enzymes in the 
control subjects (rs = -0.17), shown in Figure 4.4. 
There was a significant correlation between serum pyruvate kinase 
activity (first serum sample measurement) and the serum level of 
haemopexin in the DMD carrier group (rs = 0.45, p < 0.05) which was not 
found in the matched controls (rs = 0.14), 
No significant relationship was evident between serum levels of 
pyruvate kinase (first serum sample) and myoglobin in either the DMD 
carriers (rs = 0.39) or their matched controls (rs = 0.19). 
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Figure 4.3. Relationship Between Serum Pyruvate Kinase and Age in 
DMD Carriers and Age and Sex Matched Controls 
A. DMD Carriers 
Equation for the line: y = 1.22 + 0.003x 
r = 0.48, p = NS 
B. Controls 
Equation for the line: y = 1.48 - 0.0055x 
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Figure 4.4. Relationship Between Serum Pyruvate Kinase and Creatine 
Kinase Levels in DMD Carriers and their Age and Sex 
Matched Controls 
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Spearman's Rank Correlation Coefficient 
rs = 0.69, p< 0.01 
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The rapid decrease of pyruvate kinase activity to almost half 
initial level following 24 hour storage of serum at room temperature 
(23 °C) demonstrated the unstable nature of this enzyme, also reported by 
Smith and Thomson (1977). These workers, in comparison with serum 
creatine kinase measurement had commented on the unsuitability of 
assaying pyruvate kinase activity on posted serum samples (since some 
serum creatine kinase assays for use in DMD carrier detection must, of 
necessity, be performed on samples which may have been in the post for 
2 - 3 days, and yet produce acceptable results; refer to Chapter 3). 
In this study, whilst 4 hours at room temperature had resulted in only a 
small decrease in serum activity (1.2 %) a much greater (14.50 loss of 
pyruvate kinase activity had occurred following freezing at - 70 °C and 
subsequent analysis 24 hours later. Zatz et al. (1980) and Percy et al. 
(1979) also found pyruvate kinase activity progressively decreased on 
freezing (by approximately 50ó at - 20 °C following a two month period 
in the former study). Zatz et al. (1980) considered the results of 
some studies (Hardy et al., 1977; Yamuna et al., 1977) may have been 
affected by the use of frozen stored samples. Certainly these results 
dispute the frozen stability of pyruvate kinase M isoenzyme for up to 
one year reported by Valentine and Tanaka (1966). 
In agreement with Hardy et al. (1977) and Zatz et al. (1980) serum 
pyruvate kinase levels were not normally distributed but log (base 10) 
activities of this enzyme fitted within a Gaussian distribution. However 
some other workers did not state whether normality of distribution had 
been tested for and did not log- transform data prior to analysis 
(Alberts and Samaha, 1974; Sage et al., 1979; Seay et ál., 1978). 
These differences in treatment of samples prior to enzyme assay; in 
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assay systems used and in the treatment of data produced all severely 
adversely affect the comparison of work from different centres. However, 
despite such differences most centres have reported significantly higher 
serum pyruvate kinase activities in DMD carriers compared to control 
subjects, as was found in this study (Alberts and Samaha, 1974; Sage 
et al., 1979; Zatz et äl.,1980; Muir et al.,1983). 
Whilst no significant relationship was found between log10 mean 
serum pyruvate kinase activity and age in the DMD carriers studied (in 
agreement with Smith and Thomson, 1977) a significant negative correlation 
was evident in their matched controls. Both Sage et al. (1979) and Zatz 
et al. (1980) found serum pyruvate kinase activities were significantly 
higher in normal children compared to normal adults. Sage et al. (1979) 
also reported that in the DMD carriers (of all categories) tested, 75% 
of those with elevated serum levels of pyruvate kinase were less than 
20 years of age. Such findings suggest that the report of Percy et al. 
(1979) which contradicted the findings of this study (in that log10 
serum pyruvate kinase levels were found to be significantly correlated in 
DMD carriers but not in controls) may, at least in part, have reflected 
alterations due to the different age groups studied. Percy et al. (1979) 
used DMD carriers between 17 - 60 years of age, whilst in this study the 
youngest carrier was in her mid- twenties. 
The percentage of DMD carriers in this study who had serum levels of 
enzyme outside calculated 95% confidence limits was very low in the case 
of serum pyruvate kinase (4/14; 28.5%) compared to serum creatine kinase 
(11/14; 78.5%). Furthermore, the 4 DMD carriers selected by serum pyruvate 
kinase measurement also had elevated serum creatine kinase levels. 
These results indicate the lack of usefulness of serum pyruvate kinase 
measurements in DIM heterozygote recognition (in the age range studied) 
both alone , or in combination with serum creatine kinase measurement, 
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in agreement with the studies of Yamuna et al. (1977); Hardy et al. 
(1977); Smith and Thomson (1977) and Seay et al. (1978). Alberts and 
Samaha in 197+ had reported serum pyruvate kinase measurement was more 
sensitive than serum creatine kinase in DMD carrier detection and yet, 
in a later study from this centre encompassing the earlier data, Sage et 
al. (1979) stated that serum pyruvate kinase was more likely to be 
elevated in young (less than 20 years old) suspected carriers and was 
less sensitive in detecting carriers over 20 years. 
Percy et aí.(1979) and Zatz et al. (1980) considered heterozygote 
recognition was improved by combined measurement of both serum pyruvate 
kinase and creatine kinase levels. However both these groups of workers 
reported a much greater percentage of their genetic DMD carriers 
investigated had serum pyruvate kinase activities elevated above each 
centres' calculated "normal" limits than was found in this and other 
studies (Yamuna et al.,1977; Smith and Thomson, 1977 and Seay et al., 
1978). This is difficult to interpret since serum enzyme levels may be 
resultant of the influence of many factors related to the subjects 
studied and /or methodology used (discussed fully in Section 3 -4). For 
example, ethnic origin has been reported to influence serum enzyme levels 
(Meltzer ,_1971 ) . Percy et al. (1979) found a similarly high 
percentage of DAD heterozygotes studied had elevated levels of serum 
creatine kinase as well as serum pyruvate kinase (70% in each case), 
as did Zatz and co- workers in 1980 (71% and 78.5% respectively). However, 
in the study of Percy et al. (1979) only 2/20 (10%) genetic DMD carriers 
whose serum creatine kinase levels were considered to be within "normal" 
limits had elevated levels of serum pyruvate kinase whilst Zatz et al. 
(1980) found 214 (14.2 %) such carriers. Uhen the apparent improvement 
in DMD carrier detection is small considerable precautions must be taken 
to ensure factors other than the subjects heterozygosity have not resulted 
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in falsely elevated enzyme levels. 
Percy et el. (1979) used single serum sample determinations, whilst in 
the study of Zatz et al. (1980), where multiple serum enzyme determinations _ 
were carried out, one elevated enzyme level was considered indicative 
of DND carrier status. Seay et al. (1978) found in their study that two 
definite (and one possible) DMD carrier had single serum sample elevations 
of pyruvate kinase activity and yet the mean value of two estimations 
fell within "normal" limits. Similarly, in this study two DND carriers 
had elevated serum pyruvate kinase activities of single samples and yet 
mean results were within the calculated 95th percentile of the control 
series. In the case of serum creatine kinase estimations Seay et al. 
(1978) found that where single serum sample elevations of creatine kinase 
activity occured the mean value of two such estimations was always 
elevated as well. A similar situation was found in this study (refer to 
Table 3.4). Such results demonstrate the superior separation between 
DND carrier and control groups by use of serum creatine kinase as 
compared to serum pyruvate kinase. 
In this study serum levels of pyruvate kinase and creatine kinase 
were significantly correlated in the DMD carrier group but not in the 
controls (also found by Hardy et aí.,1977; Percy et äl.,1979; Zatz et al., 
1980 and Zatz and Otto, 1980b), as were serum levels of pyruvate kinase 
and haemopexin. Interestingly, serum levels of pyruvate kinase and 
myoglobin were not significantly correlated in the DMD carriers studied 
(or in the controls). However the one carrier selected by serum pyruvate 
kinase measurement (19 113) also had an elevated level of serum myoglobin. 
Discriminant analysis involving serum measurements of creatine 
kinase, pyruvate kinase, haemopexin and myoglobin (discussed in detail 
in chapter 7) resulted in a DMD carrier detection rate of 12/14 (85.70), 
with 14/14 (l005) controls correctly classified. Discriminant analysis 
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employing only serum creatine kinase and pyruvate kinase measurements 
resulted in only 11/14 (78.6%) DMD carriers (and all 14 controls) being 
correctly classified. Muir et al. (1983), using discriminant analysis 
found serum creatine kinase to be the most discriminating variable of 
three serum enzymes measured. These workers found 14/21 (67 %) definite 
DIN carriers were correctly classified using combined measurement of 
serum creatine kinase and serum pyruvate kinase, however two control 
subjects were misclassified. Using serum creatine kinase measurement alone 
the same percentage of DMD carriers were correctly classified (67%) and 
no misclassification of controls occured. 
These results suggest there is little value to be gained by combined 
measurement of serum pyruvate kinase with serum creatine kinase in DMD 
carrier detection in the age range studied. However Zatz et al. (1983) 
in a preliminary report has suggested that serum pyruvate kinase may be a 
more reliable test for genetic counselling purposes than serum creatine 
kinase in pregnant suspected Di'D carriers. Serum creatine kinase 
levels tend to decrease in early pregnancy in DPID carriers (refer to 
Chapter 3) whilst Zatz et al. (1983) found that in 5 women of varying 
DMD heterozygote risks, non- pregnant and pregnant serum pyruvate kinase 
estimations did not alter significantly. If this finding is confirmed 
serum pyruvate kinase may be of value in the difficult cases where 
genetic counselling-has been requested when the suspected carrier is 
already pregnant. 
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CHAPTER 5: HAEMOPEXIN 
5 -1. INTRODUCTION 
Haemopexin, molecular weight 70,000 daltons (Hrkal and 
Muller -Eberhard, 1971), is a serum glycoprotein with betal -mobility 
(Hershko, 1975). As a transport protein haemopexin is involved in the 
catabolism of the haem moiety of haemoglobin and may also serve as a 
transporter of haem from other sources such as myoglobin (Hayem -Levy 
et a1., 1973). Following intravascular haem release the serum proteins 
haptoglobin, haemopexin and albumin interact to prevent the glomerular 
filtration of haem. When haptoglobin is depleted, remaining haem is 
bound by haemopexin and albumin. Haemopexin binds haem in an equimolar 
ratio (Muller- Eberhard, 1970) and the resulting haem -haemopexin complex 
is sequestered by hepatic parenchymal cells (Hershko, 1975). 
Haemopexin is synthesized exclusively in the liver and released into 
the circulation. The clearance of circulating haemopexin by the 
reticulo- endothelial system is accelerated by formation of the haem - 
haemopexin complex. Under normal conditions very little haemopexin is 
excreted in the urine (Berggard, 1961). Elevated levels of serum 
haemopexin have been reported associated with the following: - 
(1) Duchenne muscular dystrophy 
(2) polymyositis 
(3) myasthenia gravis 
(4) rheumatoid arthritis 
(5) certain forms of cancer 
(6) diabetes mellitus 
In the case of DMD and polymyositis, Adornato et al. (1978a) suggested 
elevated levels of serum haemopexin might be a response to the increased 
level of myoglobin found in such sera since injection of myoglobin and 
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muscle crush injury both raise serum haemopexin levels in monkeys. 
These workers further suggested that elevated serum haemopexin levels 
found in patients with myasthenia gravis might be due to either a slight 
leakage of myoglobin (previously unsuspected) or the reflection of a 
dysimmune state. 
Decreased levels of serum haemopexin have been reported in 
haemolytic disease (due to the rapid clearance of the haem -haemopexin 
complex; in liver disease (caused by a decreased synthesis of haemopexin) 
and in severe renal disease, when haemopexin is lost in the urine. 
An abnormality in the immunoelectrophoretic pattern of serum from 
both DMD patients and their mothers was identified as haemopexin by 
Askanas (1966a and 1966b). Following this work, Danieli and Angelini 
(1976a) measured serum haemopexin using radial immunodiffusion in 62 DMD 
carriers and 26 normal women and found the mean carrier serum haemopexin 
level was significantly higher than that of controls. They reported 
that the combined use of serum haemopexin and creatine kinase determinations 
raised the level of carrier detection in their series of definite and 
probable carriers from 70% to 87% (Danieli and Angelini, 1976b). Some 
carriers with normal serum creatine kinase values were reported to have 
elevated levels of serum haemopexin (Danieli and. Angelini, 197611). 
Other workers (Percy et al., 1978; Adornato et a1,,(1978a) have 
confirmed that an increased amount of serum haemopexin does occur in a 
proportion of DMD carriers, although some (Tagliavini et al., 1979; 
Schiffer et al., 1979) consider the overlap between carrier and control 
measurements limits the usefulness of serum haemopexin as a method of 
carrier detection. 
-128- 
5 -2. MATERIALS AND METHODS 
Serum levels of haemopexin were measured during everyday activity 
in the following groups of subjects: 
(1) 10 patients with DIM together with 10 age- matched, 
normal healthy boys. 
(2) Carrier and control group A comprising 15 DMD carriers 
and 15 age- matched, normal healthy women. 
DMD patients, carriers and controls were selected as stated in 3 -2. 
Blood samples were processed according to the protocol described in 
Section 3 -2. 
All sera were stored in aliquots at -70 °C, being frozen and thawed 
once only and warmed to room temperature prior to analysis within 6 
creeks of collection. Frozen sera may be stored at -70 °C for at least 8 
weeks without significantly affecting the haemopexin level (Adornato 
et al., 1978) . 
Other analyses were also carried out on different aliquots of these 
serum samples as described in Table 3.5. 
None of the samples analysed showed signs of haemolysis. 
Serum haemopexin levels were measured by commercially available 
radial immunodiffusion "M- Partigen" plates (Behringwerke A.G., I ?est 
Germany). These plates use a standard radial immunodiffusion technique. 
The plates contain an agar gel incorporated with. a rabbit anti- human- 
haemopexin antibody. Haemopexin standards or test sera placed in wells 
of equal diameter diffuse out radially through the gel. Circles of 
precipitation form around the wells due to the reaction between 
anti -human haemopexin antibody and the haemopexin present in the 
standard or test sera. The diameter of each precipitation circle is 
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proportional to the concentration of haemopexin within the standard 
or sample. 
The wells on each plate were loaded with 5 pl undiluted serum 
using the same syringe (10 pl Hamilton syringe, Hamilton Bonaduz A.G., 
Switzerland). Great care was taken over accurate loading of the 
syringe and sample delivery. The syringe was rinsed several times 
(distilled water) and dried between each sample delivery. 
Three commercially prepared standards of known haemopexin 
concentration: "protein- standard -serum B" solutions no. I (haemopexin 
28 mgdl -1), no. II (haemopexin 54 mgdl -1) and no. III (haemopexin 
120 mgdl -1) (Behringwerke A.G.) were assayed on each plate and 
standard curves for each plate constructed from them. In each case 
DID patient or carrier sera were assayed on the same plate as their 
matched control. sera. 
Having filled all wells the lids were replaced tightly and the 
plates left at room temperature for 48 hours to develop. The plates 
were then photographed and diameters of the precipitation rings 
measured on 4 x enlargements. 4 independent measurements of circle 
diameter were made on each well and the mean value used (Percy et al. 
1981), 
The squared mean diameters of the standard precipitation rings 
(mm2) plotted as a function of the standard concentrations produced 
standard curves for each plate which were used to determine the 
haemopexin concentrations of the samples. 
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5-3. RESULTS 
For distributions of serum haemopexin levels in all groups studied 
refer to Figure 5.1. 
There was < 3% loss in haemopexin activity in serum stored at - 70 °C 
for up to 6 weeks (with one cycle of freeze /thaw). 
Variation in measurements between plates of the same batch 
expressed as the coefficient of variation (CV) was 3 -4gß. Technical 
variation expressed as CV was 0.7%, and biological variation measured 
in one normal 25 -year old female subject (7 serum samples taken over a 
6 -week period) was CV = 7 %. 
DID Patient and Control Group 
Mean and individual serum haemopexin values in the DMD patient and 
control group have been summarised (Tables 5.1. and 5.2. respectively). 
There was a significant difference between serum haemopexin 
levels in DPW patients and their matched controls (Wilcoxon test, 
1)4.0.05), but considerable overlap between the two groups. 
No significant relationship was found between serum haemopexin 
level and age in either DMD patients (Spearman rank correlation 
coefficient, rs = -0.32) or their controls (rs = - 0.17). 
Serum haemopexin and creatine kinase levels were not positively 
correlated in either DMD patients (r 
s 
= 0.14) or their controls 
rs = 0.08). 
No significant relationship was found between serum haemopexin 
and myoglobin in the DMD patient group (r 
s 
= 0.04 ) or the controls 
(rs = 0.4-7) although there appeared to be a trend towards a relationship 
between these proteins in the control group. 
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Figure 5.1. Distribution of Serum Haemopexin Levels in DMD 
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Table 5 -2. Individual Serum Haemopexin Levels in DMD Patients and their 
Age and Sex -matched Controls 
















1 65 48 6 112 5 87 22842 
2 77 69 1 II2 6 95 21600 
3 63 33 2 1112 6.75 81 6026 
4 82 47 7 1v2 9 102 3240 
5 65 47 3 Iv]. 9 83 4147 
6 91 80 4 III2* 10 89 1253 
7 55 82 5 III,,* 10.5 77 3672 
-8 73 55 8 1113í 10.5 71 3024 
9 71 105 9 II14* 13 59 1701 
10 53 67 10 I2` 14 95 1980 
',:heelchair bound 
CK serum creatine kinase 
::px serum haemopexin 
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DMD Carrier and Control Group 
For mean and individual haemopexin levels in DMD carriers and 
their matched controls refer to Tables 5.3. and 5.4. respectively. 
Serum haemopexin levels in DMD carriers and controls were normally 
distributed (Kolmogorov- Smirnov test). There was no significant 
difference between levels of haemopexin in DMD carriers compared to 
their matched controls (Student's paired t test). There was considerable 
overlap between the results of the two groups. 
The relationship between level of haemopexin and age was just 
significant in the carrier group (r = 0.52, p 4.0.05) but no significant 
relationship (r = 0.06) was exhibited by the control group (refer to 
Figure 5.2.). 95% confidence limits were calculated using the formula 
cited in Section 4 -3.1. In 1/15 (6.6%) carriers the serum haemopexin 
level was raised above the calculated upper 95% confidence limit. 
Serum haemopexin and creatine kinase levels were correlated in the 
DMD carrier (rs = 0.63, p4 0.01) but not in the control series (rs = 0.02) 
Refer to Figure 5.3. 
The relationship between serum haemopexin and pyruvate kinase levels 
has been discussed in Chapter 4. 
No significant relationship was found between serum haemopexin and 
myoglobin levels in the DMD carrier group (rs = 0.34) however the relationship 
between these proteins just reached significance in the matched control 
group (r' = 0.47, p . 0.05). Refer to Figure 5.4. For serum myoglobin 













































































































































































































































































































































Table 5.4. Individual Serum Haemopexin Levels in DMD Carriers and 
Age and Sex Matched Controls 
AGE AND SEX MATCHED CONTROLS 
Subject Hpx CK 
-1 _1 
No. mgdl IU1 
DMD CARRIERS 
Subject Age Hpx 
Pedigree 
_1 




1 83 27 10 II2 24 94 213 
2 63 33 11 II13 29 73 123. 
3 90 44 12 1114 33 80 103 
4 94 23 13 II2 35 76 83 
5 70 30 14 III1 38 77 179 
6 83 52 15 114 40 64 37 
7 59 80 16 II1 43 85 228 
8 85 42 17 I14 43 81 115 
9 78 49 18 115 50 95 206 
10 83 63 lo 12 51 94 327, 
11 85 48 19 113 52 87 263 
12 71 19 20 I14 55 73 56 
13 85 49 21 II1 59 91 195 
14 77 49 22 1118 60 101 269 
15 86 65 23 I1 60 120 100 
elevated levels underlined 
Hpx serum haemopexin 
CK serum creatine kinase 
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Figure 5.2. Relationship between Serum Haemopexin Level and Age in 
DMD Carriers and their Age and Sex Matched Controls 
A. DMD Carriers 
Equation for the line: y = 58.11 + 0.62x 
r = 0.52, p< 0.05 
B. Controls 
Equation for the line y = 78.56 + 0.02x 
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Figure 5.3. Relationship Between Serum Haemopexin and Creatine 
Kinase Levels in DHD Carriers and Their Age and Sex 
Matched Controls 
DMD Carriers 
Spearman's Rank Correlation Coefficient 
rs = o.63, p4. 0.01 
Controls 
Spearman's Rank Correlation Coefficient 
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Figure 5.4. Relationship between Serum Haemopexin and Myoglobin 
Levels in DMD Carriers and their Age and Sex Matched 
Controls 
DMD Carriers 
Spearman's Rank Correlation Coefficient 
rs = 0.34, p = NS 
Controls 
Spearman's Rank Correlation Coefficient 
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5 -4. DISCUSSION 
The stability of haemopexin in serum stored frozen (- 70 °C) for up 
to a 6 -week period (<3% loss in activity) was in agreement with the 
study of Adornato et al.(1978a) who found <5% loss in activity (stored 
- 70 °C for 8 weeks). 
Using the method of Percy et al. (1981) a similar level of variation 
in measurements between plates (of the same batch) was found in this 
study (3 -4ó) to the study of Percy et al. (about + 2%). 
Although serum haemopexin levels were significantly increased in 
DMD patients compared to their controls, the considerable overlap between 
values indicated the minimal discriminatory power of this protein in the 
separation of these two groups. The weak discriminatory power of serum 
haemopexin in the selection of Duchenne patients from their controls 
implied the selection of DMD carriers from their control group would be 
weaker still, since DMD carriers overall manifest either a lesser degree 
of biochemical abnormality or no demonstrable biochemical alteration from 
the norm. In fact this was the case, no significant difference was found 
in DMD carrier haemopexin levels compared to their matched controls. 
Both Lane et al. (1979) and Bundey (1981) were also unable-to find 
a significant difference in serum haemopexin level in DMD carriers 
compared to their controls, whist Tagliavini et al. (1979) found a. 
statistical difference between serum haemopexin measurements in these two 
groups but stated that the variability of the results limited the 
usefulness of this test in carrier detection. 
Daniell and Angelini (1976b) and Adornato et al.(1978a) reported 
significantly raised serum haemopexin levels in DMD carriers compared to 
controls and found a greater separation between these subject groups than 
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had other workers. I- Iowever, in both of these reports, mean control 
haemopexin levels were, on average, about 18% lower than mean values in 
studies where control subjects were in the same age range as carriers 
(Percy et al., 1981; Lane et al., 1979) or where controls were age matched 
to the carriers used, as in this study. Percy et al. (1981) considered 
such differences in mean control haemopexin values may have been ethnic 
in origin or due to an age effect. 
Lower serum haemopexin values have been reported in healthy children 
compared to healthy adults (Hanstein and Muller- Eberhard, 1968). In this 
study haemopexin levels in control boys tended to be in a lower range than 
haemopexin measurements made in the control women studied, whilst no 
significant age relationship was found in either group considered 
independently. Percy et al. (1981) found serum haemopexin levels in 
normal women 4.20 years and >50 years of age were significantly different 
from one another but reported no significant age relationship in the 
women between 20 - 50 years. 
In this study a weak positive correlation was found between serum 
haemopexin and age in DMD carriers, which was not present in their 
matched controls. An increase in serum haemopexin level with increasing 
age could reflect a concommitant decrease in clearance efficiency of this 
protein. Age correcting the DMD carrier haemopexin results did not alter 
the number found out with the calculated 95% confidence limits. If 
carriers '> 50 years of age were omitted from the calculation, the positive 
regression of haemopexin on age became non -significant. The results of 
Percy et al. (1981) suggested serum haemopexin levels are lower in women 
under 20 years; remain at fairly constant level between 20 - 50 years 
and increase in women >50 years of age. Such a pattern could be 
resultant of a hormonal influence, haemopexin levels being affected by 
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premenarchal, menarchal and postmenopausal states. 
Whilst no significant relationship was fourid between serum haemopexin 
and creatine kinase levels in either the DMD patients or their matched 
controls, a significant correlation between these proteins was evident 
in the DMD carrier group (not present in their matched controls). This 
was contrary to the findings of Percy and co- workers (1981) who reported 
a lack of correlation between serum haemopexin and creatine kinase 
measurements in their series of definite carriers of DMD. Mostacciuolo . 
et al. (1980) cited a non -significant correlation coefficient (r) for 
serum haemopexin and creatine kinase measurements of r = 0.279, but did 
not state to which subject group (DEW carriers or control women) this 
investigated figure referred. Clearly a significant correlation between 
serum haemopexin and creatine kinase levels decreases the likelihood of 
the combined usage of these parameters improving the DMD carrier detection 
capability over that obtained using serum creatine kinase estimation alone. 
Percy et el. (1981) found the combined use of serum haemopexin and 
creatine kinase measurements raised the DMD carrier detection rate in a 
series of 23 carriers and 104- controls from 27% (haemopexin alone) and 
65% (creatine kinase alone) to 82% with 5% controls misclassified (using 
logistic discrimination involving both proteins). However, Schiffer et al. 
(1979); Tagliavini et al. (1979); Bundey,(1981).and this study were 
unable to find an enhancement of carrier detection efficiency by use of 
measurements of both serum haemopexin and creatine kinase. 
In the discriminant analysis involving haemopexin and creatine kinase 
measurements undertaken in this study, haemopexin made a negative contributio: 
(discussed in Chapter 7). In the discriminant analyses involving all 
4- 
variables; haemopexin, creatine kinase, pyruvate kinase and myoglobin 
(and other combinations of 3 of these measurements) haemopexin 
decreased 
the discriminatory ability to select DMD carriers from their controls 
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(refer to Section 7-4.). 
Amongst other sources resulting in haemopexin production, Askanas 
(1966b) and Adornato et al.(197Sa) considered haemopexin could be produced 
as a response to myoglobin release from muscle. The significant 
relationship found between serum haemopexin and myoglobin levels in 
the normal control women and the trend towards such a relationship in 
the normal control boys studied are consistent with this theory. The 
lack of relationship between these two serum proteins in the D W 
patient and the DPT carrier groups could be due to an increased rapidity 
in clearance of the myoglobin- haemopexin complex (following abnormal 
muscle leakage of myoglobin and concomitantly increased haemopexin 
release) or, in the Duchenne boys, be affected by the decreased muscle 
mass and consequent reduction in serum myoglobin in the 5 wheelchair - 
bound patients (asterisked in Table 5.2.). 
Overall this study demonstrated the inability of serum haemopexin 
measurement to discriminate between DMD carriers and their controls, 
when used either alone or in combination with serum creatine kinase 
estimation. 
6 -1. INTRODUCTION 
myoglobin is a low molecular weight (17,800 daltons) protein 
possessing a haem -containing prosthetic group (Kagen, 1973). As a 
respiratory protein, myoglobin is capable of reversibly binding 
molecular oxygen and is involved in oxygen storage and transport 
within striated muscle tissues. It is a muscle- specific protein 
synthesized exclusively in skeletal and cardiac muscle, absent from 
smooth muscle ( Kagen and Gurevich, 1967) and found in highest 
concentration in muscle dependent upon oxidative metabolism. 
Nyoglobin released into the circulation is rapidly removed, 
filtered by the renal glomerulus and excreted in the urine. 
Therefore, under normal conditions the blood level of myoglobin in 
healthy individuals is very low. 
Significant myoglobinaemia occurs as a consequence of myoglobin 
release from muscle cell destruction or serious membrane damage. 
Elevated levels of serum myoglobin have been reported associated 
with the following: 
(1) acute myocardial infarction 
(2) muscular dystrophies 
(3) metabolic myopathies including: 
(i) myophosphorylase deficiency 
(ii) alcoholic myo_oathy 
(4) myositis syndromes including: 
(i) polymyositis 
(ii) systemic lupus erythematosus 
(5) skeletal muscle damage 
(6) extreme exertion in normal individuals 
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In these conditions the raised level of serum myoglobin represents a 
specific indicator of muscle cell damage. However, elevated levels 
may also result from impaired excretion of myoglobin and have been 
reported associated with severe renal failure. Roxin et al. (1979) 
found a positive correlation between galactose elimination rate and 
serum myoglobin levels in patients with liver failure and suggested 
the liver also has a role in myoglobin elimination. 
Myoglobinuria has been examined in acute myocardial infarction 
and in some metabolic myopathies. However, Roxin and his colleagues 
(1979) found no correlation between the urinary excretion of myoglobin 
and the serum myoglobin level in normal subjects. They considered 
that urinary excretion of myoglobin implied either a functional-renal 
tubular defect or a concentration of myoglobin in the primary urine in 
excess of the maximal tubular reabsorbing capacity of the kidney or both. 
Investigations of the myoglobin content of muscle from patients 
with muscular dystrophy prece qA measurements of serum myoglobin 
levels. A decreased concentration of myoglobin has been reported in 
both human dystrophic muscle (Biörck, 1949; Buscaino, 1965) and in 
affected muscle from murine muscular dystrophy model Bar Harbour 
strain 129 (Perkoff and Tyler. 1958). Reports of the existence of 
possible variants of myoglobin in dystrophic muscle (Perkoff, 1964; 
Miyoshi et al., 1968) have not been confirmed (Rowland et al., 1968a) 
and may have been artefactual. 
Rowland et al. (1968b) were unable to identify myoglobin in the 
serum of six patients with DMD. This failure was probably due to a 
lack of assay sensitivity. With the development of more sensitive 
immunoassay systems, several research groups detected elevated serum 
myoglobin levels in patients with DMD. Adornato et al.(1978b) measured 
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myoglobin using a complement fixation immunoassay and Ando et al. (1978) 
used a counterimmunelectrophoresis technique (the lower limits of 
sensitivity of these assays were 150 ngml -1 and 300 ngml -1, respectively). 
In both cases the methods were not sufficiently sensitive to detect 
serum myoglobin in normal control subjects. 
Nishikai and Reichlin (1977) and Miyoshi et al. (1978) measured 
serum myoglobin using radioimmunoassay (RIA) systems which had much 
greater assay sensitivities (lowest detection sensitivities 1 ngml 1 
and 0.3 ngml -1, respectively). Such systems were capable of detecting 
myoglobin even in the amounts present in the serum of normal control 
subjects. The myoglobin assay used by Adornato et al. (1978b) demonstrated 
myoglobinaemia in 14 of 18 (77%) DMD patients. Utilising extremely 
sensitive RIA methods, most workers since then have reported elevated 
serum myoglobin levels in all DMD patients studied (Miyoshi et al., 1978; 
Hische and Van der Helm, 1979; Kiessling and Beckmann, 1981a; Nicholson,1981, 
Measurement of serum myoglobin as a method of carrier detection was, 
first investigated by Adornato et al. (1978b) who looked at a series of 
definite DIvID carriers both before and after a forearm ischaemic exercise 
test (FIET). 9 of 16 (56%) were reported to have demonstrable 
myoglobinaemia both before and after FIET and one carrier following 
FIET only. Of 27 female relatives of DMD patients also examined, 4 
were said to have myoglobinaemia before FIET and 5 more following FIEF 
only. Four of the carriers with myoglobinaemia had normal serum creatine 
kinase levels. 
Kagen et al. (1980), using a similar complement fixation 
immunoassay, reported 7 of 16 (43%) possible DMD carriers and 6 of 
16 
(37 %) female relatives of DMD patients had myoglobinaemia 
without the 
use of FIET. They also found no direct correlation between serum 
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myoglobin and creatine kinase levels in these women. 
Employing RIA, other workers (Miyoshi et al., 1978; Ando et al., 
1980; Nicholson, 1981) have reported increased levels of serum myoglobin 
in a high proportion of DMD carriers compared to controls, although 
the degree of elevation of serum myoglobin in DMD carriers has been 
found to be lower than that of DMD patients. 
Despite some workers (NQ'rgaard -Hansen et al., 1978; Nicholson, 1981) 
reporting a correlation between serum levels of myoglobin and creatine 
kinase in DMD carriers not found by Adornato et al.,(1978b), most 
(Ando et al., 1980; Lucci et al., 1980; Nicholson, 1981) but not all 
(Fitzsimmons et al., 1980) consider serum myoglobin measurements may be 
a valuable inclusion in tests used in DMD carrier detection. 
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6 -2. MATERIALS AND METHODS 
Serum levels of myoglobin were determined during everyday activity 
in the following groups of subjects: 
(1) Ten patients with DMD together with 10 age- matched, normal 
healthy boys. 
(2) Carrier and control group A, comprising 15 DMD carriers and 
15 age- matched, normal healthy women. 
(3) Carrier and control group B, comprising 20 DMD carriers with 
normal creatine kinase levels (of which 3 samples were plasma) 
and 20 age -matched, normal, healthy women. 
The DMD patients, their matched controls and the DMD carriers and 
controls of group A were selected as stated in Section 3 -2. 
The DMD carriers of group B were classified in the following way: 
(1) Those women who are definite carriers on genetic evidence, 
i.e. - have at least one DMD son and at least one other 
affected male relative through the female line (12 subjects) 
- have daughters with DMD sons and other affected male 
relatives through the female line (1 subject). 
(2) Those women who are probable carriers on genetic evidence 
i.e. have two or more affected sons but no other family 
history of DMD (7 subjects). 
Controls of group B were age- matched to the carriers and were normal, 
healthy women volunteers with no history of neuromuscular disease. 
Blood samples were processed according to the protocol described 
in Section 3 -2. 
With the exception of 4 DMD carrier samples of group B which had 
been stored at -20 °C for a maximum of 6 years all sera were stored in 
aliquots at -70°C and frozen and thawed once only for analysis within 
9 months of collection, although repeated cycles of freezing and thawing 
serum have been reported to have no effect on myoglobin (Hische and 
Van der Helm, 1979). 
Other analyses were also performed on different aliquots of these 
serum samples as described in Table 3.5. 
In the case of the carrier sera which had been stored at -20 °C for 
a maximum of 6 years (refer to Table 6.6.) serum creatine kinase activity 
had previously been measured at the time of taking the samples by the 
Department of Human Genetics for genetic counselling purposes. Both 
the commercial kit and methodology of creatine kinase measurement used 
at that time were as employed in this study. 
Three plasma samples were included in carrier group B since no 
significant differences have been found between serum and plasma 
myoglobin levels (Rosano and Kenny, 1977). 
None of the samples analysed showed signs of haemolysis, however, 
haemoglobin is not thought to interfere with the assay (Hische and 
Van der Helm, 1979). 
Serum myoglobin levels were measured by a commercially available 
RIA kit "Myok" (Cis UK Ltd.) following the procedure suggested by the 
manufacturers. The kit employs a standard RIA technique Which may be 
summarised by the following equations: 
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Antigen (myoglobin Antigen -Antibody 
in sample or > Complex 
standard) 
Antibody (rabbit 





1251- Antigen -Antibody 
Complex 
The antibody used has an equal affinity for both myoglobin standards and 
myoglobin present in samples. Competitive binding to a limited number 
of antibody binding sites occurs between radioactively- labelled myoglobin 
and myoglobin present in the sample. Unlabelled myoglobin binding to 
the antibody reduces the amount of radioactively- labelled bound fraction. 
Following an incubation period, bound and free iodinated myoglobin are 
separated by precipitation of the bound fraction using polyethylene 
glycol in which a second antibody has been pre -precipitated and is present 
in excess. After decanting the supernatants the radioactivity of the 
precipitate is counted in a scintillation counter. The amount of 
radioactively- labelled myoglobin bound is inversely related to the 
concentration of myoglobin in the sample or standard. 
For greater sensitivity, the half hour preincubation of samples with 
antibody (in the absence of tracer) was followed. Tubes were vortex -mixed, 
centrifugation was carried out at +4 °C using a muliisample centrifuge and 
supernatants were decanted by inverting the entire batch of tubes and 
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blotting the rims. A Packard auto -gamma scintillation spectrometer was 
used and the precipitates counted for one minute per tube. Samples, 
standards and a control serum of known myoglobin concentration were run 
in duplicate in each assay. The mean nett counts per minute of each 
myoglobin standard were used to construct a standard curve of percentage 
binding versus concentration of myoglobin, and unknown sample myoglobin 
levels determined by comparison with this curve. 
Samples from two DMD patients with very high serum myoglobin levels 
were reassayed according to kit instructions, using the zero standard 
as diluent. 
The lower limit of sensitivity of this RIA system was 8 ngml -1 (the 
amount of myoglobin causing a 5% decrease of initial binding ability). 
Serum myoglobin and creatine kinase measurements of DMD carrier 
group B and their matched controls were subjected to discriminant analysis 
to determine whether the combined use of both parameters would improve 
DMD heterozygote selection from control subjects over the separation 
obtained using serum creatine kinase alone. Measurements were logged 
(base 10) prior to analysis and serum myoglobin levels below the sensitivity 
of the RIA system used were taken as 8 ngml -1 (for method of discriminant 




Distributions of serum myoglobin levels in all groups studied have 
been shown in Figure 6.1. 
Repeated measurement of serum myoglobin from one normal 24 -year 
old female subject gave a within -batch coefficient of variation of 
4.8%. Less than 4% loss in myoglobin level occurred in serum measured 
following 8 weeks storage at - 70 °C and subsequently remeasured 9 months 
later (separate aliquot of sample stored - 70 °C throughout and thawed 
once only). 
DAN Patient and Control Group 
In the DMD patient and control group (mean and individual 
myoglobin values summarised in Tables 6.1. and 6.2. respectively) all 
the DMD had considerably elevated levels compared 
to control values, with no overlap between results of the two groups. Two 
controls (numbers 3 and 4) had myoglobin levels below the sensitivity 
of the RIA system employed (<8 ngml -1). The difference between 
Duchenne dystrophy patients and their matched controls was significant 
by Wilcoxon test (p < 0.01). Using this non -parametric test enabled all 
20 results to be taken into account. 
There was a general trend in the Duchenne patients studied towards 
a decrease in serum myoglobin level with increasing age. Serum 
myoglobin was significantly correlated with age in the DMD patient 
group (rs = -0.79, p 4_0.01) but not in their controls (rs = 0.27) 
(refer to Figure 6.2.). When the Duchenne dystrophy group were 
subdivided into pre -wheelchair and post- wheelchair subjects, 
-153- 
Figure 6.1. Distribution of Serum Myoglobin Levels in DMD 
Patients, Their Age and Sex Matched Controls and 
in DMD Carrier Groups A and B and Their Respective 
Age and Sex Matched Controls 
N.B. The following subjects had serum myoglobin 
levels below the sensitivity of the RIA system used: 
2 normal controls (boys) 
1 normal female control (Group B) 
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Table 6.2. Individual Serum Myoglobin Levels in 
DMD Patients and their Age and Sex Matched Controls 
AGE AND SEX MATCHED CONTROLS DMD PATIENT'S 
Subject My CK Subject Age My CK 
Pedigree 
-1 -1 -1 -1 











10 48 6 II2 5 910 22,842 
20 69 1 II2 6 850 21,600 
nm* 33 2 1112 6.75 475 6026 
nm' 47 7 IV2 9 242 3240 
12 47 3 IV1 9 402 4147 
17 80 4 III2 10 367 1253 
10 82 5 1113 10.5 395 3672 
12 55 8 1113 10.5 390 3024 
10 105 9 III 13 185 1701 
8 67 lo I17 14 315 1980 
+ wheelchair bound 
nm* myoglobin below measurable level 
My serum myoglobin 
CK serum creatine kinase 
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Figure 6.2. Relationship Between Serum Myoglobin and Age in DIID 
Patients and Age and Sex Matched Controls 
DMD Patients 
Spearman's Rank Correlation Coefficient 
rs = 0.79, p _0.01 
Controls 
Spearman's Rank Correlation Coefficient 
rs = 0.27, p = NS 
Note that 2 controls had serum myoglobin levels 
below the sensitivity of the RIA system and therefore 







o DMD PATIENTS n =10 








(refer to Table 6.2.) the relationship of myoglobin and age remained 
significant in the pre -wheelchair group (rs = - 0.97, p< 0.05) but 
became non -significant in the post -wheelchair subjects (r 
s 
= 0.56). 
Serum myoglobin and creatine kinase levels were significantly 
correlated in DMD patients (rs = 0.88, p4.. 0.01) but not in their matched 
controls (rs = 0.42), shown in Figure 6.3. 
The relationship between serum myoglobin and haemopexin levels in 
the DMD patient and control group has been discussed in Chapter 5. 
DMD Carrier and Control Group A 
For mean and individual myoglobin levels in DMD carrier and control 
group A refer to Tables 6.3. and 6.4. 
A significant difference was found between serum myoglobin levels in 
DMD carrier gm up A compared to their controls (Wilcoxon test, p . 0.01) 
although some overlap was found between results in the two groups. 
Serum myoglobin levels did not appear to be normally distributed. 
However, using an adaptation of the method of Herrera (1958) a cumulative 
log probability plot of myoglobin levels in control subjects was 
reasonably linear (refer to Figure 6.4.). The adaptation of the method 
involved taking the best straight line fit seen by eye. Using this method 
the 95th percentile of the control series was found to be 46 ngml -1. 
9 of 15 (60/) DMD carriers group A had serum myoglobin results greater 
than the 95th percentile of the control series. 
No significant relationship was found between serum myoglobin level 
and age in either the Group A DMD carriers (rs = 0.036) or their controls 
(rs = - 0.035). 
Serum myoglobin and creatine kinase levels were significantly 
correlated in DMD Group A carriers (rs = 0.79, p< 0.01) but not in the 
matched controls (r' = 0.14). (refer to Figure 6.5.) 
s 
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Figure 6.3. Relationship Between Serum Myoglobin and Serum Creatine 
Kinase Levels in DMD Patients and their Age and Sex 
Matched Controls 
DMD Patients 
Spearman's Rank Correlation Coefficient 
rs = 0.88, p <0.01 
Controls 
Spearman's Rank Correlation Coefficient 



































































































































































































































































































































































































































































Table 6.4. Individual Serum Myoglobin Levels in DMD Carriers of 
Group A and their Age and Sex Matched Controls 
AGE AND SEX MATCHED CONTROLS 
Subject My CK 
-1 _l 











1 24 27 10 II2 24 105 213 
2 10 33 11 II1 29 46 123, 
3 25 44 12 II14 33 81 l03 
4 18 23 13 II2 35 27 83 
5 18 30 14 III, 38 190 179 
6 46 52 15 114 4o 14 37 
7 15 80 16 II, 43 138 228 
8 12 42 17 I14 43 38 115 
9 16 49 18 115 5o 105 206 
10 36 63 10 12 51 102 327 
11 35 48 19 I13 52 155 263 
12 15 19 20 II4 55 42 56 
13 45 49 21 II, 59 22 195 
14 11 49 22 1118 60 125 269 
15 17 23 I, 6o 17 100 
elevated levels underlined 
My serum myoglobin 
CK serum creatine kinase 
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Figure 6.4. Cumulative Percentage Frequency of the Logarithm's 
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FisTure 6.5. Relationship Between Serum Myoglobin and Serum Creatine 
Kinase in Group A DMD Carriers and Their Age and Sex 
Matched Controls 
DMD Carriers 
Spearman's Rank Correlation Coefficient 
rs = 0.79, p . 0.01 
Controls 
Spearman's Rank Correlation Coefficient 



































o DMD CARRIERS n =15 
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Of the 6 DMD carriers whose serum myoglobin levels were within the 
95th percentile of the control series, 3 of these subjects had serum 
creatine kinase activities that were outwith the 95th percentile of the 
control series, whilst 3 carriers were considered "normal" by both tests. 
The relationship between serum myoglobin and the proteins pyruvate 
kinase and haemooexin in DMD carriers and controls of Group A have been 
discussed in Chapters 4 and 5 respectively. 
The results of this study and the findings from the discriminant 
analyses (discussed in Chapter 7) implied the possibility of an improvement 
in DMD carrier detection capacity by combined use of serum myoglobin and 
creatine kinase measurements over that obtained using serum creatine 
kinase estimation alone. Therefore a group of known genetic carriers of 
DIW whose serum creatine kinase activities did not exceed the 95th percentile 
of the control series for this enzyme, along with age and sex matched 
normal, healthy women were investigated (DND Carrier and Control Group B). 
DIW Carrier and Control Group B 
For mean and individual serum myoglobin levels in this group of DMD 
carriers and controls refer to Tables 6.5. and 6.6. respectively. 
There was no significant difference between serum myoglobin levels 
in DMD carriers and their matched controls by Wilcoxon test. Considerable 
overlap was present between myoglobin levels in these two groups of 
subjects. 
3/20 (15%) Group B DND carriers had serum myoglobin levels greater 
than 46 ngml -1, the calculated 95th percentile of the control series 
(refer to Figure 6.4.). 
One carrier (36 12) and one control (number 26) had serum 
myoglobin levels below the sensitivity of the RIA system used. 















































































































































































































































































































































































































































































































































































Table 6.6. Individual Serum Myoglobin Levels in DMD Carriers of 
Group B and their Age and Sex Matched Controls 
AGE AND SEX MATCHED CONTROLS 
Subject My CK 
-1 _1 











16 31 9 45 24 11112 32 14+ 64+ 
17 37 41 49 24 1116 35 10 22 
18 35 33 43 25 1117 35 25 52 
19 35 45 33 26 112 36 11 41 
20 36 19 38 27 1111 37 .L 71 
21 38 35 62 24 III10 38 2 83+ 
22 39 20 21 28 II2 39 19 33 
23 39 10 24 29 1I12 39 35s 29 
24 40 24 37 30 II1 40 40s 71 
25 4o 15 24 31 114 4o 9S 38 
26 41 nm* 30 24 III5 41 8 43 
27 41 16 52 32 II14 42 13 29 
28 42 30 33 33 1112 42 . 15 48 
29 42 20 39 34 II 42 42 80 
3o 5o 36 79 35 113 42 los 44 
31 44 12 30 36 I2 44 nm* 25 
32 47 33 44 37 IV 3 47 29 45 
33 47 33 24 38 1112 47 35 7o 
34 5o 23 48 39 112 50 23 62 
35 65 45 51 24 I13 71 82+ 83+ 
elevated levels underlined 
nm* myoglobin below measurable level 
+ plasma -166 - 
s serum stored - 20 °C 
was found between serum myoglobin and age in either Group B DMD 
carriers (r' = 0.08) or their matched controls (r' = 0.16). 
Serum myoglobin and creatine kinase measurements were significantly 
correlated in Group B DMD carriers (rs = 0.77, p.. 0.01), in agreement 
with Group A carrier results. These proteins were also significantly 
correlated in Group B controls (rS = 0.45, p < 0.05) whilst no such 
relationship was evident in Group A controls. 
Discriminant analysis of serum myoglobin and creatine kinase 
measurements using all Group B DMD carriers and their controls gave 
the following standardised canonical discriminant function coefficients: 
serum creatine kinase: 1.242 
serum myoglobin: - 0.807 
The negative sign of the myoglobin coefficient indicated that this 
parameter made a negative contribution towards the separation of carriers 
from controls (for detailed explanation of the analysis refer to Chapter 7). 
The greater size of the serum creatine kinase coefficient demonstrated the 
larger contribution this enzyme made to the analysis compared to serum 
myoglobin. 13/20 (65%) DMJJ carriers were correctly classified as carriers 
in this analysis but only 11/20 (55%) of controls were correctly classified, 
leaving an unacceptably high number of controls misclassified: 9/20 (45 %). 
(refer to Figure 6.7.) For comparison the analysis was repeated using 
serum creatine kinase alone. In this analysis the same number of carriers 
were correctly classified (13/20; 65%) and a larger number of controls 
were correctly classified (14/20; 70 %), the misclassification of control 
subjects being 6/20 (30%). 
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Figure 6.6. Relationship Between Serum Myoglobin and Serum 
Creatine Kinase in Group B DMD Carriers (with Serum 
Creatine Kinase Levels Within the Normal Range) and 
Their Age and Sex Matched Controls 
A. 95th Percentile of the Control series for Serum 
myoglobin 
B. 95th Percentile of the Control Series for Serum 
Creatine Kinase 
DMD Carriers o 
Spearman's Rank Correlation Coefficient 
r 0.77, p x-0.01 
Controls 
Spearman's Rank Correlation Coefficient 
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Figure 6.7. Discriminant Analysis of Group B Carriers and Controls: 
Computer Generated Graphs 
Upper Graph: Discriminant analysis using serum 
myogi_obin and creatine kinase 
measurements 
Lower Graph: Repeat of discriminant analysis above 
omitting: serum myogobin measurements 
Note that all subjects whose results fall into the 
area on the graph denoted as "CONTROL" would be 
classified as normal women and those falling into the 
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6-4. DISCUSSION 
The good stability of myoglobin in serum stored frozen ( -70 °C, 
9 months) was in agreement with the study of Roxin et al. (1979), 
where no significant alteration in myoglobin level occurred following 
storage at -25 °C for 2 years. Continued stability in serum, despite 
repeated cycles of freeze /thaw, has also been noted (Hische and 
Van der Helm, 1979). 
The greatly elevated serum myoglobin levels found in all DMD 
patients studied compared to control subjects has been reported by 
other workers employing RIA systems (_ Miyoshi et á 1.; 19.78; Hische and 
Van-der Helm, 1979; Kiessl tg and Beckmann, 1981a). :Such a good 
separation between DMD patients and their matched controls by use of 
this test indicated the possibility of finding a reasonable proportion 
of genetic carriers of DMD with elevated serum myoglobin levels 
compared In was case, 9/15 (60%) DMD 
carriers Group A had serum myoglobin levels greater than the 95th 
percentile of the control series. Other workers using RIA have also 
reported a high percentage of genetic carriers of DMD with increased 
levels of serum myoglobin: Miyoshi et al., in 1978 (70%); Ando et al. 
in 1980 (71%) and Nicholson in 1981 (78%). In each case, however, the 
separation between DMD carrier and control groups has been much smaller 
than that observed between Duchenne patient and control groups. 
Rosano and Kenny (1977), Nicholson (1981) and this study found 
serum myoglobin measurements in normal control populations to be 
non -Gaussian. Other workers (Miyoshi et al., 1978; Ando et al., 1980; 
Lucci et al., 1980) have not indicated whether they have tested for 
normality of serum myoglobin distribution. Clearly uncorrected non - 
normality in the distribution of this protein could adversely affect 
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the interpretation of results in such studies. 
Serum myoglobin level decreased significantly with increasing age 
in the Duchenne patients (in agreement with Kies e ng and Beckmann, 1981a; 
Nicholson, 1981). Kagen et al. (1980) considered there was a tendency 
for serum myoglobin to be lower in older less active DMD patients than 
in younger ambulatory DMD subjects. In this study, separating the DI'ID 
patients into pre- and post -wheelchair groups resulted in the relationship 
with age losing significance in the latter group whilst remaining 
significant in the ambulatory patients. However the small number of 
subjects used (n = 10) requires caution in interpretation of these results. 
Kiessling and Beckmann (1981a) examined 50 DMD patients and also found 
serum myoglobin levels diminished significantly with increasing age. 
This diminu ti." in serum myoglobin level may be result of the gradual 
decrease in effective muscle mass which occurs during the degenerative 
course of Duchenne dystrophy, although other factors including level 
of exercise and renal clearance of myoglobin may also play a part. 
Nicholson (1981) reported serum myoglobin levels decreased with increasing 
age in wheelchair -bound DMD patients but found serum myoglobin slightly 
but significantly increased as age advanced in ambulant patients. 
Nicholson considered the situation in ambulant patients to be related 
to an apparent increasing muscle bulk (in patients less than 6 years 
old) prior to disease progression overtaking physical growth. 
In this study all DMD carriers (Group A and B) and their matched 
controls (with one exception in Group B) fell within the 24 -60 year age 
group. In this age range there was no evidence of any relationship 
between serum myoglobin and age in any group studied. Similar results, 
in the age range 17 -60 years, were found by Nicholson (1981). However, 
in Nicholson's study a group of normal women greater than 60 years of 
age, were found to have significantly increased serum myoglobin levels 
-171- 
compared to those less than 60 years of age, which might be related to 
a slight decrease in glomerular filtration rate which occurs with increasing 
age (Roxin et al., 1979). 
A significant positive correlation between serum measurements of 
myoglobin and creatine kinase found in the DMD patients examined in this 
study was in agreement with the findings of N0rgaard- Hansen et al.,(1978") 
and Kiessling and Beckmann (1981a). Such a relationship would tend to 
indicate the diminuLk:,,, in release of these muscle specific proteins 
through gradually decreasing numbers of muscle fibres during the disease 
process. Whilst the lack of relationship found between these serum 
proteins in DMD patients reported by Adornato et al. (1978b) and Kagan 
et al. (1980) could be at least partially explained by the lack of 
assay sensitivity in these studies. Hische and Van der Helm (1979) 
used a sensitive RIA test and also failed to detect a significant 
correlation. Kiessling and Beckmann (1981b) considered these results 
may have been affected by misinterpretation of diluted high myoglobin 
measurements. However, Kagen (1981) suggested the lack .of._ 
correlation could be resultant of a greater diurnal variation in serum 
myoglobin levels compared to serum creatine kinase measurements and 
kinetics might also be involved (since the longevity of myoglobin in 
plasma is not comparable to that of enzymes). 
Several workers have reported the significant positive correlation 
between serum levels of myoglobin and creatine kinase in DMD carriers 
also found in this study (Nergaard- Hansen et al., 1978; Ando et al., 
1980; Nicholson, 1981). In the relatively large study of Nicholson 
(1981) the correlation between these two proteins was significant in 
both categories of DMD carriers examined (definite, n = 23 and possible, 
n = 33). In terms of carrier detection potential the closer the 
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correlation the lesser the likelihood of the use of both parameters 
improving DMD heterozygote recognition. However, Nicholson (1981) 
found 18/23 (78 %) definite carriers had increased serum myoglobin levels 
of which 7/23 (30%) were carriers with normal serum creatine kinase 
measurements. As explained in Section 6.3., following discriminant 
analysis involving all 4 parameters measured in Group A carriers, serum 
myoglobin levels were investigated in 20 genetic carriers of DMD whose 
serum creatine kinase levels were within the 95th percentile of the 
control series. Only 3/20 (15 %) of these (Group B) carriers had serum 
myoglobin values outwith the 95th percentile of the control series. In 
these 3 carriers, serum creatine kinase measurements were close to the 
upper 95th percentile of the control series (see Figure 6.6.) and in 
these cases, with reference to the "h" value involved in assessing risk 
of DMD heterozygosity (refer to Section 3.4.), each would have been given 
a greater probability of being a DMD heterozygote than the other carriers 
examined (with lower serum creatine kinase levels). These results 
indicated the minimal gain achieved by the additional use of serum 
myoglobin measurement in testing for DMD carrier status in non -pregnant 
women of the age range studied. 
Fitzsimmons et al. (1980) considered serum myoglobin estimation 
had no advantage over serum creatine kinase measurement in DMD carrier 
detection work. In a small study, Nygaard- Hansen and Hein -Sorensen 
(1982) reported only one of 6 (16.6 %) definite carriers of DMD had an 
elevated serum myoglobin level in the absence of an elevated serum 
creatine kinase measurement, whilst in one (16.6%) carrier only serum 
creatine kinase activity was elevated. In 3 (50 %) of the carriers neither 
protein was outside their "normal" range and in one (16.6 %) carrier both 
of these serum proteins were elevated. In 1980 Ando et al. had concluded 
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that serum myoglobin estimation was a valuable inclusion in DMD carrier 
detection tests although in their study only 2/14 (14.2 %) carriers (and 
these were both possible DMD carriers) demonstrated an elevated level of 
serum myoglobin and yet serum creatine kinase activities were within 
Ando and his co- workers "normal" range (not clearly defined). One of 14 
(7.1ó) of these carriers showed an elevation in serum creatine kinase 
activity, although serum myoglobin remained within the "normal" range, 
whilst 3/14 (21.4%) and 8/14 (57.1 %) DMD carriers were considered to have 
levels of both proteins that were "normal" or elevated respectively. 
Assessment of the true improvement in DMD heterozygote detection capability 
obtained by the use of both serum myoglobin and creatine kinase measurements 
in such studies (already only a small apparent improvement) is extremely 
difficult. The situation is complicated by the possibility that the 
actual level of serum creatine kinase activity (in terms of the "h" value 
discussed earlier and in Chapter 3) may have detected those carriers 
selected by an elevated serum myoglobin level alone, as was the case in 
this study. 
A similar relationship between serum levels of myoglobin and creatine 
kinase in control subjects as that found in DMD carriers would obviously 
aid recognition using these two parameters. In this study the relationship 
between serum myoglobin and creatine kinase measurements did not reach 
significance in the Group A control subjects although there was a trend 
towards a significant positive correlation between these proteins which 
was significant in the Group B controls. Roxin et a1. (1979),in a study 
involving 42 healthy women,and Nicholson and Walls (1983), investigating 
50 healthy females, also found serum myoglobin and creatine kinase levels 
were significantly positively correlated. 
The results of the discriminant analysis of serum myoglobin and 
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creatine kinase levels in Group B carriers and controls showed that inclusion 
of myoglobin values contributed adversely to the analysis. No improvement 
in the number of carriers correctly identified (13/20; 65 %) was obtained 
by the addition of myoglobin levels to this analysis than was found by 
the analysis of serum creatine kinase results alone. Furthermore, using 
both parameters together or serum creatine kinase alone, unacceptably 
high percentages of controls were misclassified as carriers (9/20; 45% 
and 6/20; 30% respectively). 
However, in certain categories of DMD heterozygote (outside the scope 
of this thesis) the measurement of serum myoglobin might be of value. 
The assessment of DMD carrier status by measurement of serum creatine kinase 
activity is adversely affected in young girls up to and including the 
teenage years and in pregnant women by, in the former an increased and, 
in the latter a decreased level of the enzyme (refer to Chapter 3). 
Nicholson and Walls (1983) have very recently reported that serum 
myoglobin levels in pre- and post -menarchal teenagers and in women of 
varying stages of pregnancy did not differ from menstruating, post- 
menopausal or non -pregnant women, whilst serum creatine kinase activities 
differed widely between these subject groups. Obviously, confirmation of 
this study and evidence that pre -pubertal to teenage DMD carriers and 
pregnant DMD heterozygotes exhibited similar trends are required. 
However, in such situations, full account should be taken of other factors 
which might affect the serum level of this protein. Bombardieri et al. 
(1981) and Nicholson and Walls (1983) have reported a significant diurnal 
variation in serum myoglobin level in normal control subjects, not 
paralleled by serum creatine kinase activity (a 39% decrease in serum 
myoglobin level from 9 am to 6 pm in Bombardieri et al.'s study, a 20% 
decrease between 9 am and 5 pm in Nicholson and Wall's study). Konagaya 
et al. (1982) found that in 5/11 (45.4%) DMD carriers serum myoglobin 
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increased significantly following a standard exercise test, with 2/11 
(18.1 %) control females exhibiting a small but non -significant increase 
following exercise. Other factors, including smoking and the use of the 
contraceptive pill have been reported not to affect serum myoglobin levels 
in control women (Nicholson and Walls, 1983). Clearly much more research 
is required in both young and pregnant DMD carrier and matched control 
categories before the possible useful potential of serum myoglobin in 
these subjects can be assessed fully. 
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CHAPTER 7: COMBINED TESTS 
7 -1. INTRODUCTION 
Many possible tests of DMD carrier detection have been reported 
in attempts to improve the rate of heterozygote recognition above 
that achieved by the routinely used serum creatine kinase test. The 
difficulty lies in estimating the likelihood of a subject being a DMD 
carrier or not when distributions between DMD heterozygote and normal 
populations overlap. One approach has been to apply several different 
tests to a series of DMD carriers. Radu et al. (1968), in a study 
involving 21 genetic DI +D carriers, examined a battery of tests 
including serum enzymes, EKG's and muscle biopsies. These workers 
reported 21/21 (100 %) genetic DMD carriers were successfully 
identified by the combined results of all these tests. However, the 
necessity of employing correct confidence limits and the possibility 
of generating false positive results by chance in normal subjects if 
enough tests are performed, have been pointed out (Tukey, 1977). 
Schiffer et el. (1979); Hausmanowa-Petrusewicz et al. (1980) and Lane 
et al. (1979) have all submitted UND carrier groups of varying size 
to an extensive variety of different possible tests for DMD carrier 
recognition. Of the considerable range of tests employed few were 
considered by the authors to be of possible value in DMD heterozygote 
detection, these were: muscle biopsy in the absence of abnormal serum 
creatine kinase measurement (Schiffer et al., 1979); examination of 
peripheral blood cells and serum creatine kinase measurement following 
hydrocortisone injection (Hausmanowa -Petrusewicz et al., 1980). Lane 
et al. (1979) comparing a series of 12 DMD carriers with 12 control 
women also found most tests failed to distinguish DMD heterozygotes 
from normals, however 11/12 (91.7%) DiID carriers and 10/12 (83.3%) controls 
were correctly identified by manual muscle testing. The DMD carrier 
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group also exhibited ECG abnormalities and these workers considered 
such measurements may have value in testing DMD carriers whose serum 
creatine kinase levels are within "normal" limits. 
Percy et al. (1980) achieved a DMD carrier detection rate of 87% 
with correct classification of 98% control subjects by measurement of 
serum levels of creatine kinase, pyruvate kinase, lactate dehydrogenase 
and haemopexin analysed by logistic discrimination. However Percy et al. 
(1982b) considered that up to one third of genetic DIM carriers 
remained indistinguishable from controls using logistic discrimination of 
these 4 tests. Zatz and Otto (1980b) reported that discriminant 
analysis involving both serum creatine kinase and pyruvate kinase 
measurements correctly selected 25/30 (83.3%) and serum pyruvate 
kinase 24/30 (80 %) DMD carriers . The combined 'analysis of both 
serum enzymes appeared to give a slight improvement in carrier 
detection rate (1/30, 3.3%). However it should be noted that the 
discriminatory power of serum pyruvate kinase reported by Zatz and 
Otto (1980b) was higher than that obtained by this and other studies 
(refer to Chapter 4). 
Muir et al. (1983) very recently employed discriminant analysis 
involving serum measurements of creatine kinase, pyruvate kinase and 
aldolase. Fourteen of the 21 (67 %) genetic carriers were identified 
by the discriminant analysis involving log (base 10) serum creatine 
kinase; 11/21 (52c/1) using log(base'10) serum pyruvate kinase and 
7/21 (33%) by log (base 10) serum aldolase. Since no further 
increase in discrimination occurred using discriminant analysis of 
combined log (base 10) serum creatine kinase and pyruvate kinase 
measurements than had occurred by use of the former measurement alone 
Muir et al. concluded that serum creatine kinase was sufficient by 
itself and that the other tests applied did not improve DMD 
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7-2. I'MIATERIALS AND METHODS 
7 -2.1. Discriminant Analysis 
Measurements of creatine kinase; pyruvate kinase; haemopex_in and 
myoglobin made on serum samples from the DMD carrier and matched control 
group (labelled A in Chapter 6), referred to in Table 3.5., were 
combined and analysed using discriminant analysis. The SPSS computer 
program used for this purpose (Pie et al ., 1975) was run by Dr. Susan 
Holloway, Department of Human Genetics, University of Edinburgh. 
All serum results were logged (base 10) prior to analysis in order 
to aid group discrimination and at least partially normalise some of 
the data. The results of all 4 tests were combined in the first analysis. 
Subseouently different combinations of either 3 or 2 tests were analysed 
separately. One DMD carrier (17 III) and matched control no. 8 were 
omitted from all analyses since pyruvate kinase was not measured in the 
second sample from this carrier (refer to Section 4-2.). 
7 -2.2. Summary of Relationships between Serum Proteins Measured in 
this Study. 
The relationship between proteins measured in this study have been 
discussed in the relevant preceeding chapters and have been summarised 
in this chapter. 
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7 -3. RESULTS 
7 -3.1. Discriminant Analyses 
For results of the discriminant analyses undertaken using all 4 
serum tests and with different combinations of either 3 or 2 tests 
refer to Table 7.1. When the discriminant analysis program was run 
employing only the logged results of serum creatine kinase estimation 
12/14 (85.7%) of Group A DID carriers and 13/14 (92.9%) controls were 
correctly classified. DI'ID carriers 15 II, and 20111, and matched control 
no.10 were misclassified. 
The computer generated graphs of the discriminant analyses 
involving all 4 serum tests and involving serum pyruvate kinase, 
haemopexin and myoglobin tests can be seen in Figure 7.1. 
7 -3.2. Summary of Relationships between Serum Proteins Measured in 
DMD Carriers and Controls, Group A. 
In this study serum creatine kinase levels were significantly 
positively correlated to serum levels of pyruvate kinase; haemopexin 
and myoglobin in the DIíTJ carriers Group A, but no significant 
relationship was evident between these serum proteins in their age and 
sex matched controls. 
Serum pyruvate kinase was significantly positively correlated to 
serum levels of haemopexin in this DMD carrier group although no such 
relationship was evident in their controls. No significant relationship 
Iras found between serum levels of pyruvate kinase and myoglobin in 
either subject group. 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 7.1. Discriminant Analyses of Group A Carriers and Controls: 
Computer Generated Graphs 
Upper Graph: Discriminant analysis using serum creatine 
kinase, pyruvate kinase, haemopexin and 
myoglobin measurements 
Lower Graph: Repeat of discriminant analysis above 
omitting serum creatine kinase measurements 
Note that all subjects whose results fall into the area on the 
graph denoted as "CÇ1 RCLS" would be classified as normal women 
and those falling into the area marked "CARRIERS" would be 
classified as DID heterosyTotes. 
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of haemopexin and myoglobin in DMD carriers, Group A, but this 
relationship was significant in the control subjects. 
For a summary of these relationships refer to Table 7.2. 
Using the confidence limits for the control series calculated for 
each serum protein individually (refer to Chapters 3,4,5 and 6) of the 
14 DDID carriers of Croup A examined (excluding DMD carrier 17 IIL from 
the series of 15) in 3/14 (21.420 of these DMD carriers (13 I12; 15 IIL; 
20114) serum measurements of all 4 proteins were within the calculated. 




















































































































































































































































































































































































































































































7 -4.1. Discriminant Analyses 
From the magnitude of the standardised canonical discriminant function 
coefficient in the discriminant analysis involving all 4 serum tests 
(note that in all the discriminant analyses undertaken in this study 
results discussed were logged base 10, prior to analysis) it can be seen 
that serum creatine kinase made by far the largest contribution of the 
variables, between 2.5 and. 3 times that of either serum pyruvate kinase 
or myoglobin (refer to Table 7.1., vi). The latter 2 variables made 
similar levels of positive contribution towards the discriminant function 
whilst serum haemope :.in provided only a smaller and negative contribution 
to the 'analysis. 
In most of the discriminant analyses undertaken which involved 
combinations of 2 or 3 serum tests, in each case both the nature and 
levels of contribution of each variable to the discriminant function 
obtained. was similar to that shown in the discriminant analysis involving 
all 4 serum tests. In discriminant analyses which included serum creatine 
kinase this variable always made the largest positive contribution to the 
discriminant function concerned and both serum pyruvate kinase and serum 
myoglobin made similar levels of contribution (relative to one another) 
in these analyses. Serum haemopexin was found to be the least important 
variable in all discriminant analyses undertaken. By omitting serum 
haemopexin as a variable from the discriminant analysis using all 4 
serum tests, IND heteror.ygote recognition increased. from 11/14 (78.6%).to 
12/14 (85.. 
'. ihen serum creatine kinase was not included as one of the variables 
in the discriminant analyses (refer to Table 7.1., vii and viii) the 
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number of subjects correctly classified decreased (relative to the number 
of subjects correctly identified in discriminant analyses which included 
serum creatine kinase as a variable). In these 'analyses serum myoglobin 
macle the greatest positive contribution of the variables. 
None of the discriminant analyses involving 2, 3 or 4 variables 
improved on the number of DMD heterozygotes correctly classified by 
discriminant analysis employing serum creatine kinase as sole variable 
(1214, 85.7%). However one control subject misclassified by the 
discriminant analysis involving serum creatine kinase alone was correctly 
classified by several discriminant analyses which employed, serum creatine 
kinase and either 1 or 2 further variables (refer to Table 7.1., i - v) . 
Comparison of the contributions of each of the variables to the 
discriminant analyses undertaken clearly demonstrated serum creatine 
kinase to have by far the greatest DMD carrier discriminatory power of 
the variables examined. Of the remaining serum tests investigated, 
examination of the standardised canonical discriminant function 
coefficients for each variable in each discriminant analysis implied 
that serum myoglobin was the next most discriminating variable. 
The possibility that serum myoglobin, when used additionally to 
serum creatine kinase, might improve DMD heterozygote selection over 
that obtained using serum creatine kinase as sole determinant was 
explored in Chapter 6. In fact discriminant analysis of Group B carriers 
and controls (20 genetic DMD carriers whose serum creatine kinase levels 
were within the calculated 95th percentile of the control series and 20 
age matched normal women) using both serum creatine kinase and serum 
dyoglobin indicated that inclusion of serum myoglobin as a variable 
adversely affected discrimination between these DMD carriers and control 
subjects. 
Overall the results of this study indicate that (in the subject age 
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range studied) using discriminant analysis as a method of DMD carrier 
detection,when serum creatine kinase is present as a variable little 
advantage is gained from the additional use of serum measurements of 
pyruvate kinase, haemonexin and myoglobin, either singly or in combination. 
7-4.2 Summary of Relationships between Serum proteins measured in 
this study 
The possible mechanisms involved in the abnormal release of 
muscle- residing proteins into the bloodstream of DMD patients have 
been discussed in detail by Pennington (1977) and Rowland (1980). 
Elevated (above the 95th percentile of the control series) serum 
levels of these muscle -specific proteins in DMD heterozygotes are 
thought to originate from the population of dystrophic cells within 
Lyonised DMD carrier muscle (refer to Sections 1 -3.3. and 1- 6.3.). 
Of the serum proteins investigated in this study the serum levels 
of myoglobin and the serum activities of the muscle. isoenzyme forms 
of creatine kinase and pyruvate kinase are thought to derive from 
leakage from the muscle cell cytosol compartment. In the case of 
serum haemopexin (a transport protein of haem) it has been suggested 
that elevated levels of this protein occur in response to an abnormal 
muscle leakage 6f myoglobin (refer to Oh .pter.5). 
The leakage process involved in muscle -specific protein release 
is itself more complex than a simple relationship to molecular size 
(see Pennington 1977) and has yet to be elucidated. Furthermore, 
following release of proteins into the bloodstream many factors 
influence the actual serum level measured. The factors known to 
interact with each serum protein studied have been discussed in the 
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relevant preceding Chapters (3,4,5 and6). Overall the serum proteins 
examined in this study ultimately depend, either directly (or in the 
case of haemopexin,: indirectly) on the population of muscle cells 
manifesting the abnormal X chromosome within the DMD heterozygote, 
it was felt that differences affecting each protein (due to the muscle - 
leakage process and due to other factors influencing serum levels) 
might result in different DMD carrier detection capabilities for each 
protein. In fact, in the subjects studied serum creatine kinase 
estimation achieved the greatest number of correctly cl assified DMD 
carriers. The significant correlations in DMD heterozygotes between 
the serum levels of each of pyruvate kinase, haemopexin, and 
myoglobin were apparently too high to enable the identification of DD 
carriers who remained unselected by serum creatine kinase. 
The lack of relationship between serum haemopexin and myoglobin 
measurements in the DID carriers studied (discussed fully in Chapter 
5) may have arisen due to an increased renal clearance of the 
haemopexin- myoglobin complex following a polsi ble_ increased muscle 
release of myoglobin and consequent generation of haemopexin in these 
subjects. 
The DI'ID carriers of Group -A who remained unidentified by any of 
the + serum tests (or by discriminant analysis employing combinations 
of these tests) may represent DI.D heterozygotes in whom, following 
Lyonisation, there are too few muscle fibres to attain serum levels 
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percentile of the control series. In this study, 
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of this enzyme in female relatives of DMD 
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information in the determination of DMD carrier 
status, actual serum creatine kinase levels 
in these relatives were all greater than 1.5 X 
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